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Abstract
Nitric oxide (NO) functions widely as a signalling molecule in the brain and has been 
implicated in several types of synaptic plasticity, including NMDA receptor- 
dependent long-term potentiation (LTP) in the hippocampus. The precise role played 
by NO in this and related phenomena is uncertain and the aim of my research was to 
explore this question.
The principal receptor for NO possesses guanylyl cyclase activity, so that NO 
binding results in cGMP formation. NO has also been claimed to modify thiol 
residues (S-nitrosation) and, through this mechanism, exert a negative feedback on 
NMDA receptors. Tests of this hypothesis were conducted by recording NMDA 
receptor-mediated field excitatory postsynaptic potentials in the CA1 region of rat 
hippocampal slices. Neither manipulation of endogenous NO levels nor application of 
exogenous NO had any effect. The reported inhibition of synaptic NMDA receptor 
function when NO is released by UV light from a caged derivative was confirmed, but 
a similar result was obtained using a combination of exogenous NO and UV light, 
casting doubt on the physiological relevance this effect.
There has been debate over the isoform of NO synthase (endothelial, neuronal, 
or both) needed for hippocampal LTP and it has been suggested that LTP requires not 
only a phasic NO signal associated with tetanic stimulation but also a tonic level of 
NO. cGMP measurements in hippocampal slices indicated that endothelial NO 
synthase was largely responsible for the basal NO tone, and that T-type voltage-gated 
calcium channels may elicit the steady output of NO, presumably from endothelial 
cells. Electrophysiological tests conducted in CA1 found a deficit in LTP both in 
eNOS-deficient mice and in wild type mice subjected to selective nNOS inhibition. 
The results indicate that both isoforms of NO synthase participate in LTP but may 
perform distinct roles.
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Chapter 1 
General Introduction
h ----------------------------------------------------------------------------------------------------------------------------
1.1 Historical background to nitric oxide
Nitric oxide (nitrogen monoxide radical; NO) is one of the smallest biologically active 
messenger molecules. It is also one of the first discovered gaseous biological 
messengers with a wide range of physiological and pathophysiological actions. NO is 
a colourless and odourless gas at standard temperature and pressure, with limited 
solubility in water (maximum concentration ~ 1 mM), but like CO2  or O2 it can cross 
cell membranes easily by diffusion, thereby obviating any direct control of its actions 
by release or uptake mechanisms.
NO first came to medical prominence as a poison when it almost brought an 
end to Sir Humphrey Davy (1778 -  1829). Davy was famous for his investigations 
into nitrous oxide as an anaesthetic agent. When he inhaled pure nitrous oxide he 
described "losing connections with external things, trains o f vivid visible images 
passed through my mind”. He also noted that nitrous oxide relieved his toothache -  
“as nitrous oxide in its extensive operation appears capable o f destroying physical 
pain, it may probably be used with advantage during surgical operations in which no 
great effusion o f  blood takes place ”. The pioneering anaesthetist also tested other 
gases for comparison with nitrous oxide, one of which was NO. Upon the inspiration 
of NO he described “a sense o f  burning in his tongue and his throat, and pain in his 
chest”, and recorded he would “never design again to attempt such a rash 
experiment” (Davy, 1800).
Despite Davy’s experience, and his warning that even low doses of NO as a 
contaminant of nitrous oxide had caused him to feel “somewhat depressed and 
dilapidated”, no steps were taken to monitor the NO content of nitrous oxide for 
many years. NO was rediscovered as a poison in 1966 at the Bristol Royal Infirmary 
when a contaminated stock of nitrous oxide killed one patient, and gravely injured a 
second. Post-mortem examination of this patient revealed excessive formation of
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methaemoglobin leading to severe cyanosis, pulmonary oedema, and culminating in 
cardiac arrest (Clutton-Brock, 1967).
For the last two centuries NO has been viewed as a noxious, and generally 
troublesome, pollutant. It is a toxic gas that is a known constituent of car fumes, a 
component of cigarette smoke, and is widely believed to be involved in the depletion 
of ozone layer. NO is also a recognised by-product of microbial metabolism. In 1916 
it was noted mammals excreted more nitrate than they consumed in their diet 
(Mitchell et al, 1916), but it was not till the 1980s that nitrogen oxides were 
recognised as normal products of mammalian metabolism (Green et al, 1981a,b). 
Interestingly, the use of organic nitrates such as nitro-glycerine has been advocated 
for the treatment of conditions such as angina and heart failure for over a century 
(Brunton, 1867). The first anti-anginal effect of nitro-glycerine was discovered in the 
late 1860s by Alfred Nobel (the founder of the Nobel Prize) who utilised nitro­
glycerine in his factories to synthesise dynamite. It was here that Nobel made two 
very interesting observations regarding his factory workers. Firstly, many of his 
workers often complained of headaches on weekdays that appeared to disappear over 
the weekends. Secondly, workers which suffered from angina pectoris or heart failure 
often experienced relief from chest pain during the work week, but which recurred at 
weekends. Both effects were attributed to the vasodilatory action of nitro-glycerine, 
although the mechanism of action was not elucidated until the late 1970s and found to 
involve its metabolic conversion to NO (Arnold et al, 1977; Katsuki et al., 1977; 
Ignarro et al., 1981).
In an apparently disparate field of research, the investigation into the role of 
acetylcholine (ACh) -  induced relaxation of smooth muscle (Furchgott, 1980) led to 
the discovery of NO. In the late 1970s, Furchgott began to examine the effect of ACh 
on smooth muscle. At the time isolated arteries were cleared of endothelium in order 
to obtain a “pure” smooth muscle preparation, and ACh usually caused contraction. 
On one occasion Furchgott’s technician, Zawadzki, did not remove the endothelium 
and ACh was found to induce a potent relaxation. It was quickly established that the 
relaxation only occurred if the endothelium was present, and that the observed 
relaxation was blocked by atropine, a muscarinic antagonist. The implication was that 
ACh was acting on endothelial cells to produce a substance able to diffuse to the 
smooth muscle and induce relaxation. This substance was termed endothelium-
+ 2
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derived relaxing factor (EDRF). In 1987, two separate laboratories published 
definitive evidence that NO was EDRF (Ignarro et al.y 1987; Palmer et al., 1987).
The discovery that NO can also act as a neuronal messenger in the brain 
originated from studies in the Garthwaite laboratory. In the central nervous system 
(CNS), the ability of glutamate to evoke large increases in cyclic guanosine 3’5’~ 
monophosphate (cGMP) concentration had been known for many years (Ferrendelli et 
al, 1974). These increases were shown to be particularly prominent in the cerebellum, 
and were primarily mediated by specific populations of glutamate receptors 
(Garthwaite & Balazs, 1981). In 1987, it became apparent from investigations in the 
cerebellum that increases in cGMP did not occur in the cells that were stimulated by 
glutamate receptor agonists (Garthwaite & Garthwaite, 1987). Instead, N-methyl-D- 
aspartate (NMDA) receptor activation was found to induce the release of a diffusible 
intracellular messenger that bore a remarkable resemblance to EDRF (Dumuis et al, 
1988; Garthwaite et al, 1988). Investigators subsequently appreciated that glutamate- 
stimulated cGMP formation in cerebellar tissues was due to the production of NO 
(Bredt & Snyder, 1989), thereby initiating investigations into the role of NO as a 
neural messenger molecule.
Parallel investigations in the immune system identified the ability of NO to 
serve a very different purpose from that of the signalling molecule in the vasculature 
and nervous system. As early as 1982, NO was implicated in the immune system as a 
marked increase in urinary nitrate excretion was observed in patients suffering from 
diarrhoea and fever (Hegesh & Shiloah, 1982; Wagner et al, 1984). Further 
investigation revealed that activated macrophages exhibited increased nitrite and 
nitrate production in vitro (Stuehr & Marietta, 1985), however it was not until 1987 
that a role for NO in macrophage cytotoxicity was first described (Hibbs et al, 1987). 
Subsequently it has been realised that activated macrophages are capable of 
generating high levels of NO (Hibbs et al, 1988), and that the NO-dependent 
mechanism of cytotoxicity is via a metabolic inhibition of DNA synthesis, 
mitochondrial respiration and aconitase activity (Granger et al, 1980; Granger & 
Lehninger, 1982; Drapier & Hibbs, 1986, Stuehr & Nathan, 1989; MacMicking et al, 
1997) which culminates in the induction of apoptosis (Albina et al, 1993). 
Furthermore, the cytotoxic action of NO appears to extend to the macrophages that 
produce it, because the activity of NO synthase in these cells correlates inversely with 
their life span in culture (Albina et al, 1989).
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Following these initial reports, NO has been the focus of much attention and 
research over the past two decades. It has attracted sufficient interest to be named 
molecule of the year in 1992 (by Science; Koshland, 1992) and go on to earn three 
scientists (Robert F. Furchgott, Louis J. Ignarro and Ferid Murad) the 1998 Nobel 
Prize for the discovery of NO as a signalling molecule in the cardiovascular system.
Although originally described in mammalian systems, NO has now been 
realised to be a ubiquitous signalling molecule across species. NO has been shown to 
act as a signalling molecule in fish (Saeij et al, 2000), insects (Regulski et al, 1995), 
marine sponges (Giovine et al, 2001), myxomycetes (Golderer et al, 2001) bacteria 
(Liu et al, 2001), and even in plants (Dumer et al, 1999). The elucidation of the 
diverse roles of NO has revealed NO to be important in a number of surprising 
contexts. For example, NO has been found to be essential for the determination of 
firefly bioluminescent flashing (Trimmer et al, 2001), and salivary NO has been 
demonstrated to act as a vasodilator in blood-sucking insects (Ribeiro & Nussenzveig, 
1993). Novel NO-controlled physiological functions have also been uncovered, such 
as the contribution of NO signalling to olfactory-like feeding behaviour in Hydra 
vulgaris (Colasanti et al, 1997), and a Ca -sensitive NO synthase (NOS) has been 
implicated in melanin production in the ink-gland of Sepia officinalis (Palumbo et al, 
1997). These observations reveal NO to be a signalling molecule with a very ancient 
history, serving diverse biological functions in even the most primitive organisms.
1.2 Mechanism for nitric oxide generation: nitric oxide synthase
Subsequent to the discovery of NO as an important signalling molecule in the 
vasculature and nervous systems, a mechanism for its generation was rapidly sought. 
The family of enzymes responsible for the synthesis of NO in biological systems was 
first described in 1989 to be the Ca2+/calmodulin-dependent NOS. These enzymes 
catalyse the production of NO and L-citrulline from the guanidine nitrogen of L- 
arginine, a process consuming five electrons.
Three distinct isoforms of NOS are present in mammalian systems, each of 
which have been purified and well characterised: endothelial NOS (eNOS; Palmer et 
a l , 1989), neuronal NOS (nNOS; Bredt et a l, 1991), and inducible NOS (iNOS; 
Hevel et a l, 1991). Recent studies have indicated that a fourth isoform of NOS may 
also exist: mitochondrial NOS (mtNOS; Lacza et al, 2003). Since the first indication
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of mitochondrial NO production in 1994 (Loesch et al, 1994) the identity of this 
isoform has been subject to much controversy as to whether it is identical to one of 
the other known isoforms. Recent evidence however indicates that mtNOS may be a 
novel NOS isoform (Lacza et al, 2003).
Two of the isoforms, eNOS and nNOS, are constitutively expressed 
throughout the brain, requiring Ca2+ and calmodulin (CaM) for their activation. eNOS 
is typically expressed in the endothelial cells of cerebral blood vessels, whereas nNOS 
tends to be localised to neuronal structures. In contrast, iNOS is not ordinarily found 
in any healthy cell. iNOS may be induced in a variety of cell types including 
macrophages, smooth muscle, cardiomyocytes and microglia, following activation of 
the cells with products of infection (including bacterial endotoxin or exotoxin), or 
certain inflammatory mediators (including the cytokines tumour necrosis factor or 
interleukin-1). Once induced, iNOS is constitutively active, leading to the long-term 
production of NO to cytotoxic levels that acts as a host defence mechanism.
The classification of the NOS family is summarised in table 1.1, and is based 
on their cellular location, in addition to their physical and biochemical characteristics. 
For completeness, the novel isoform mtNOS has been included.
Neuronal
NOS
(nNOS)
Inducible
NOS
(iNOS)
Endothelial
NOS
(eNOS)
Mitochondrial
NOS
(mtNOS)
Other
nomenclature Type I Type II Type III
Protein size 
(kDa) 160 130 135 125-130
Chromosomal
location 1 2 17 7
?
Cellular
Location Neurones Macrophages
Endothelial
cells Mitochondria
Subcellular
location
Cytosolic/
particulate
Predominantly
cytosolic
Predominantly
particulate
Expression Constitutive Inducible Constitutive Constitutive
Calcium
dependence Yes No Yes Yes
Table 1.1: Characteristics of the NOS isoforms
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Splice variants of the NOS isoforms have also been reported in various tissues, 
although the biological significance of these variants are poorly understood. To date, 
four nNOS splice variants have been detected (nNOS/?, nNOSy, nNOS// and nNOS-2). 
nNOS/? and nNOSy were initially identified in the brain of nNOS-knockout mice 
(Huang et al., 1993; Eliasson et al., 1997) but have since been reported to also be 
present at low levels in the testes (Wang et al., 1997). nNOS// is selectively expressed 
in rat heart and skeletal muscle (Silvagno et al, 1996), and in both rat and human 
penis and urethra (Magee et al., 1996). Only mRNA has so far been detected for 
nNOS-2 (Ogurae/a/., 1993).
Relatively little information exists on the iNOS splice variants, with 
alternatively spliced mRNA transcripts of iNOS detected in human epithelial and 
alveolar macrophages (Eissa et al., 1996). No splice variants of eNOS have yet been 
reported.
1.2.1 Structure of nitric oxide synthase
The three main NOS isoforms share a common general structure, consisting of two 
subunits with molecular masses of approximately 130 kDa (iNOS), 135 kDa (eNOS) 
and 160 kDa (nNOS). All three isoforms require five bound co-factors and prosthetic 
groups for activity: flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), 
tetrahydrobiopterin (BH4), iron protoporphyrin IX (haem) and CaM.
The active enzyme exists as a homodimer (Masters et al., 1996; Stuehr, 1997), 
each monomer consisting of two major domains: an N-terminal oxygenase domain 
(homologous to haem-thiolate proteins) and a C-terminal reductase domain 
(homologous to the cytochrome P450s). The former contains binding sites for one 
molecule of nicotinamide adenine dinucleotide phosphate (NADPH), FAD and FMN, 
whereas the latter binds haem, BH4 and L-arginine. An interlinker domain exists 
between the oxygenase and reductase domain which contains a CaM-binding 
sequence. The domain structure of the NOS isoforms is shown in figure 1.1.
Association of the monomers into active dimers creates an extensive interface 
between the oxygenase domains of the two subunits. Comparative analysis of NOS 
domain interactions using yeast two-hybrid systems reveal that subunit association of 
eNOS and nNOS involves both oxygenase and reductase domains, whereas for iNOS 
only the oxygenase domain is involved (Venema et al., 1997). Haem, BH4, and L- 
arginine all promote and/or stabilise the active dimeric form of all the NOS isoforms.
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The presence of haem appears to be mandatory, with BH4  and L-arginine acting to 
promote dimer formation and stabilisation (Klatt et al., 1995, 1996).
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Figure 1.1: Domain structure of the three main NOS isoforms.
(adaptedfrom Alderton et al., 2001). All three NOS isoforms exist as a homodimer, each 
monomer consisting of two major domains: an N-terminal oxygenase domain and a C- 
terminal reductase domain, with an interlinker domain between the oxygenase and reductase 
domain which contains a CaM-binding sequence. The autoinhibitory loop present in the 
middle o f  the FMN binding domains o f  nNOS and eNOS regulates the Co2 dependence 
of eNOS and nNOS, which is absent in the iNOS isoform.
The crystal structure of the of iNOS (Crane et a l, 1997, 1998; Fischmann et 
al., 1999; Li et al., 1999a) and eNOS (Raman et al., 1998) oxygenase domains have 
recently been elucidated, and reveal a structure considerably different from other 
haem-based oxygenases such as cytochrome P450s, peroxidases, and catalases. The 
NOS oxygenase domain is an elongated structure with a novel single-domain a-P fold 
that the authors describe as resembling “a baseball catcher’s mitF with the haem 
clasped in the webbed p-sheet palm of the mitt (Crane et al., 1997). The NOS distal 
haem pocket differs from other haem-binding proteins as it is predominantly 
constructed from p structures, as opposed to a-helical.
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Another notable feature of the oxygenase domain is the presence of a zinc ion 
tetrahedrally co-ordinated to two pairs of symmetry-related cysteine residues at the 
dimer interface (Raman et al, 1998). The zinc ion appears to play a role in dimer 
stability, as there is a net gain of eight hydrogen bonds when comparing the zinc-free 
and zinc-bound forms of human iNOS (Li et al., 1999a), however the zinc ion does 
not appear to affect enzyme activity (Hemmens et al., 2000). Comparison of the 
oxygenase domains of iNOS and eNOS reveal them to be very similar in molecular 
shape, relative orientation of co-factors, and have stereochemistry within their 
catalytic centres (Fischmann et al., 1999). To date there is no published crystal 
structure for the oxygenase domain of nNOS.
The N-terminal region varies between NOS isoforms, and confers the unique 
properties of each isoform. The N-terminal region of nNOS contains a PDZ domain 
which allows its interaction with several other proteins including the NMDA receptor, 
to which it is directly coupled via an intermediary adaptor protein, post synaptic 
density (PSD-95; Brenman et al., 1996a). This interaction directs nNOS to sites of 
signal transduction. The N-terminus of eNOS contains consensus sequences for N- 
myristoylation and cysteine palmitoylation, which allows its association with
^  I
membranes, hence localising the enzyme to sites of Ca entry (Busconi & Michel, 
1993, Liu et al., 1995). In contrast, iNOS lacks these N-terminal consensus sequences 
and is therefore a cytosolic enzyme, usually found in glial cells, macrophages and 
neurones following damage and infection.
1.2.2 Catalytic mechanism
The biosynthesis of NO by NOS involves a two-step oxidation of L-arginine to L- 
citrulline, with the concomitant production of NO (figure 1.2). Arginine is derived 
primarily from dietary sources, but can also be synthesised in the kidney. The 
conversion of L-arginine to NO occurs at a catalytic site within the oxygenase domain 
which binds L-arginine in such an orientation so that the guanidine group of L- 
arginine is adjacent to the ferric iron of the haem prosthetic group.
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Figure 1.2: Catalytic mechanism for the two-step biosynthesis o f NO.
Both steps in the biosynthesis of NO require the transfer of NADPH-derived 
electrons from the reductase domain to the haem group. Electrons provided by 
NADPH are transported through the reductase domain via FAD and FMN (Adak et 
al, 1999), and are ultimately passed to the haem prosthetic group. Recent studies 
indicate that the electron transfer pathway between the domains is from the FMN in 
the reductase domain of one monomer to the haem bound in the oxygenase domain of 
the partner monomer (Siddhanta et al., 1998). BH4  has also been suggested to play a 
redox role in NOS catalysis, in which bound BHs+ donates one electron to haem, 
forming BH4 ' +, which is then returned to a reduced state by accepting an electron 
from a flavin in the reductase domain (Bee et al, 1998). The electron flow through 
the domains is summarised in figure 1.3.
Iron is initially reduced by the transfer of an electron from NADPH, which 
allows the haem iron to bind molecular oxygen, resulting in its cleavage. One oxygen 
atom is released as water, and the other is incorporated onto one of the terminal 
guanidine nitrogens of arginine to yield the intermediate N-hydroxyl-L-arginine. 
Subsequent activation of a further molecule of oxygen facilitates the subsequent 
oxidation of N-hydroxyl-L-arginine to produce water, NO, and L-citrulline.
+ 9
1. General Introduction
L-citrulllne +  NO
L-arginine
+ o ,
NADPH
Haem
FAD
BR
FMNFMN
BH
e ? FAD
Haem
NADPH
L-arginine
+ o ,
L-citrulline +  NO
NADPH
NADP‘t
FADH
FADH,
FMNK
FMNH
Fe3+
Fe2+
Figure 1.3: Electron flow within the NOS dimer.
(a) Schematic representation of the flow of electrons through the NOS homodimer 
(b) Schematic representation of the electron transfer chain 
(Adaptedfrom Alderton et al, 2001).
1.2.3 Regulation of nitric oxide synthase
The binding of CaM is essential for NOS activity, and functions as a sensor of 
intracellular Ca2+ concentrations. CaM acts to induce a conformational change 
between the reductase and oxygenase domains in the dimer that regulates the electron 
transfer both within the reductase domain and the interdomain transfer of electrons 
between FMN and the haem prosthetic group (Panda et al., 2001). For constitutive 
NOS isoforms, elevation of Ca2+ levels promotes the binding of CaM to NOS, 
whereas iNOS is unusual in that it binds CaM tightly even at low Ca2+ concentrations 
(Matsuda & Iyanagi, 1999). This has the effect of holding iNOS in an activated state 
that is largely independent of calcium, although a 2 -fold increase in its activity is 
observed in the presence of 2.5 mM Ca2+ compared to that in 10 mM EGTA (Venema
H-------------------------------------------------------------------------------------------------------  10
1. General Introduction
-H----------------------------------------------------------------------------------------------------------------------------------------------------------
et al, 1996). The dependence of nNOS and eNOS on Ca2+ is due to an autoinhibitory 
loop present in the middle of the FMN binding domains of nNOS and eNOS which is 
not present in iNOS (Salerno et al, 1997). This insert acts to destabilise CaM binding
 ^I
at low Ca concentrations by inhibiting the transfer of electrons from FMN to haem 
in the absence of Ca2+/CaM (Nishida & Ortez de Montellano, 1999; Daff et al, 1999).
Apart from the regulation of NOS by Ca2 +/CaM, nNOS and iNOS appear to be 
relatively free of further regulatory controls. In contrast, eNOS is by far more 
complicated in terms of both regulation and subcellular targeting, being regulated by 
multiple mechanisms involving both protein-protein interactions with several different 
proteins, post-translational modifications (such as N-myristoylation and cysteine 
palmitoylation), and multi-site phosphorylation. One protein to which eNOS is known 
to associate is caveolin-1 , an integral membrane protein that serves as a structural 
scaffold within caveole. The interaction of eNOS with caveolin-1 is inhibitory:
' y i
Ca /CaM weakens the eNOS-caveolin-1 interaction, and therefore the enzyme is 
activated by the combined loss of the caveolin interaction and the direct effect of 
Ca2+/CaM on the enzyme itself (Ju et al, 1997; Michel et al, 1997a,b).
Phosphorylation is considered to be one of the most important mechanisms by 
which eNOS is regulated, and occurs at multiple sites on the enzyme. The two most 
extensively studied phosphorylation sites on eNOS have been the activation site, 
human Ser 1177 (bovine Ser 1179) in the enzyme’s C-terminal tail, and an inhibitory 
site, human Thr 495 (bovine Thr 497) located in the CaM-binding site sequence. 
Phosphorylation at Ser 1179 reduces the enzymes Ca2+-dependence (Chen et al,
1999), increases the rate of electron flux from the reductase domain to the oxygenase 
domain (McCabe, 2000), and increases the rate of NO production (Fulton et al, 1999, 
Dimmeler et al, 1999, Gallis et al, 1999). In contrast, phosphorylation at Thr 497 
decreases eNOS activity by increasing Ca /CaM dependence (Chen et al, 1999, 
Michell et al, 2001, Fleming et al, 2001).
Physiologically, the phosphorylation and dephosphorylation of these sites 
occurs in a highly co-ordinated manner. For example, application of bradykinin (a 
well-characterised activator of eNOS) to endothelial cells results in a transient 
dephosphorylation of the inhibitory site Thr 497, which is accompanied by 
phosphorylation of Ser 1179 (Fleming et al, 2001, Harris et al, 2001). Various 
studies propose a signal transduction pathway in which activation of 
phosphatidylinositol
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3-kinase (PI3-K) and serine/threonine protein kinase Akt leads to the phosphorylation 
of eNOS (Igarashi and Michel, 2000). Akt has been found to activate the enzyme 
directly via phosphorylation of the Ser 1179 residue, whereas the mutant eNOS 
(S1179A) is resistant to phosphorylation and activation by Akt (Fulton et al., 1999, 
Dimmeler et al., 1999, Chen et al, 1999). Ser 1179 is also the target of multiple 
protein kinases in addition to Akt, including protein kinase C (PKC), protein kinase A 
(PKA), cGMP-dependent protein kinase (cGK), and CaM II protein kinase (CaM-KII; 
Feron et al, 1999; Butt et al, 2000; Fleming et al, 2001).
Other sites of phosphorylation of eNOS have also been reported, including Ser 
116 in response to sheer stress (Gallis et al, 1999), Ser 635 as a target of PKA and 
cGK in vitro (Butt et al, 2000), and more recently Ser 617 in response to Akt and 
PKA (Michell et al, 2002). Mimicking phosphorylation at Ser 635 (S635Asp) 
induces ~ 2 -fold increase in activity of the purified protein, whereas mimicking
phosphorylation at Ser 617 does not alter maximal activity but significantly increases
2+
Ca /CaM sensitivity (Michell et al, 2002). Figure 1.4 summarises the various 
phosphorylation sites and signal transduction pathways by which eNOS is regulated.
Wortmannin
LY294002±
 ► (PI3J 9
K T5720— 1 ^ ^
Phosphorylation
S635
S116- CaM S1179
eNOS S617
Figure 1.4: Phosphorylation pathways associated with eNOS. eNOS contains multiple 
phosphorylation sites, the phosphorylation and dephosphorylation of which occurs in a highly 
co-ordinated manner. Pharmacological inhibition ofPB-K by wortmannin and LY294002;
inhibition of PKA by KT5720.
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Phosphorylation has not been as extensively studied with either of the two 
alternative NOS isoforms, although there is evidence that nNOS may also be 
regulated by phosphorylation (Brune & Lapetina, 1991; Nakane et al., 1991; Bredt et 
al, 1992; Dinerman et al., 1994b): CaM-kinase II (CaM-KII) has been found to 
induce phosphorylation of the Ser 847 residue, resulting in a reduction of nNOS 
activity which is thought to be partially due to the suppression of CaM binding 
(Hayashi et al., 1999; Komeima et al., 2000, 2001). More recently, the 
phosphorylation of Ser 741 has also been reported via CaM-KI (Song et al, 2004), 
which again culminates in the inhibition of nNOS activity.
1.2.4 Pharmacological inhibition of nitric oxide synthase
Despite the importance of NO in many physiological processes, overproduction of 
NO can be detrimental, and has been implicated in a number of pathological 
conditions. Inappropriate activation of nNOS has been implicated in chronic visceral 
pain, migraine headaches, seizures, post-ischaemic stoke damage, long-term 
depression, as well as in various neurodegenerative diseases (such as Alzheimer’s 
disease, Parkinson’s disease, Schizophrenia, and AIDS dementia). Excess NO 
production resulting from sustained overexpression of iNOS has been also been 
implicated in septic shock, various autoimmune disorders (such as multiple sclerosis 
and rheumatoid arthritis), and tissue damage following inflammation. On account of 
the harmful effects created by excess NO, selective inhibition of the individual NOS 
isoforms will provide a useful pharmacological and therapeutic tool for both 
furthering the knowledge and understanding of the pathological mechanisms which 
underlie these conditions, and in the introduction of clinical therapies to treat such 
diseases.
Considerable effort has been directed at the development of selective
inhibitors for nNOS and iNOS but which spare the eNOS isoform as its activity is
essential for the maintenance of blood flow and pressure. However the design of
isoform-specific inhibitors presents a challenging problem, in that the crystal
structures reveal the active site residues for iNOS and eNOS to be nearly identical
(Fischmann et al, 1999; Li et al., 1999a). Many different strategies have been
developed in the search for isoform-specific NOS inhibitors, and can be divided into
compounds which focus on the cofactor-binding sites, and those which target the L-
arginine binding site. The inhibitors which target the cofactor-binding sites include 
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those which have actions on the haem binding site (such as 7-nitrindazole [7-NI] and 
trimethylphenylfluoroimidazole [TRIM]), those with actions on the BH4 binding site, 
or those with effects on the flavoproteins (such as diphenyleneiodonium) or CaM 
(such as trifluoperazine). Although some of these compounds display some specificity 
and potency, they do not appear to be promising therapeutic NOS inhibitors as they 
may also interfere with the enzymatic activities of other enzymes which utilize similar 
cofactors.
The group of NOS inhibitors which target the L-arginine binding site have 
been more successful in the identification of isoform-selective NOS inhibitors. This 
group can be further divided into competitive inhibitors and mechanism based 
inhibitors (MBIs), which in addition to being competitive inhibitors of L-arginine 
binding are recognised by NOS enzymes as false substrates and are thereby 
metabolised during catalysis to products that irreversibly inactivate NOS.
The first series of competitive inhibitors created were analogues of the 
substrate L-arginine, the most commonly used being N-nitro-L-arginine (L-NNA) and 
NG-nitro-L-arginine methyl ester (L-NAME). These compounds act as simple 
competitive inhibitors at the arginine binding site, have potencies in the low 
micromolar range (Alderton et al., 2001), and show essentially no selectivity between 
isoforms. Despite their lack of specificity, these initial L-arginine analogues have 
proved to be of great value in the investigation of the physiological roles of NO, as 
well as in the treatment of clinical conditions associated with sustained iNOS activity 
such as septic shock (Petros et al., 1991).
The first MBI to be identified that could function as an alternative substrate 
was N-methyl-L-arginine (L-NMMA), but again this compound did not possess a high 
degree of specificity between isoforms. The search for more selective inhibitors and 
L-arginine analogues revealed N-propyl-L-arginine (NPA) to be potent against the 
nNOS isoform (Zhang et al., 1997; Cooper et al., 2000), although this specificity has 
yet to be confirmed in vivo (Gowda et al., 2004).
Since the initial series of L-arginine analogues, there have been a number of 
different inhibitors created which exhibit varying degrees of specificity. One group of 
MBIs which has recently been developed takes advantage of the inhibitory activity 
conferred by an amidine group. Compounds which contain an amidine group have 
been found to exhibit more selectivity and increased potency when compared to many
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of the early compounds. Two promising compounds, a-fhioro-N-(3-(aminomethyl)- 
phenyl)-acetamidine [ARL-17477] and (+)cis-4-methyl-5-pentylpyrollidin-2-imine 
[1400W], have both been tested in intact tissue preparations, and share no structural 
homology with L-arginine or other amino acids although they are related to 
guanidine. ARL-17477 has been shown to exhibit at least a 100-fold selectivity for 
nNOS over eNOS and iNOS, whereas 1400W was found to be 5000-fold or 200-fold 
more selective for iNOS over eNOS or nNOS, respectively (Garvey et al, 1997). Non 
L-arginine-based amino acid structural analogues which contain an amidine group 
also show promise as potent NOS inhibitors. Despite the initial compounds such as L- 
N5-(l-iminoethyl)-omithine [L-NIO] showing little inhibition specificity between 
NOS isoforms, recently N5-(l-imino-3-butenyl)-L-omithine (L-VNIO; Babu & 
Griffith, 1998) has been developed which is the most potent and nNOS-selective 
inhibitor to date. Table 1.2 compares the structures of the different generations of 
NOS inhibitors which target the L-arginine binding site.
It is clear that there is still much work remaining in the elucidation of the 
structure and mechanism of action of all three NOS isoforms. As the complete crystal 
structure becomes clear, this will assuredly aid both the understanding of NOS action 
and the discovery of new potent isoform-specific NOS inhibitors.
+ 15
1. General Introduction
2
o*■>
is
N-nitro-L-arginine
(L-NNA)
N-nitro-L-arginine methyl ester 
(L-NAME)
JB
a
at
>
0ia.
E
NH,
H H 1 2
/ N .  .N . X  
° 2N Y  COOH
NH
NH,
H H 1 2
^ N . .N .  y v  Y  
0 2N Y  COOCH3
NH
o
u
s
3
ZL
O
N-methyl-L-arginine
(L-NMMA)
N-propyl-L-arginine
(NPA)
(M
B
Is
)
cae
«
at■
"5
k
3i
-J
NH H N ^ C O O H
X  ^  JL
HN N ^ ^ C O O H  
1 H
CH3
NH NH,
X  ^  I
HN N CO O H  
1 H
c h 3
V)Im
O
wat
3
I
L-l^-tl-im inoethyl^ornithine
(L-NIO)
^-(l-im ino^-butenyty-L-ornithine
(L-VNIO)
Ba
se
d 
In
hi
t 3
3
3
2*33
O
3
E
<
NH NH2
H X  n ^ ^ Y - q o o h  
3 H
NH NH2
2 H
Ep
E
a
Xi
"O
3
3
O
a-fluoro-N-(3-(aminomethyl)-phenyl)- 
acetamidine 
(ARL-17477)
cis-4-methyl-5-pentylpyrollidin-2-imine
(1400W)
atft
£
Eoat
TJat
22u
H
NH
at
3
3
*3
3
3
a
< y V ^
Table 1.2: Chemical structures of NOS inhibitors which target the L-arginine binding site. 
L-arginine analogues act as simple competitive inhibitors at the L-arginine binding site. In 
addition to being competitive inhibitors of L-arginine binding mechanism based inhibitors 
are recognised by NOS as false substrates, and thereby are irreversibly metabolised during 
catalysis to inactive products. The amidine group which conferred an inhibitory activity is
indicated in red.
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1.3 Interaction of glutamate and nitric oxide synthase in the CNS
L-glutamate is well known to be the principal excitatory neurotransmitter in the CNS. 
The first suggestion that L-glutamate may have the ability to play an excitatory role in 
neurotransmission was made by Hayashi in 1954 following his discovery that 
injection of the amino acid into either the ventricles or the carotid artery caused 
convulsions in dogs and monkeys (Hayashi, 1954). A few years later, in 1959, Curtis 
and colleagues went on to show that L-glutamate depolarised and excited individual 
spinal cord neurones in the cat (Curtis et al., 1959). Despite these initial findings it 
was not for another 20 years that full acceptance of the transmitter role for L- 
glutamate was achieved.
Glutamate receptors are now known to be categorised into two distinct classes, 
ionotropic and metabotropic receptors. The ionotropic receptors contain cation- 
specific ion channels that can be further subdivided into three groups based on their 
affinity for different exogenous agonists: a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionate (AMPA), kainate and NMDA receptors. In contrast, the 
metabotropic receptors are coupled to GTP-binding proteins (G-proteins) and 
modulate the production of intracellular messengers. The current classification of 
glutamate receptors is summarised in figure 1.5.
Glutamate
Receptors
Ionotropic
(Ion channels)
Metabotropic
(G-protein linked)
NMDA
*  AMPA
Kainate
mGluRI
(PLC linked)
>  mGluRII
(AC linked)
- C
- C
- c
- c
NR1 (a-g) 
NR2 (A-D)
GluR 1-4
GluR 5-7 
KA 1,2
mGluRIII
(AC linked)
mGlul (a-d) 
mGlu5 (a,b)
mGlu2
mGlu3
mGlu4 (a,b) 
mGlu6 
mGlu7 (a,b) 
mGlu8 (a,b)
Figure 1.5: Schematic representation of glutamate receptor subtypes, subunits and splice
variants (Adaptedfrom Watkins, 2000).
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Glutamate receptors are now appreciated to underlie the majority of excitatory 
neurotransmission in the CNS. Glutamate typically mediates fast (millisecond) 
synaptic transmission through AMPA and kainate receptors, and a slightly slower 
(tens of milliseconds) excitation through NMDA receptors. The latter glutamate 
receptor usually participates only under depolarising conditions, due to blockade of 
the ionic channel by magnesium ions at resting membrane potential. Glutamate can 
also act on postsynaptically located metabotropic receptors to generate a slow 
(seconds) form of synaptic excitation (Batchelor & Garthwaite, 1997). Of particular 
importance for NO production is the NMDA receptor, where its activation leads to a 
transient influx of Ca into the postsynaptic cell with the consequent activation of 
NOS (Garthwaite et al, 1988); a process inhibited by D-AP5.
The predominant NOS isoform responsible for synthesising NO in the CNS 
under normal conditions is nNOS (Huang et al, 1993). In 1996, the interesting 
observation was made that nNOS possesses an amino-terminal PDZ domain which 
interacts with PSD proteins such as PSD-95 and PSD-93 (Brenman et al, 1996a,b). 
Furthermore, the NMDA receptor NR2 subunit (and certain NR1 splice forms) also 
contains a Ser/Thr-X-Val-COOH motif (tSXV) that enables its interaction with PSD- 
95 (Komau et al, 1995). By facilitating the proximity of NMDA receptors to the
^  I
enzyme, the scaffolding protein directly exposes nNOS to the influx of Ca entering 
the postsynaptic cell following the activation of NMDA receptors (Brenman et al, 
1996a). The nNOS splice variants, p and y, both lack the PDZ domain and are 
therefore presumed to exist free in the cytoplasm, although their distribution generally 
follows that of nNOSa.
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1.4 Guanylyl cyclase, the endogenous receptor for nitric oxide
A unique property of NO that sets it apart from other signalling molecules is its ability 
to diffuse freely and rapidly across cellular membranes. This gives NO the 
opportunity to spread three-dimensionally and act on neighbouring cellular elements 
in a non-synaptic fashion, irrespective of anatomical connectivity. It is predicted that 
the physiological sphere of influence of a single point source of NO has a diameter of 
approximately 2 0 0  microns, corresponding to a volume of brain enclosing around 2  
million synapses (Wood & Garthwaite, 1994; Lancaster, 1997). However, despite NO 
being able to exert its influence on an extended area, NO is able to demonstrate 
relative selectivity of action due to the NO-receptor characteristics of the surrounding 
cells.
The only established physiological transduction pathway for NO involves the 
activation of guanylyl cyclase (GC). Given evidence that endogenously produced NO 
has effects independent of GC (Jacoby et al., 2001; Lev-Ram et al, 2002), it appears 
likely that other targets for NO exist which have not yet been identified. Guanylyl 
cyclases are a family of enzymes that catalyse the conversion of guanosine 5’- 
triphosphate (GTP) to the second messenger cGMP. Although cGMP-forming activity 
was first described to be present in mammalian tissues in 1969 (Hardman & 
Sutherland, 1969; Ishikawa et al., 1969; Schultz et al., 1969; White & Aurbach, 1969; 
Goldberg et al., 1969), it took until the mid-1970s to determine that there were two 
different isoforms of GC (Garbers & Gray, 1974; Kimura & Murad, 1974; Chrisman 
et al., 1975), which were consequently found to differ in their cellular location, 
structure and regulation (for review see Lucas et al., 2000).
The two isoforms of GC which have been characterised include a membrane- 
bound isoform known as particulate GC (pGC) which is activated by natriuretic 
peptides or heat stable enterotoxins, and a soluble (or cytosolic) isoform which is 
activated by endogenous NO. The latter isoform was initially designated soluble GC 
to distinguish the enzyme from its membrane-bound counterpart, however recently 
one form of soluble GC was found to associate with the cell membrane (Russwurm et 
al., 2 0 0 1 ) and therefore this isoform (whether in solution or membrane bound) will be 
referred to as NO-activated GC. The following section focuses solely on the NO- 
activated GC.
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1.4.1 Structure of guanylyl cyclase
NO-activated GC is a heterodimeric enzyme expressed in the cytoplasm of almost all 
mammalian cells and is composed of two different subunits, a and P, both of which 
are required for catalytic activity. Purification of the NO-activated GC was first 
achieved from rat and bovine lung (Koesling et al., 1988, 1990; Nakane et al, 1988, 
1990), leading to the subsequent cloning and sequencing of the ai and Pi subunits and 
were found to have molecular masses of 73 - 80 kDa and 70 kDa, respectively. The ai 
and Pi subunits represent the most abundant forms of a and p subunits and have been 
determined to be widely distributed throughout the brain, although interestingly they 
are not necessarily expressed in a 1:1 ratio. The physiological relevance of the 
differing expression levels however remains unclear.
Homology screening has revealed the existence of alternative a and p subunits 
which include an a 2  subunit of ~ 82 kDa, and a p2  subunit of ~ 76 kDa. The <X2 subunit 
was initially identified in human foetal brain (Harteneck et al, 1991), and more 
recently has been found at a protein level in the placenta and uterus (Russwurm et al, 
1998; Budworth et al, 1999). In situ hybridisation reveals ct2  mRNA to be widely 
expressed in the brain, with particular abundance in the cerebellum and the 
hippocampus (Gibb & Garthwaite, 2001). In contrast, mRNA of the P2 subunit has 
been identified in the rat kidney, with lower expression levels present in the liver 
(Yuen et al, 1990). The p2  subunit however has yet to be found at the protein level. 
Furthermore, a ffameshift has been found in the human gene of the P2  subunit that is 
seemingly incompatible with the occurrence of a p2  subunit on a protein level in 
humans (Behrends & Vehse, 2000), thereby questioning the physiological relevance 
of the P2 subunit. Two additional subunits have been cloned, (X3 and p3 (Giuili et al, 
1992), although these subunits have since been understood to represent human 
variants of the ai and pi subunits (Zabel et al, 1998). Various splice variants of each 
subunit exist, however their physiological relevance is also unclear.
The two major types of a and P subunits so far identified permits four different 
heterodimeric possibilities: aipi? aiP2 ; GI2 P1, (X2 P2 . To date only two of the isoforms have 
been shown to exist at the protein level in vivo. The aiPi heterodimer represents the 
most abundant enzyme which exhibits widespread tissue distribution. The 012P1 
heterodimer was originally identified in human placenta (Russwurm et al., 1998), but 
has since been found to also have a widespread distribution. Currently the highest
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Figure 1.6: Domain structure of NO-activated GC.
concentration of the ct2 pi isoform has been found in the brain, where it is present in a 
comparable amount to the aipi isoform (Mergia et al., 2003) and has been shown to 
associate with the synaptic scaffolding protein, PSD-95 (Russwurm et al., 2001). This 
isoform has been identified to be present at low levels in all other tissues tested so far.
The primary structure of each subunit of NO-activated GC can be divided up 
into three domains: a C-terminal catalytic domain, a dimerisation domain, and an N- 
terminal regulatory haem-binding domain (figure 1.6). The C-terminal catalytic 
domains are highly conserved among the subunits of NO-activated GC and show a 
high degree of homology to the respective regions of pGC and the adenylyl cyclases 
(AC). Analysis of N-terminally truncated mutants of NO-activated GC (which retain 
an intact dimerisation domain) reveal that the catalytic domains are sufficient for 
cGMP-forming activity, whereas NO stimulation requires the intact N-termini (Wedel 
et al., 1995). Although NO-activated GC has not yet been crystallised it can be 
assumed from the high degree of sequence homology that the catalytic domain
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resembles that of AC (Sunahara et al., 1998; Tucker et al, 1998) with a potential 
analogous binding site to that identified for the activator of AC, forskolin (see chapter 
4 for details on enhancers of NO-activated GC).
The N-terminal regions of NO-activated GC are responsible for the binding 
and co-ordination of the haem prosthetic group. Each heterodimer binds a single haem 
moiety, the presence of which is essential for NO-induced enzyme activity as removal 
of this haem group abolishes NO-induced activity, which can be reversed after 
reconstitution with haem (Ignarro et al, 1986, Foerster et al, 1996). The electronic 
absorption spectrum for NO-activated GC, with an absorbance peak at 430 nm, is 
characteristic of a five-coordinated ferrous haem iron with a histidine at the fifth co­
ordinating position (Stone & Marietta, 1994). The histidine 105 residue of the pi 
subunit has been identified as the proximal haem ligand (Wedel et al, 1994; Zhao et 
al, 1998a), and mutation of this histidine residue generated an NO-insensitive, haem- 
depleted enzyme (Wedel et al, 1994). Additionally, two cysteine residues (Cys 78 
and Cys 214) adjacent to the histidine residue on the Pi subunit assist in the formation 
of the haem-binding pocket (Friebe et al, 1997).
In contrast, the function of the N-terminal region of the a subunit remains 
unclear. The N-terminal region of the a subunits share approximately only 30% 
homology, with the histidine 105 residue not being conserved in either subunit. One 
study indicated that the N-terminal portion of the a i subunit may be required for haem 
binding (Wedel et al, 1995), whereas a recent study claimed that deletion of the 259 
N-terminal amino acids of the ai subunit had no effect on the properties of the 
enzyme at all (Koglin & Behrends, 2003). Interestingly it should be noted that despite 
the differences in the primary structure of the two a subunits, extensive analysis of the 
purified aiPi and (X2 P1 isoforms did not reveal any functionally relevant differences 
with catalytic rates or sensitivity towards NO (Russwurm et al, 1998).
An important feature of NO-activated GC is that, unlike other haemoproteins 
such as myoglobin and haemoglobin, the haem environment virtually excludes the 
binding of O2 (Gerzer et al., 1981). The consequence of which is that in the aerobic 
environment of the cell, NO-activated GC activity is not influenced by competition 
between NO and O2 . Furthermore, in contrast to other haemoproteins, the reaction of 
NO and O2  resulting in the oxidation of the haem iron and the consequent formation 
of nitrate also will not occur, thereby allowing NO to freely associate and dissociate 
from the enzyme.
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1.4.2 Activation of guanylyl cyclase
Among the three redox forms of NO (NO , NO’, and NO4), only the uncharged NO
radical has been shown to significantly activate NO-activated GC (Dierks & Burstyn,
1996). Activation of the enzyme is initiated by NO binding to the haem prosthetic 
group, resulting in up to 200-fold activation of the enzyme (Stone & Marietta, 1994; 
Humbert et al, 1990).
Several different models exist to explain the activation of NO-activated GC by 
NO, the simplest involving a two-state model (figure 1.7): the binding of NO to the 
sixth coordinating position of the haem iron leads to the formation of a six- 
coordinated Fe2+-haem complex with an absorption maximum of 420 nm (Zhao et al., 
1998b). The subsequent breakage of the histidine-iron bond yields a five-coordinated 
nitrosyl-haem complex with an absorption maximum at 399 nm (Makino et al, 1999). 
The opening of the histidine-iron bond is believed to initiate a conformational change, 
presumably propagated to the enzyme’s active site, resulting in a several hundred-fold 
increase in cGMP formation. In support of this simple model is evidence that 
protoporphyrin IX activates NO-activated GC independently of NO (Ignarro et al., 
1982), and that the six-coordinated haem intermediate does not activate the enzyme 
which supports the idea that breakage of the histidine-iron bond is a prerequisite for 
enzyme activity (Zhao et al., 1998b).
Inactive Intermediate Active
431 nm 420 nm 399 nm
His
[Fe2
NO
NO
His
NO
Figure 1.7: Two-state model of NO-activated GC activation.
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Alternative models have also been suggested to explain the activation of NO- 
activated GC by NO. One model suggests that NO not only activates the enzyme by 
binding to the haem iron, but also regulates the velocity of activation via binding to a 
second non-haem binding site (Zhao et al, 1999). However, this model is under 
dispute as the data has since been reinterpreted in favour of the two-state simple 
model (Bellamy et al., 2002). A second alternative model has been suggested on the 
basis of comparison with microbial cytochrome c \  in that two molecules of NO bind 
to the haem-binding site (Sharma & Magde, 1999). Interestingly, a recent 
crystallographic study revealed that cytochrome c ’ binds NO on the proximal side of 
the haem-iron, rather than the distal side, a possibility that had never been observed or 
considered previously (Lawson et al, 2000). Furthermore, cytochrome c ’ has been 
found to form a transient six-coordinated species analogous to NO-activated GC 
(Zhao et al, 1999). The proposed mechanism based on these findings is that NO 
initially binds to the (cytochrome c ’ and NO-activated GC) haem iron in the distal 
position, and the subsequent displacement of the histidine and the distal NO by a 
second NO molecule, which forms a bond at the proximal side (Lawson et al, 2003). 
However the haem environment differs between these enzymes and therefore the 
physiological relevance to this comparison remains to be seen.
Generally the dissociation of NO from the haem group is considered to trigger 
deactivation of NO-activated GC. Initial studies carried out on purified enzyme from 
bovine lung indicate that NO dissociates slowly, the half life being at least two 
minutes (Kharitonov et al., 1997a). More recent studies however report the half life of 
NO dissociation to be between 0.2 s and 18 s (Kharitonov et al, 1997b; Russwurm & 
Koesling, 2002; Margulis & Sitaramayya, 2000; Bellamy & Garthwaite, 2001). In 
addition to deactivation, NO-activated GC is also known to undergo rapid 
desensitisation within its natural physiological environment (Bellamy et al, 2000) 
although the mechanism of desensitisation is not completely understood.
1.4.3 Catalytic mechanism
The conversion of GTP to cGMP was elucidated to be an inversion of configuration at
the proximal phosphate of GTP (Senter et al, 1983; figure 1.8). This indicates the
catalytic mechanism to be a simple displacement reaction without the formation of a
covalently bound enzyme-substrate intermediate, a mechanism common to the related
ACs. A nucleophilic amino acid residue is required to accept a proton from the 
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hydroxyl group at position 5 of the ribose moiety of GTP, which allows the 
subsequent displacement of pyrophosphate and the formation of cGMP. The identity 
of this basic residue has not yet been determined, but it has been speculated that the 
histidine 105 residue (after bonding with the haem group) could provide the necessary 
base for catalysis (Sharma & Magda, 1999).
"Gua
HO
NO-sensitive GC
PPiO
o - p
‘Gua
HO
BH
NO-sensitive GC
catalytic site catalytic site
Figure 1.8: Proposed mechanism for catalysis of cGMP from GTP.
Nucleophilic residue designated B.
(Adaptedfrom Senter et al., 1983)
1,4.4 Pharm acological inhibition o f guanylyl cyclase
Several compounds have been developed to inhibit NO-activated GC. Early drugs 
such as methylene blue and LY83583 exhibit poor selectivity, and have been shown 
to interfere with NO synthesis (Mayer et al, 1993a) and affect nucleotide-gated ion 
channels (Leinders-Zufall & Zufall, 1995a). The quinoxalin derivative, 1-H-[1,2,4]- 
oxadiazolo-[4,3-a]-quinoxalin-l-one (ODQ) was characterised in 1995 and found to 
be a potent and selective inhibitor of NO-activated GC in brain slices (Garthwaite et 
al, 1995b). Studies on purified NO-activated GC reveal that ODQ competes with NO 
in a competitive manner and irreversibly inhibits NO-stimulated activity, leaving 
basal enzymatic activity unchanged. Spectral analysis suggests that ODQ acts by slow 
reversible oxidation of the haem iron (Schrammel et al, 1996; Zhao et al, 2000).
A number of compounds have also been developed which sensitize NO- 
activated GC towards NO. These will be discussed in chapter 4.
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1.5 The cellular targets of cGMP
The cyclic nucleotide second messenger, cGMP, has been shown to regulate a wide 
variety of signal transduction pathways throughout the body. There are four well- 
established intracellular targets for cGMP: cGMP-regulated phosphodiesterases 
(PDEs), cGMP-dependent protein kinase (protein kinase G; PKG; cGK), cyclic 
nucleotide-gated (CNG) ion channels, and hyperpolarisation-activated cyclic 
nucleotide-regulated non-selective cation (HCN) channels.
1.5.1 Phosphodiesterases
The social use of PDE inhibitors, such as caffeine, dates back several millennia, 
although the first medicinal use was only reported by Henry Hyde Salter in 1860 
entitled “On asthma: Its pathology and treatment”. In this work, Salter recommends
the administration of “two breakfast cups o f strong co ffee  given on an empty
stomach” as a remedy that “in many cases is more efficacious than any other”. This 
dosing regime has been since realised to optimise absorption, achieve high peak 
serum levels, and specifically target the exaggerated diurnal variation in pulmonary 
function which is characteristic of asthma (Persson, 1985). However it was not until 
1957 that the mechanistic understanding of cyclic nucleotides and PDEs began to 
evolve. In that year, Sutherland and Rail (Sutherland & Rail, 1957, 1958) first 
described the properties of a cyclic adenine ribonucleotide (now known as cAMP), 
and inhibition of its hydrolysis by sodium fluoride and caffeine. Over the ensuing 
decades, the importance of cyclic nucleotide second messengers in cellular signalling 
came to be appreciated and considerable effort has been directed towards the 
elucidation of PDEs and the pharmacological regulation of this pathway by PDE 
inhibitors.
The biological effects of cGMP are dependent on its intracellular 
concentration which is determined by the balance between its rate of synthesis and its 
rate of breakdown. PDEs are a superfamily of enzymes which catalyse the hydrolysis 
of cyclic nucleotides to the inactive 5’-nucleoside monophosphate (i.e. cAMP to 5’- 
AMP; cGMP to 5’-GMP), and therefore are responsible for the regulation of 
intracellular concentration of cyclic nucleotides. To date, PDEs have been categorised 
into 11 different families (PDE1 - PDE11) based on their substrate specificity and 
characteristic regulation by inhibitors and activators (table 1.3).
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PDE
isoform
Splice
variants
Tissue distribution Characteristics
1 3 Heart, brain, lung, smooth muscle Ca5+/CaM dependent
2 1 Adrenal gland, heart, lung, liver, platelets cGMP-activated PDE
3 2 Heart, lung, liver, platelets, adipose tissue, immunocytes cGMP-inhibited PDE
4 4 Sertoli cells, kidney, brain, liver, lung, immunocytes cAMP-specific
5 1 Lung, platelets, smooth muscle cGMP-specific
6 3 Photoreceptors cGMP-specific
7 2 Skeletal muscle, heart, kidney, brain, pancreas, T lymphocytes cAMP-specific
8 2 Testes, eye, liver, skeletal muscle, heart, kidney, ovary, brain, T-lymphocytes
cAMP-selective 
IBMX insensitive
9 1 Kidney, liver, lung, brain cGMP-specific IBMX insensitive
10 1 Testes, brain cAMP-selective cAMP-inhibited cGMP PDE
11 1 Skeletal muscle, prostate, kidney, liver, pituitary and salivary glands, testes
Table 1.3: Classification of the PDE family
Additional heterogeneity within the PDE family is achieved through the 
presence of multiple splice variants which makes the total number of PDE isozymes 
currently recorded to exceed 30. Specific PDE isoforms display remarkably selective 
cellular and subcellular localisations (Bolger et al., 1997; Jin et al., 1998; Lobban et 
al., 1994), and are therefore likely to participate in discrete signal transduction 
pathways in discrete physiological and pathophysiological processes.
Almost all PDEs exist as homodimers, with monomer molecular weights 
ranging from 50 to 135 kDa. They are composed of two broad functional domains: a 
catalytic C-terminal domain, and a regulatory N-terminal domain. The C-terminal 
catalytic domains are highly homologous across families (> 50 % sequence identity at 
the amino acid level), whereas the N-terminal domain contains one or more regulatory 
segments which impart specific subtypes and isoforms their unique functional 
fingerprints.
PDE families 2, 5, 6 , 10, and 11 contain two non-catalytic allosteric sites in 
their N-terminal regions which were originally observed to bind cGMP (Charbonneau 
et al., 1990). These sequences were later named “GAF domains” to reflect the names 
of the first three classes of proteins in which they were identified: cGMP-regulated
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PDEs, the cyanobacterial Anabaena adenylate cyclase, and the E.coli transcription 
factor FhlA (Aravind & Ponting, 1997). A molecular model of cGMP binding to the 
GAF domain is displayed in figure 1.9.
GAF domains represent one of the largest and most widespread of all the small 
molecule binding domains found in proteins involved with cyclic nucleotide 
signalling. The ligands for most GAF domains have yet to be identified, however 
cGMP is the only known ligand to bind to the GAF domain in PDEs (PDE 2, 5, 6 , and 
10). Interestingly, PDE 11 exhibits a truncated GAF domain and neither cGMP nor 
cAMP binding to the domain has been reported to date. Crystallisation studies of the 
regulatory sequences have revealed that both the GAF-A and GAF-B domain are 
capable of cGMP-binding (cGMP binds to the GAF-B domain in mouse PDE2A, 
whilst cGMP binds to the GAF-A in bovine PDE5A), although what determines 
which domain binds cGMP is unclear. It is also currently not clear what the function 
is of the GAF domains which do not bind cGMP. In PDE2, the GAF-A domain may 
function as a dimer interface, although the role for the GAF-B domain in PDE5A is 
harder to predict.
+
Figure 1.9: Molecular model of cGMP binding to the GAF domain.
(Martinez et al., 2002)
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PDE2 is a homodimer consisting of two 100- 150 kDa subunits, and catalyses 
the hydrolysis of both cGMP and cAMP (with a higher affinity for cGMP). This 
family was initially identified in the liver, heart and adrenal gland, but it is now 
known to be widely distributed. As described above, cGMP has been found to bind to 
a regulatory GAF sequence on the enzyme resulting in an enhancement of the rate of 
hydrolysis of both cGMP and cAMP. PDE2 is therefore also known by the alternative 
name of “cGMP-activated PDE” (Juilfs et al, 1999). This modulatory effect by 
cGMP is an important mechanism by which cross-regulation may occur between 
cGMP and cAMP pathways.
PDE5 and PDE6  isoforms share a high degree of homology (45 -  48 % 
identity at the amino acid level) between catalytic domains, and are both highly 
selective for cGMP. PDE5 is a homodimer consisting of two 95 kDa subunits, and 
found abundantly in lung, platelet and smooth muscle. Binding of cGMP at the 
catalytic site of PDE5 stimulates cGMP to bind to the GAF-A domain, which in turn 
promotes the phosphorylation of the serine 93 residue by PKA or cGK (Thomas et al., 
1990; Turko et al, 1998). It has been suggested recently that phosphorylation induces 
a conformational change which increases the affinity of the GAF-A domain for cGMP 
by ~ 10-fold (Francis et al., 2002), and consequently increases the catalytic activity of 
the enzyme by ~ 2-fold (Corbin et al., 2000). This mechanism represents a negative 
feed forward regulatory pathway by which increased cGMP levels accelerate cGMP 
degradation. This PDE isoform is the target of the selective drug Viagra (sildenafil 
citrate; Turko et al., 1999), which interestingly boosts its own effectiveness by 
increasing its affinity once bound to the enzyme (Corbin et al., 2002).
PDE6  is a key phototransduction enzyme which exists as a membrane-bound
heterodimer in rod and cone photoreceptors, and is composed of two large
catalytically active subunits (a and (3 in rods; two a ’ in cones) associated with two
identical smaller inhibitory subunits (y) and a regulatory 8  subunit. In the dark, PDE6
activity is blocked by the presence of two inhibitory Py subunits. Recently it has been
demonstrated that cGMP binds to the GAF-A domain of PDE6  and enhances the
affinity between Py and the catalytic subunits, and reciprocally Py-binding enhances
cGMP-binding to the GAF-A domain (Muradov et al., 2004). Upon light stimulation,
the enzyme is activated by GTP-bound transducin-a, which displaces Py from the
catalytic core. cGMP hydrolysis results phototransduction by the closure of cGMP-
gated channels and the consequent hyperpolarisation of the photoreceptor cell (Beavo, 
H------------------------------------------------------------------------------------------------------  29
1. General Introduction
H---------------------------------------------------------------------------------------------------------------------------
1988). Most PDE5 inhibitors, including Viagra, inhibit PDE6  with similar potency 
due to the high homology between their catalytic domains.
PDE10 and PDE11 have only been recently described (Fujishige et al, 1999a; 
Loughney et al, 1999; Fawcett et al, 2000; Soderling & Beavo, 2000), and have the 
capacity to hydrolyse both cGMP and cAMP. PDE 10 binds cAMP with higher 
affinity than cGMP, although the enzyme hydrolyses cAMP five-fold less effectively 
than cGMP. In vitro analysis has revealed that cGMP hydrolysis is potently inhibited 
by cAMP, and it therefore been suggested that PDE 10 may function as a cAMP- 
inhibited cGMP PDE in vivo (Fujishige et al, 1999b). Preliminary studies indicate 
PDE 10 contains a low-affinity cGMP-binding GAF domain, and in vitro binding 
studies indicate that the dissociation constant (Kd) for cGMP binding to the GAF 
domain is well above 9 pM (Soderling et al, 1999). As in vivo cGMP concentrations 
are unlikely to reach such levels, it appears likely that either the affinity of PDE 10 for 
cGMP is increased by some regulatory mechanism, or that the primary function of the 
GAF domain in PDE 10 may be for something other than for cGMP-binding. PDE 10 
expression appears to be limited to the striatum and testes (Fujishige et al, 1999b).
PDE11 also belongs to the GAF-containing PDEs although it has the unique 
structural feature of containing a truncated GAF domain in many of its splice variants. 
Preliminary studies indicate that neither cAMP nor cGMP act as allosteric effectors of 
this enzyme (Fawcett et al, 2000). PDE11 is expressed at high levels in the prostate 
and skeletal muscle, but has also been identified in the kidney, liver, testes, and in the 
pituitary and salivary glands.
PDE1 is another dual-substrate PDE and is one of the key enzymes involved in
 ^I
the complex interactions between the cyclic nucleotides and Ca -second messenger
systems. The PDE1A and PDE IB isoforms hydrolyse cGMP more effectively than
cAMP, whereas the PDE 1C isoform hydrolyses cGMP and cAMP with equal
efficiency (Beavo, 1995). Competitive inhibition of cGMP hydrolysis can be achieved
via an elevation in cAMP levels, and vice versa. PDE1 is activated by the binding of
CaM in the presence of Ca2+, resulting in an increase in cyclic nucleotide hydrolysis.
Enzyme activity is additionally regulated by phosphorylation, which is accompanied
by an increase the binding affinity for CaM, effectively reducing the sensitivity of
PDE1 to Ca2+ (Hashimoto et al, 1989; Sharma & Wang, 1986). The role of this
isoform is of particular interest in the NO-cGMP pathway due to its activation by
Ca2+/CaM (Kakkar et al, 1999). It has been hypothesised that elevation in 
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intracellular Ca2+ levels simultaneously activates nNOS and PDE1 (Baltrons et al,
1997), thereby accumulation of cGMP in stimulated cells are inhibited whilst
*y j
neighbouring cells containing low cytosolic Ca levels are free to respond (Mayer et 
al, 1993b). PDE1 exhibits widespread distribution.
PDE3 can be distinguished from other PDEs by their high affinity for both 
cAMP and cGMP, and is often referred to as the cGMP-inhibited isoform. In contrast 
to PDE2, inhibition of the enzyme by cGMP is not achieved by cGMP binding to a 
non-catalytic site. Instead, cGMP is hydrolysed ten-times less effectively than cAMP 
and therefore when cGMP is bound to the catalytic site it acts as a competitive 
antagonist to cAMP degradation (Degerman et al, 1997). PDE3 has been 
demonstrated to be activated two-fold by phosphorylation by either PKA or PI3-K 
(Manganiello & Degerman, 1999). Similar to other PDE isoforms, the N-terminal 
region also confers regulatory properties on the enzyme. Residues in the N-terminal 
region have been demonstrated to be important for membrane association (Shakur et 
al, 2000) and are phosphorylated in response to insulin (Kitamura et al, 1999). 
Therefore subcellular localisation could influence the specificity of protein kinase 
interactions with PDE3.
PDE9 reveals the highest affinity for cGMP so far recorded for any PDE 
isoform (Km = 0.07 pM; Soderling et al, 1998a), and is selective over cAMP by 
several hundred-fold (Soderling et al, 1998a; Fisher et al, 1998a). This high affinity 
for cGMP results in the cells that express PDE9 maintaining very low basal levels of 
cGMP, and therefore potentially is very important in cGMP signalling. PDE9 
expresses wide tissue distribution and is widely expressed throughout the brain. The 
pattern of enzyme expression within the brain has been found to closely resemble that 
of NO-activated GC, suggesting a possible functional association or coupling of these 
two enzymes in the regulation of cGMP levels (Andreeva et al, 2001). Interestingly, 
PDE9 is not effectively inhibited by the non-selective PDE inhibitor IBMX.
PDE4, PDE7, and PDE8  are all termed “cAMP-specific PDEs” and therefore 
these PDE families are not thought to play a role in cGMP signalling. PDE4 has been 
demonstrated in a number of vascular smooth muscle tissues, and has recently been 
discovered to play a critical role in cell homeostasis (Jin et al, 1999). PDE7 and 
PDE8  appear primarily to be expressed at high levels in discrete cell types. PDE7 is 
expressed in lymphocytes and is involved in the regulation of cAMP-mediated 
immunosuppressive responses (Bloom & Beavo, 1996; Li et al, 1999b), whereas
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PDE8  is expressed at high levels in the testis, but is also present at lower levels in 
other tissues such as the liver, heart and ovaries (Soderling et al., 1998b; Fisher et al, 
1998b). Like PDE9, PDE8  has been demonstrated to be unaffected by the PDE 
inhibitor IBMX. (Hayahashi et al., 1998)
1.5.2 cGMP-stimulated protein kinases
The cGKs have emerged as important signal transduction mediators of the effects of 
certain hormones, inter/intracellular signals, toxins and drugs (Lohmann et al., 1997). 
The first protein kinase to be selectively activated by cGMP was reported in lobster 
tail muscle extracts (Kuo & Greengard, 1970), but other similar kinases have 
subsequently been observed in a number of different tissues which will be described 
below.
There are two distinct forms of cGMP-dependent protein kinases: type I 
(cGKI) of which there are two splice variants, cGKIa and cGKip, and type II (cGKII). 
Recent investigations also reveal the presence of a splice variant of cGKJI which 
appears to lack intrinsic protein kinase activity, instead functioning as an endogenous 
inhibitor of cGKI and cGKII (Gambaryan et al, 2002). cGKI is a cytosolic 76 kDa 
homodimer widely expressed in mammalian tissues, with especially high levels in the 
cerebellum, platelets and in smooth muscle (Lohmann et al, 1997). The two splice 
variants of cGKI differ only in their N-terminal domain, and confers different binding 
affinities for cGMP. cGKIa contains a high and a low affinity binding site for cGMP 
which display positive co-operative behaviour, whereas cGKip has two cGMP 
binding sites characterised by lower affinity and co-operability (Pfeifer et al, 1999). 
In contrast, cGKII exists as an 8 6  kDa membrane-bound homodimer which is absent 
from the cardiovascular system but can be abundantly detected in the brain and 
intestine, with lower levels in lung, bone and kidney (Lohmann et al., 1997). cGKII 
differs from cGKI primarily in the N-terminal region which confers subcellular 
localisation and substrate selectivity. Furthermore, cGKI and cGKII appear to be 
expressed in different cell types, with the exception of the growth plate in the tibia of 
newborn mice (Pfeifer et al., 1996).
Each isoform of cGK exists as a dimer comprised of two identical monomers. 
Each monomer is composed of three functional domains: an N-terminal domain, a 
regulatory cyclic-nucleotide binding domain, and a C-terminal catalytic domain
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(Lucas et al, 2000). The N-terminal region contains four regulatory sites which 
include:
(a) Dimerisation site containing an a-helix with a conserved leucine/isoleucine 
heptad repeat, or “leucine zipper”.
(b) Autoinhibitory site responsible for the inhibition of kinase activity in the 
absence of cGMP.
(c) Autophosphorylation site which increases the basal catalytic activity of the 
enzyme in the presence of cGMP.
(d) Intracellular localisation site including a myristoylation site in cGKII which 
determines its membrane association, and an acetylation site in cGKI.
The regulatory domain contains two homologous cyclic nucleotide-binding sites 
arranged in tandem that allow for full activation of the enzyme after the binding of 
two cGMP molecules, and a catalytic site which contains binding sites for
I
Mg /adenine triphosphate (ATP) and the target protein. When cGK is inactive, the 
regulatory and catalytic sites are covalently fused. Binding of two molecules of cGMP 
induces a conformational “elongation” in the enzyme that appears to distance the 
autoinhibitory region from the catalytic domain, resulting in the consequent activation 
of cGK (Wall et al., 2003b). Additionally, activation can be achieved by 
autophosphorylation in the autoinhibitory domain.
The catalytic action of cGK is through the transfer of a y-phosphate from a 
molecule of ATP to a serine or threonine residue on the target protein although the 
physiological substrates for cGKI and cGKII remain unclear. Probably the best 
characterised substrate for cGKI is the phosphatase inhibitor known as G-substrate, 
located primarily in cerebellar Purkinje cells (Endo et al, 1999). Other target proteins 
of phosphorylation include inositol 1,3,4-triphosphate (IP3) receptors which result in 
smooth muscle relaxation, vasodilator-stimulated protein (VASP) which results in 
platelet activation, and vimentin which results in neutrophil activation. DARPP-32, a 
phosphatase inhibitor sharing homology with G-substrate, has also been suggested as 
a target for cGKI (Tsou et al, 1993). To date, the only recognised target substrate for 
cGKII is the cystic fibrosis transmembrane conductance regulator (CFTR) chloride 
channel which plays an important role as a mediator of salt and fluid transport across 
numerous epithelial tissues (Vaandrager et al, 1998). Table 1.4 summarises the 
isoforms of cGK and their target substrates.
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Isoform
Chromosomal
location
Subcellular
localisation
Tissue
distribution Substrate Function
cGKIa 10 Cytoplasm • Smooth muscle 
• Lung 
• Platelets 
•Brain / neurons
• G-substrate
•IP*
•VASP
• Vimentin
• DARPP-32
• Septin 3 
• PDE5
• FHOD1
• Control of smooth 
muscle.
• Regulation of 
smooth muscle 
migration, proliferation 
& differentiation.
• Platelet aggregation.
cGKip 10 Cytoplasm
cGKII 4 Membrane
• Brain
• Intestine
• Lung
• Bone
• Kidney
•CFTR
• Increased Cl ‘ 
secretion 
•Control of intestinal 
secretion
• Inhibition of renin
release
• Promotion of bone
growth
Table 1.4: Distribution and physiological functions of cGK.
(Formin homology domain-containing protein (FHOD1)).
Insight into the physiological roles of the cGMP-dependent protein kinases has 
been gained from the analysis of transgenic mice deficient in either cGKI or cGKII. 
Homozygous deletion of the cGKI gene in mice abolishes the NO/cGMP dependent 
relaxation of vascular, visceral, and penile smooth muscle (Hedlund et al., 2000; Ny 
et al., 2000; Pfeifer et al., 1998), and results in severe vascular and intestinal 
dysfunction and death at an early age. In contrast, cGKII knockout mice exhibited a 
normal lifespan, although the mice did reveal decreased longnitudinal bone growth, 
decreased intestinal chloride secretion and altered renin secretion (Pfeifer et al, 1996; 
Vaandrager et al., 2000; Wagner et al., 1998).
cGK signalling is also known to play an important role in the nervous system. 
cGKI is highly expressed in the cerebellar Purkinje cells where they are closely 
associated with NOS-containing granule and basket cells, throughout all the cellular 
layers in the hippocampus (Kleppisch et al., 1999), and limited localisation elsewhere 
in the brain. Selective deletion of the cGKI gene results in impairment of long term 
potentiation (LTP) in the hippocampus, and reduced long term depression (LTD) in 
the cerebellum (Feil et al., 2003; Kleppisch et al., 2003). In contrast cGKII is widely 
distributed throughout the brain (de Vente et al, 2001), and many regions expressing 
cGKII also contain or receive innervation from NO positive neurons.
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1.5.3 Cyclic nucleotide gated ion channels
CNG channels are class of ion channels that are structurally related to voltage-gated 
ion channels, but have no apparent voltage sensitivity and additionally possess a 
cyclic nucleotide binding region. The first ion channels to be directly activated by 
cyclic nucleotides were discovered in the plasma membrane of retinal photoreceptors 
(Fesenko et al, 1985), and have since been shown to play an essential role in visual 
and olfactory sensory signal transduction where they change sensory information into 
membrane potential (Zufall et al., 1994; Finn et al., 1996). CNG channels exhibit 
widespread distribution within the CNS, although their presence has additionally been 
demonstrated in a variety of non-sensory tissues such as the heart, testes and kidney 
(Biel et al., 1996; Finn et al., 1996).
Functional CNG channels exist as tetramers composed of three principal a- 
subunits which have the ability to form active channels when expressed alone, and 
one P-subunit which is unable to form an active channel by itself but appears to act to 
modulate the channel properties of the a-subunits (Bradley et al, 1994; Liman & 
Buck, 1994; Zhong et al., 2002). Properties controlled by the P-subunit include single­
channel flickering, increased apparent affinity for cyclic nucleotides, and altered
^  I
interaction with Ca .T o  date, four distinct isoforms of the a-subunit have been 
cloned: CNGal from rod photoreceptors (Kaupp et al., 1989), CNGa2 from cone 
photoreceptors (Bonigk et al., 1993), and CNGa3 and a4 from olfactory neurons 
(Dhallan et al., 1990, Kaupp, 1995). Additionally, three genes encoding p-subunits 
have also been identified: CNGpia in rod photoreceptors (Korschen et al., 1995), 
CNGpib in olfactory neurons (Sautter et al., 1998) and CNGp3 in cone 
photoreceptors (Gerstner et al., 2000)
All CNG channel subunits share a common modular architecture which
includes a six transmembrane (6 TM) domain homologous to that of the voltage-gated
potassium channel family, consisting of six transmembrane segments (SI -  S6 ) with
an ion conducting pore between S5 and S6  (figure 1.10). Additionally, CNG channels
contain two interactive regulatory domains on the cytoplasmic side of the membrane
which represent the N- and C-termini. A cyclic nucleotide binding domain
homologous to that found in cGK is present on the C-terminus which consists of three
a-helices and an eight-stranded antiparallel p-roll (Zagotta & Siegelbaum, 1996; Biel
et al., 1999). Two unconventional CaM binding sites have also been identified, one in
each of the N- and C- termini of the P-subunit (Weitz et al, 1998; Grunwald et al., 
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1998). Zhong and colleagues have also recently identified a leucine zipper motif in 
the C-terminus of all a-subunits which appears to be involved in trimerisation of the 
a-subunits (Zhong et al., 2002). This zipper motif is lacking in p-subunits.
pore region
extracellular
intracellular
cGMP-binding site
Figure 1.10: Transmembrane topology of a CNG channel subunit and the 
composition of the cone CNG channel.
(http://www.fz-juelich.de/ibi/ibi-l/Achromatopsia)
CNG channels are directly and co-operatively activated by the binding of 
intracellular cGMP and cAMP to the cyclic nucleotide binding site located in the C- 
terminal domain (Fesenko et al., 1985; Nakamura & Gold, 1987), inducing a 
conformational change which culminates in the opening of an ion-conducting pore. 
Similar to cGK, the a-subunit is more sensitive to cGMP than cAMP (Zagotta & 
Siegelbaum, 1996), although the critical amino acids which confers this sensitivity 
differs between the two proteins. However, in contrast to most voltage-gated and
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ligand-gated ion channels, CNG channels do not exhibit desensitisation, and instead 
remain open continuously in the presence of cyclic nucleotides.
I ^ j
All CNG channels have the ability to conduct both Na and Ca ions, but the 
channels are more permeable to Ca2+ than to Na+ under physiological conditions 
(Frings et al, 1995). Within the CNS, CNG channels appear to represent a cGMP- 
dependent Ca2+-channel that has the ability to regulate neuronal synaptic efficacy by
modulating Ca levels in response to changes in cyclic nucleotide concentrations. In
• ^  | this way, the channels are able to trigger a variety of Ca -dependent processes.
Although CNG channels do not desensitize, their activity is indirectly modulated by
- j i
the interaction of Ca with the high affinity CaM binding sites identified on the p- 
subunit (Weitz et al., 1998; Grunwald et al., 1998). Ca2+-binding results in the 
reduction of cyclic nucleotide-binding affinity. The inhibitory action of Ca2+ has 
therefore led to the suggestion that the P-subunit is able to act as an internal regulator 
of CNG channel activity, and an increasing body of evidence suggests that these 
channels may serve as an important feedback mechanism in the regulation of Ca2+ 
influx into cells (Frings et al., 1995; Leinders-Zufal! et al., 1995b; Bradley et al,
1997).
Although the function of CNG channels within the CNS is not yet fully 
understood, the channels have been proposed play a role in a number of physiological
 ^t
processes which require Ca signalling, including axonal guidance and synaptic 
plasticity (Zufall et al, 1997; Barnstable et al., 2004). The spatial expression of CNG 
channels in mammalian CNS neurons reveals an interesting correlation to the 
elements of NO signal transduction pathways. Of particular relevance to the current 
work is the demonstration using in situ hybridisation and patch clamp recording 
techniques that CNG channels are present in the hippocampus. The channels were 
observed in the soma and proximal dendrites of pyramidal neurons, and in the granule 
cells of the dentate gyrus (Leinders-Zufall et al., 1995b; Kingston et al., 1996). This 
localisation places CNG channels in an ideal position to play a role in synaptic 
plasticity.
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1.5.4 HCN channels
HCN channels are a specific subfamily of CNG channels which represent a potential, 
but as of yet unconfirmed, target for NO/cGMP signalling. Activation of HCN 
channels occurs upon hyperpolarisation of the membrane and leads to the slow onset 
of an inward non-selective cation current (Ih), and consequent membrane 
depolarisation. Ih currents were first described in the rabbit cardiac sino-atrial node 
(Noma & Irisawa, 1976), and shortly thereafter a similar hyperpolarisation-activated 
cation current was discovered in the brain (Bader et al, 1979; Halliwell & Adams, 
1982). Ih exhibits pacemaker activity in some cell types (such as in sino-atrial node 
cells and in thalamocortical relay neurons), being activated by the membrane 
hyperpolarisation following an action potential and acting to depolarize the membrane 
towards the threshold for firing a subsequent action potential. Ih is also known to play 
a significant role in determining the resting membrane potential of neurons (Pape, 
1996; Robinson & Siegelbaum, 2003).
To date, four isoforms of HCN have been cloned in mammals (HCN1 - 
HCN4) which govern the kinetic and functional properties of the resultant channels. 
Consistent with CNG channels, all four HCN isoforms possess a structure similar to 
that of the voltage-gated potassium channel, and are highly conserved in their core 
transmembrane regions and cyclic nucleotide binding domains (80 -  90 % identical). 
Each subunit is composed of a 6 TM domain (SI -  S6 ), a positively charged voltage 
sensor on the S4 segment, a pore forming region between S5 and S6 , and cytosolic C- 
and N- termini. Additionally, the C-terminus contains a cyclic nucleotide-binding 
domain homologous to those found in cGKs and CNG channels.
Each HCN subunit however exhibits distinct, yet overlapping, patterns of
mRNA expression within the brain. HCN1 is expressed predominantly in cortical
structures, with high levels observed in the hippocampus, neocortex, and cerebellum,
whereas HCN3 and HCN4 are almost exclusively expressed in subcortical regions
mainly concentrated in the hypothalamus and thalamus, respectively (Notomi &
Shiemoto, 2004). In contrast, HCN2 is widely distributed throughout the brain, with
prominent expression in the hippocampus, thalamus and neocortex (Santoro et al,
1998; Ludwig et al, 1998). Furthermore, the HCN subtypes exhibit substantial
differences in their biophysical properties, namely in terms of their kinetics and cyclic
nucleotide sensitivity (Robinson & Siegelbaum, 2003). HCN1 homotetramers show
fast activation kinetics but low cyclic nucleotide sensitivity; HCN2 are slower, but 
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exhibit greater cyclic nucleotide sensitivity, whilst HCN4 have the slowest activation 
kinetics and are strongly regulated by cyclic nucleotides. HCN channels are believed 
to exist as tetramers, although the presence of homomeric HCN channels is 
insufficient to explain the properties of physiological Ih currents. Instead native 
channels are best described by a combination of properties of the homomeric 
channels. For example hippocampal pyramidal neurons co-express HCN1 and HCN2, 
and the Ih current in these neurons exhibit activation kinetics intermediate between 
those exhibited by HCN1 and HCN2 homomers (Ulens & Tytgat, 2001).
One striking feature of HCN channels is that their activity can be potentiated 
by the direct binding of cyclic nucleotides. HCN channel regulation by cAMP has 
been described in several neuronal systems, and has been implicated to play a role in a 
number of physiological functions, including LTP and the modulation of membrane 
conductance (Cuttle et al., 2001; Huang & Hsu, 2003). Recently, cGMP activation of 
HCN channels has also been demonstrated (Zagotta et al., 2003), making HCN 
channels a putative targets for cGMP signalling, although direct evidence for this is 
lacking. Exogenously applied cGMP increases Ih in nodose and trigeminal neurons 
(Ingram & Williams, 1996) and in the calyx of Held (Cuttle et al., 2001), whilst 
exogenous NO modulates Ih in thalamocortical relay neurons in a manner that is 
mimicked by the application of 8 -Br-cGMP (Pape & Mager, 1992). However, a 
physiological link between NO synthesis and subsequent cGMP-mediated effects on 
Ih has yet to be uncovered.
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1.6 Functions of nitric oxide in CNS physiology
Since its discovery as a signalling molecule within the CNS, NO has attracted a 
wealth of attention in an effort to understand its unorthodox role in CNS physiology. 
One of the most striking features of NO as a central messenger is that it does not 
mediate direct, classical neurotransmission -  that is, it does not mediate a signal from 
one side of a single synaptic cleft to another and evoke excitatory or inhibitory 
changes in membrane potential. Rather, within the CNS, NO tends to play an ancillary 
role, instead modulating the properties of neural cells where synaptic signalling is 
mediated by neurotransmitters such as glutamate and y-aminobutyric acid (GABA).
NO has been implicated in numerous physiological functions within the CNS, 
which appear to impinge on nearly every aspect of neural function and dysfunction 
(Garthwaite & Boulton, 1995a). Roles for NO have been ascribed in the visual system 
(Cudeiro & Rivadulla, 1999), central control of autonomic function (Paton et al., 
2002), monoaminergic projection systems (Kiss, 2000), neurotransmitter release 
(Prast & Philippu, 2001), Ca2+-signalling (Clementi & Meldolesi, 1997), synaptic 
plasticity (Holscher, 1997), development of the CNS (Moreno-Lopez et al., 2004), 
behaviour (Nelson et al., 1997), and in the regulation of blood flow (Mitchell & Tyml, 
1996). However, this is by no means exhaustive of all the biological roles of NO 
within the CNS, new ones of which are constantly being discovered. The following 
section focuses on three areas of NO research which are attracting a lot of interest: 
CNS development, acute neuronal modulation and synaptic plasticity.
1.6.1 NO and development of the CNS
NO has been implicated in three chronologically distinct steps in the development of 
the CNS: inhibition of proliferation and promotion of differentiation, the directionality 
of neurite growth, and the refinement of topographical projections.
Accumulating evidence suggests that NO physiologically regulates 
neurogenesis by negatively controlling the proliferation rate of undifferentiated 
precursors, and by facilitating the neuronal differentiation process. Proliferation of 
cultured immature cortical neurons was enhanced by both NOS inhibition and the 
application of the NO scavenger, haemoglobin, whilst application of exogenous NO 
had the reverse effect (Cheng et al., 2003). Furthermore, in several cell types there is 
evidence that endogenous NO produced in response to growth factors, such as nerve 
growth factor (NGF) and brain-derived neurotrophic factor (BDNF), may act as a 
H--------------------------------------------------------------------------------------------------------40
1. General Introduction
- i ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
permissive agent to restrict cell cycle progression and promote differentiation 
(Peunova & Enikolopov, 1995; Phung et al, 1999; Rialas et al, 2000; Moreno-Lopez 
et al, 2004). In this way it appears that NO acts in a paracrine fashion, being released 
from nearby differentiating neurons to stop neuronal precursors from proliferating and 
to induce a neuronal phenotype (Cheng et al, 2003). Exogenous NO has also been 
demonstrated in Drosophila to modulate the balance between cell proliferation and 
differentiation in developing imaginal discs, and in the embryo (Kuzin et al, 1996, 
2000; Wingrove & O’Farrell, 1999).
There are also several lines of evidence which indicate that NO may control 
neurogenesis in the vertebrate brain. NO is produced abundantly in the developing 
brain, and the spatiotemporal pattern of NOS expression is compatible with the 
possibility that NO is an anti-proliferative agent. In the developing rodent brain and 
spinal cord, transient increases in NOS expression correlate with the cessation of 
proliferation and the beginning of differentiation, and in the adult brain, NOS-positive 
neurons lie adjacent to, but not within, areas of adult neurogenesis (Packer et al, 
2003; Moreno-Lopez et al, 2000). Further evidence of NO as an anti-proliferative 
agent comes from mice lacking nNOS which exhibit an increased number of 
proliferating cells and a reduction in the complexity of neuronal dendrites (Inglis et 
al, 1998), and from eNOS knockout animals which demonstrate thicker arterial walls 
than their wild type siblings (Rudic et al, 1998). This indicates that NO derived from 
both eNOS and nNOS may contribute to the control of proliferation and 
differentiation in the CNS. The mechanism by which NO exerts these effects, 
however, remains unknown. No experiment appears to have directly tested the 
involvement of the NO-activated GC/cGMP pathway, however immunohistochemical 
studies detect only low levels of NO-activated GC and cGMP in neurons prior to 
differentiation, which opens up the possibility that an alternative signalling pathway 
may be involved (Amhold et al, 2002).
The proposed role for NO in controlling the direction of neurite outgrowth is
more uncertain. Studies reveal contradictory results; some demonstrate NO-induced
collapse and retraction of growth cones (Gallo et al, 2002; He et al, 2002), whereas
other groups find NO and cGMP to be attractants and act protectively against growth
cone collapse (Schmidt et al, 2002; Steinbach et al, 2002). These apparently
opposing results may be explained by the concentration of NO donors: studies
utilizing high non-physiological concentrations of NO tend to observe growth cone 
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collapse, whereas investigations using lower concentrations, or cGMP analogues, 
observe growth cone attraction and protection. Evidence therefore points to a role for 
NO in controlling neurite outgrowth, although the physiological relevance remains 
unclear as only one study to date has demonstrated that blockade of endogenous NO 
synthesis can block neurite outgrowth (Yamazaki et al., 2001).
A role for NO in the refinement of topographical projections in specific brain 
areas has also been suggested. The spatial and temporal expression of NOS in the 
chick and rodent tectum and colliculus during the period of refinement is consistent 
with a role in refinement (Campello-Costa et al., 2000; Wu et al., 2001), and blockade 
of NO synthesis has been demonstrated to prevent the refinement of retinotectal 
projections (Wu et al, 2001). Transgenic eNOS/nNOS double knockout mice reveal a 
more diffuse ipsilateral retinocollicular projection, which nevertheless becomes more 
refined with age (Wu et al., 2000). The organisation of the other sensory projections 
appears to be independent of NO and lack the gross changes in neuroanatomy and 
behaviour following chronic in vivo NOS inhibition (Contestabile, 2000).
1.6.2 NO and acute neuronal modulation
NO can influence neuronal function in an acute manner by altering membrane 
excitability and neurotransmitter release. The molecule has been implicated to play a 
role in the release of the majority of neurotransmitters including ACh (Okada et al,
2001), noradrenaline (Satoh et al., 1996), dopamine (Hanbauer et al., 1992), 
glutamate (Montague et al., 1994), GABA (Segovia et al., 1994), serotonin (Bogers et 
al, 1991) and ATP (Olearczyk et al., 2004). Additionally, in different brain regions 
the same receptor may be modulated by NO in different ways via different 
mechanisms, presumably due to the target proteins present in the specific area.
The ability of NO to inhibit neuronal activity has been demonstrated in a 
number of cell types. Exogenous NO decreases peak sodium currents in nodose 
ganglion neurones via the enhancement of the slow inactivation of voltage-dependent 
sodium channels (Bielefeldt et al., 1999), whilst spinally-projecting paraventricular 
nucleus (PVN) neurones respond to exogenous NO or increased NO synthesis by 
enhanced GABA release (Li et al, 2002). Furthermore, it has been recently 
determined that the subpopulation of PVN neurons in the hypothalamus which project 
to the rostral ventrolateral medulla are subject to a tonic inhibition by NO, and
+ 42
1. General Introduction
_l---------------------------------------------------------------------------------------------------------------------------
therefore increase their discharge rate upon inhibition of endogenous NO synthesis 
(S te rn a al., 2003).
NO has also been demonstrated to induce disinhibition via the reduction of 
GABAergie transmission. In the cerebellum, Golgi cells are subject to a tonic NO-
 ^I j
dependent hyperpolarisation, possibly via large conductance Ca -activated K 
channels, which results in a decreased rate of GABA release from these cells (Wall, 
2003a). The net effect of NO is thereby a decrease in GABAergie transmission and a 
subsequent disinhibition of downstream granule cell activity. A similar effect has also 
been reported to occur in posterior pituitary nerve terminals (Ahem et al., 1999) and 
in the rat hippocampus where inhibition was found to be partially through the 
NO/cGMP pathway, and partially via an NO-dependent, but cGMP-independent, 
pathway (Hada et al., 2003).
NO may also have a more direct effect on excitability leading to increased 
glutamate release (Hirsch et al., 1993; Montague et al., 1994; Huang et al., 2003), 
increased Na+ currents in striatal intemeurons, increased Ih in the thalamus (Pape & 
Mager, 1992) and increased tonic firing in Purkinje cells (Smith & Otis, 2003).
1.6.3 NO and synaptic plasticity
The function of NO that has been most extensively studied in the CNS is the 
molecule’s involvement in the activity-dependent changes in synaptic signal strength, 
commonly referred to as synaptic plasticity. The first reproducible example of 
synaptic plasticity was the long-term enhancement of synaptic signal strength (long 
term potentiation; LTP) in the rabbit hippocampus following brief periods of high 
frequency stimulation (HFS; Bliss & Lomo, 1973). This long-lasting activity- 
dependent increase in the efficacy of synaptic transmission has since been 
demonstrated in numerous brain regions (Garthwaite et al., 1995a), and can last for 
hours, days or even weeks. LTP has been best characterized in the hippocampus, 
where it is believed to be a cellular event involved in the acquisition and storage of 
information (Martin et al., 2000).
Hippocampal LTP is dependent on the post-synaptic activation of one class of 
glutamate receptor, the NMDA receptor. The NMDA receptor is unusual as it 
combines elements of ligand- and voltage-gated receptors -  it gates in response to
j
glutamate binding, but membrane depolarization is required in order to expel the Mg
ion which blocks the pore in the resting state. This means that the NMDA receptor 
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acts as a coincidence detector: only being activated when glutamate is released into 
the synaptic cleft and the postsynaptic membrane is depolarized. Following the
*yi
activation of the NMDA receptor, there is a subsequent entry of Ca into the post­
synaptic cell leading to a cascade of intracellular events culminating in the 
enhancement of synaptic strength (Madison & Malenka, 1991; Malenka, 1991; 
Chittajallu et al, 1998).
LTP is a field that comprises of many controversies. One question that has 
attracted a lot of interest is the relative importance of presynaptic and postsynaptic 
mechanisms for enhancing the efficacy of synaptic transmission in LTP. Postsynaptic 
changes include increased receptor density and/or increased sensitivity to 
neurotransmission (Edwards, 1995), whereas evidence for a presynaptic change came 
from the finding that there was an enhanced release of transmitters from presynaptic 
terminals during LTP induction (Dolphin et a l , 1982; Williams et al., 1989; Larkman 
et al., 1995). Given the well-established postsynaptic involvement of the NMDA 
receptor in LTP induction, it therefore followed that a presynaptic modification would 
require a retrograde signalling system from the postsynaptic terminal to the 
presynaptic cell. Several molecules were suggested as candidates for diffusible 
messengers including arachidonic acid (Williams et al., 1989), NO (Gaily et al., 
1990), carbon monoxide (Zhuo et al., 1993) and platelet-activating factor (Kato et al., 
1994). Amongst these candidates NO received the most attention, given that NO was 
synthesized in neurons following NMDA receptor activation and facilitated by the 
physical coupling of nNOS to the NMDA receptor. The first studies to implicate NO 
in the establishment of LTP appeared in 1991 (Bohme et al., 1991; Schuman & 
Madison, 1991), although investigations carried out over the subsequent decade have 
yielded very controversial results. Some studies demonstrated a complete block of 
LTP in the hippocampus following application of NOS inhibitors (Bohme et a l,  1991; 
O’Dell et al., 1991; Schuman & Madison, 1991; Bon et al, 1992; Doyle et al, 1996), 
other groups observed only a partial block of LTP (Holscher et al, 1999; Gribkoff & 
Lum-Ragan, 1992; Chetkovich et al., 1993; Haley et al., 1993; Iga et al, 1993; 
Musleh et al, 1993; Boulton et al, 1995), whilst others found no effect at all of NOS 
inhibitors (Williams et al, 1993a,b; Bannerman et al, 1994; Cummings et al, 1994,; 
Murphy et al, 1994). Alternative studies additionally utilized an NO scavenger, 
haemoglobin, which also prevented the induction of LTP (Bon et a l, 1992; Haley et 
al., 1992; Schuman & Madison, 1991).
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As research has progressed it has become clear that LTP can be established by 
multiple, independent, effector mechanisms, some of which are NO-dependent and 
some of which are NO-independent. It also appears the stimulation protocol utilised is 
of utmost importance in determining the pathway by which LTP established. For 
example HFS that is usually subthreshold for LTP can enhance synaptic responses 
when combined with exogenously applied NO (Bon et al., 1992), whilst stronger HFS 
is able to induce forms of LTP that are insensitive to NOS inhibitors (Chetkovich et 
al., 1993). Interestingly, there are also observations that exogenous NO is able to 
inhibit synaptic transmission but goes on to induce a rebound potentiation that 
occludes LTP (Bon & Garthwaite, 2001a). The NO-dependence of LTP has 
additionally been demonstrated to be affected by various experimental conditions 
such as temperature, animal age, or even different strains of rat (Williams et al., 
1993a, Holscher et al., 2002).
The reciprocal phenomenon to LTP is long term depression (LTD) of synaptic 
strength. LTD has been best characterised in the cerebellum, where it occurs 
following co-activation of parallel fibre and climbing fibre inputs to a Purkinje cell by 
a prolonged low frequency stimulation. LTD has been implicated in particular forms 
of motor learning such as adaptation of the vestibulo-ocular reflex (Nagao & Ito, 
1991; De Zeeuw et al., 1998). Experimental evidence has identified three common
4^-requirements for the induction of cerebellar LTD; influx of Ca through voltage- 
gated Ca channels, activation of the metabotropic glutamate receptor mGluRl, and 
activation of AMP A receptors (Linden et al., 1993).
The participation of NO in cerebellar LTD was first proposed in 1990 (Ito & 
Karachot, 1990; Crepel & Jaillard, 1990), although similar to LTP, its role has been a 
matter of controversy for many years. It has been demonstrated by a number of 
different groups that LTD can be blocked by NOS inhibition or application of 
haemoglobin (Crepel & Jaillard, 1990; Shibuki & Okada, 1991; Daniel et al., 1993), 
whereas application of exogenous NO or a cGMP analogue induces an LTD-like 
phenomena that partially occludes LTD (Shibuki & Okada, 1991; Daniel et al, 1993; 
Lev-Ram et al., 1995: but see Linden & Connor, 1992). The role of NO in LTD has 
been most thoroughly investigated in the cerebellum and striatum, where NO appears 
to be generated presynaptically, or in intemeurones, and has a postsynaptic action 
(Daniel et al., 1998, Casado et al., 2002, Centonze et al., 1999).
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The role of NO in both the LTP and LTD phenomena suggests that NO may 
be physiologically important in the regulation of metaplasticity within the brain, 
acting to fine tune synaptic responses to even subtle changes in external conditions.
1.7 N itric  ox id e  s ign a llin g  in th e  h ip p ocam p u s
The hippocampus is one of the most thoroughly studied regions of the mammalian 
CNS, named after its highly unusual and distinctive shape which resembles a seahorse 
(in Greek hippo means “horse” and kampos means “sea monster”; figure 1.11). The 
hippocampus is also sometimes referred to as the Ammon’s horn due to its 
resemblance to a ram’s horn (the Egyptian god, Ammon, had ram’s horns).
hippocampus
Figure 1.11 Nissl-stained transverse section through the rat brain.
The hippocampus can be observed below the cortex, with the dark layers containing stained
cell bodies.
The hippocampus is one of a group of structures within the limbic system typically 
referred to as the hippocampal formation. This structure can be divided into the 
dentate gyrus, the hippocampus, the subiculum, presubiculum and parasubiculum, and 
the entorhinal cortex. The dentate gyrus, hippocampus and subiculum have a single 
cell layer with less cellular or acellular layers located above and below it. The other 
parts of the hippocampal formation have several layers to them. The hippocampus and 
dentate gyrus are highly laminated structures, with both the neuronal cell bodies and 
zones of connectivity arranged in orderly layers, and therefore have been the target of 
many neuroanatomical and electrophysiological studies. The various regions of the 
hippocampal formation are illustrated in figure 1.12.
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The hippocampus is a region which has generated a lot of scientific interest 
over the years since it was recognised in the early 1950s to play a fundamental role in 
some forms of learning and memory. In a landmark paper by Scoville & Milner 
(1957), a patient known only by his initials, H.M., underwent bilateral hippocampal 
removal for treatment of intractable epilepsy. The result of the operation was 
alleviation of the epilepsy, however H.M. was additionally left with a permanent loss 
of the ability to form new long-term declarative memories.
Schaffer Collateral CA1 subiculum
CA3
Figure LI 2: Cajal illustration o f the various regions o f the hippocampal formation (1901).
Representative neurons and their respective projections are also shown.
1.7.1 Hippocampal anatomy
Dentate gyrus
The dentate gyrus consists of three layers: the principal (or granule) cell layer, the 
largely acellular molecular layer that is located above the granule cell layer, and the 
diffusely cellular polymorphic cell layer (or hilus) located below the granule cell 
layer. Granule cells are arranged 4 - 6  cells thick with dendrites extending 
perpendicularly into the molecular layer where they receive synaptic connections 
which will be discussed in 1.7.2. The axons of the granule cell are known as mossy 
fibres, and originate from the basal portion of the cell body extending into the 
polymorphic cell layer. The mossy fibres then synapse onto some of the neurons, such 
as mossy cells, in the polymorphic cell layer before coalescing into a bundle of fibres 
that enters the stratum lucidum of CA3. The polymorphic cells are of various types, 
but they only project to other regions of the dentate gyrus.
H---------------------------------------------------------------------------------------------------  47
Projection
entorhinal cortex
dentate gyrusMossy fibres
1. General Introduction
-4---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Hippocampus
The hippocampus also has a principle cell layer known as the pyramidal cell layer. 
Hippocampal pyramidal neurons are arranged 3 - 6  cells thick, with elaborate 
dendritic trees extending perpendicularly to the cell layer in both directions. The 
apical dendrites are longer than the basal dendrites, extending towards the centre of 
the hippocampus traversing three distinct regions: the stratum lucidum, the stratum 
radiatum, and the stratum lacunosum-moleculare (figure 1.13). The basal dendrites 
extend from the base of the pyramidal cell body into the stratum oriens. Dendrites in 
each of these regions receive different types of synaptic contacts.
The hippocampus can be broadly divided into two major regions; a large- 
celled layer close to the dentate gyrus, and a smaller-celled distal region (Ramon y  
Cajal, 1911). In 1934, Lorente de No further subdivided the hippocampus into three 
regions, which are now known as CA1, CA2 and CA3. He also named a region CA4, 
although this referred to the polymorphic layer of the dentate gyrus. In addition to the 
size differences observed between subdivisions, there is also a clear connectional 
difference which can be observed: the CA3 pyramidal cells receive a mossy fibre 
input from the dentate gyrus, whereas the CA1 cells do not. The CA2 region refers to 
a narrow zone of cells interposed between CA1 and CA3, which has large cell bodies 
like CA3, but does not receive mossy fibre innervation like CA1.
APICAL DENDRITE
Stratum laconosum- 
moleculare
Stratum radiatum
PYRAMIDAL CELL
Stratum oriens
BASAL DENDRITE
Figure 1.13: CA1 hippocampal neuron (A) Optical trace of hippocampal CA1 neuron 
(adapted from www.krasnow.gmu.edu/alexei/cinema). (B) Golgi stain of hippocampal CA1
neuron (www. synapses.mcg.edu).
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Interneurons
The vast majority of intemeurons within the dentate gyrus and hippocampus have 
local target regions, lack spines and are GABAergie. The most prominent intemeuron 
in the dentate gyrus is the pyramidal basket cell, the cell bodies of which are typically 
located at the border between the granule cell layer and the polymorphic cell layer. 
There are at least five different types of basket cell (Ribak & Seress, 1983), and the 
axons from these neurons innervate the cell bodies of granule cells. Intemeurons can 
also be found in the molecular layer and the polymorphic cell layer of the dentate 
gyms. One interesting class of intemeuron found in the polymorphic layer is called 
the mossy cell. These are excitatory neurons that project only to the molecular layers 
of the dentate gyms both ipsilaterally and contralaterally, and tend to project to distant 
septotemporal levels of the dentate gyms rather than locally.
Intemeurons in the hippocampus have cell bodies in or near the pyramidal cell 
layer and can be classified into three groups on the basis of their synaptic targets:
(i) axo-axonic cells -  synapse onto the initial segment of pyramidal 
neurons, thereby exerting a strong control over action potential 
initiation.
(ii) basket cells -  synapse onto the somata of pyramidal neurons. One 
basket cell can make multiple contacts onto a single pyramidal 
neuron.
(iii) bistratified cells -  synapse onto apical and basal dendrites of 
pyramidal neurons.
Dendrites of all three cell types project into the stratum radiatum and stratum oriens, 
and therefore may receive excitatory inputs from Schaffer-Collaterals, commissural- 
associational fibres and feedback synapses from pyramidal neurons in the region of 
the intemeurons (Buhl et al, 1996; Halasy et al, 1996). There are also mutual 
inhibitory connections among these intemeurons which are thought to synchronize 
their oscillation frequencies (Jefferys et al, 1996). GABAergie intemeurons also exist 
within the stratum radiatum and stratum lacunosum-moleculare which receive 
excitatory inputs from Schaffer collaterals and perforant path fibres, respectively, and 
synapse onto pyramidal neuron dendrites in various regions.
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1.7.2 Synaptic connections within the hippocampal formation
Most sensory information reaches the hippocampus via the entorhinal cortex. Neurons 
located in layer II of the entorhinal cortex give rise to a pathway, the perforant path, 
which projects through the subiculum and terminates in a laminar pattern in both the 
dentate gyrus and in the CA3 region of the hippocampus. Neurons located in layer III 
of the entorhinal cortex do not project to the dentate gyrus or CA3, but instead project 
to CA1 and the subiculum. In this case, the projection is organised in a topographical 
fashion.
The dentate gyrus is the next step in the progression of connections through 
the hippocampal formation, and it gives rise to the mossy fibres that terminate on the 
proximal dendrites of the CA3 pyramidal cells. The granule cells also synapse onto 
cells of the polymorphic layer, which provides association connections to other levels 
of the dentate gyrus. The CA3 pyramidal cells, in turn, project heavily to other levels 
of CA3, as well as to the CA1. The projection from CA3 to CA1 is typically called the 
Schaffer Collateral projection. Each CA3 neuron is capable of making contact with 
numerous CA1 neurons (for example one CA1 neuron may be innervated by more 
than 5000 ipsilateral CA3 cells). CA1 pyramidal cells, unlike those from the CA3 
make few connections within CA1, but instead give rise to connections which extend 
to both to the subiculum and to the deep layers of the entorhinal cortex. The 
subiculum additionally originates a projection to the deep layers of the entorhinal 
cortex. The deep layers of the entorhinal cortex, in turn, originate projections to many 
of the same cortical areas that originally projected to the entorhinal cortex. In this way 
information entering the entorhinal cortex from a particular cortical area is able to 
traverse the entire hippocampal circuitry, and ultimately be returned to the same 
cortical area from which it originated. Figure 1.14 summarises the synaptic 
connections made within the hippocampal formation.
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Presubiculum
Figure 1.14: Major intrinsic connections in the hippocampal formation.
(Adaptedfrom Johnston & Amaral, 1998)
1.7.3 Localisation of NO within the hippocampus.
Dramatic variations in immunoreactivity occur throughout the rat brain. In the adult
hippocampus, nNOS staining was originally thought to be largely confined to a
subpopulation of GABA-containing intemeurons in the CA1 region (Bredt et al.,
1991; Valtschanoff et al, 1993; Lumme et al., 2000). Increasing evidence also
describes limited nNOS expression in CA1 pyramidal cells (Endoh et al, 1994;
Wendland et al, 1994; Blackshaw et al., 2003), and dendritic spines (Burette et al,
2002) when obtained by weak fixation. Some laboratories have failed to reproduce
this finding, although this can likely be explained by the potential cross reactivity of
the antibodies, the method of fixation, and the differing antibody incubation time
required to stain intemeurons and pyramidal cells. In order achieve optimal staining
for intemeurons, the reaction must be stopped before it would reveal any trace of
nNOS in pyramidal cells. Therefore it is possible that the absence of nNOS staining
observed by certain groups reflects lower levels of nNOS expression and insufficient
time of incubation with antibodies, rather than complete lack of presence.
As discussed previously, biochemical investigations reveal an association of
nNOS with PSD-95, together forming a complex with the NMDA receptor (Brenman 
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et al, 1996a; Christopherson et al, 1999). The importance of the NMDA receptor in 
synaptic plasticity and the association of nNOS and the NMDA receptor places NO in 
a perfect position to modulate synaptic events. Consistent with this idea are various 
ultrastructural studies which demonstrate the presence of nNOS at axospinal synapses 
(Aoki et al, 1997; Faber-Zuschratter et al, 1996; Valtschanoff & Weinberg, 2001). 
Additionally, NO-activated GC has been found to associate with nNOS at 
subpopulations of synapses in the hippocampus (Burette et al, 2002): nNOS 
accumulation is observed at the postsynaptic density of asymmetric axospinous 
synapses, whereas NO-activated GC concentrates in presynaptic axon terminals. 
Furthermore, the anatomical relationship between presynaptic NO-activated GC and 
postsynaptic nNOS is spatially precise; although only a modest fraction of synapses 
express either nNOS or NO-activated GC, NOS-positive post synaptic densities are 
usually post synaptic to NO-activated GC-positive axon terminals and vice versa 
(Burette et al, 2002).
In contrast to nNOS, eNOS expression appears to be restricted to the vascular 
endothelium (Seidel et al, 1997; Stanarius et al, 1997; Topel et al, 1998), although 
there are a few reports that eNOS may also be present in CA1 pyramidal neurons 
(Dinerman et al, 1994a; Doyle & Slater, 1997). Physiologically, NO produced from 
endothelial cells has been demonstrated to contribute to the maintenance of cerebral 
blood flow via the regulation of small artery and ateriolar tone (Umans & Levi, 1995; 
Wolf, 1997). However, capillaries lack smooth muscle cells (and therefore NO- 
activated GC). Instead in these blood vessels NO has been shown to attenuate the 
expression of intracellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1) in vitro (Biffl et al, 1996; Takahashi et al, 1996). It has 
therefore been suggested that NO has the ability to modify capillary blood flow by 
modulating local haemoconcentration and leukocyte adhesion, thereby increasing 
microvascular blood flow (Mitchell & Tyml, 1996). Additionally, NO has been 
demonstrated to alter the microvascular permeability in the intact and inflamed 
vasculature (Kubes, 1995), and consequently affect the blood brain barrier (Shukula et 
al, 1996).
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1.8 General aim of the study
NO is an important signalling molecule throughout the entire body, where the three 
‘classical’ NO-mediated functions are smooth muscle relaxation, platelet aggregation 
and neurotransmission. Within the CNS, the function of NO that has been most 
extensively studied is the molecule’s involvement in synaptic plasticity. The aim of 
my research was to further characterize the role that NO plays in hippocampal 
synaptic plasticity, focussing in particular on two important questions as described 
below:
i. Does NO regulate the NMDA receptor?
The principle physiological receptor for NO is guanylyl cyclase, whose activation 
results in cGMP formation. An alternative transduction pathway perceived to be of 
widespread importance is the modification of protein function by nitrosation of thiol 
groups. A prototypic protein that is considered to be regulated in this way is the 
NMDA receptor, the result of which is an inhibition of receptor function. 
Physiologically, this would represent an important negative feedback mechanism. 
However, despite extensive research, there is little direct evidence that NO regulates 
NMDA receptor function. The aim of this study was to directly investigate the effect 
of NO on native and cloned NMDA receptors in hippocampal slices and HEK-293 
cells, respectively, using electrophysiological techniques.
ii. Which isoform of NOS is involved in hippocampal synaptic plasticity?
One form of synaptic plasticity that has attracted much attention over the past 
decade is LTP. NO has been implicated in LTP in the CA1 region of the 
hippocampus, although there is a longstanding debate as to which isoform of NOS is 
responsible. Both constitutive isoforms have been demonstrated to be present in the 
hippocampus, although due to the absence of selective NOS inhibitors 
pharmacological studies have not yet been able to resolve this issue. Genetic 
knockout studies of one or both of the NOS isoforms present in the hippocampus 
have been created, but have yielded contradictory results. The aim of this study was 
to further investigate which isoform of NOS mediates the involvement of NO in 
LTP using transgenic mice lacking eNOS using a combination of 
electrophysiological, biochemical, and molecular biological techniques.
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2.1 Chemicals and reagents
Table 2.1 summarises the actions and source of all the pharmacological compounds 
utilised in the following chapters; all other standard chemicals were purchased from 
Sigma Aldrich unless otherwise stated.
Compound Action Source Company
1400W iNOS inhibitor Calbiochem
Acetylcholine Cholinergic neurotransmitter Sigma Aldrich
(o-Agatoxin IVA P/Q Ca2+-channel antagonist Tocris Cookson
(+>A J 76 Dopamine antagonist Tocris Cookson
AM 251 Cannabinoid antagonist Tocris Cookson
L-arginine NOS substrate Sigma Aldrich
Atropine Muscarinic antagonist Sigma Aldrich
BAY 41-2272 Enhancer of NO-activated GC Sigma Aldrich
Benzoquinonium Nicotinic antagonist Tocris Cookson
Bradykinin eNOS stimulator Sigma Aldrich
w-Conotoxin GV1A N-type Ca2+ channel antagonist Tocris Cookson
u-Conotoxin MVI1C N/P/Q Ca2+-channel antagonist Tocris Cookson
CNQX Kainate/AMPA antagonist Tocris Cookson
D-AP5 NMDA antagonist Tocris Cookson
DEA/NO NO donor Alexis Biochemicals
DPCPX Adenosine antagonist Tocris Cookson
EHNA PDE2 antagonist Sigma Aldrich
IBMX General PDE antagonist Sigma Aldrich
Ketamine NMDA antagonist Alexis Biochemicals
L-NIO General NOS inhibitor Alexis Biochemicals
L-NNA General NOS inhibitor Tocris Cookson
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LY294002 PI3-K inhibitor Sigma Aldrich
M CPG mGluR antagonist Tocris Cookson
M ethysergide 5HT-antagonist Tocris Cookson
M ibefradil T-type Ca2+-channel antagonist Sigma Aldrich
Naloxone Opioid antagonist Tocris Cookson
NBQX AM PA antagonist Tocris Cookson
Nicergoline General a  agonist Tocris Cookson
Nickel R/T-type Ca2+ channel antagonist Sigma Aldrich
Nifedipine L-type Ca2+ channel antagonist Sigma Aldrich
NM DA NM DA receptor agonist Sigma Aldrich
NPA nNOS inhibitor A lexis Biochemicals
ODQ NO-activated GC inhibitor Sigma Aldrich
Picrotoxin GABAa antagonist Sigma Aldrich
Potassium pentachloronitrosylruthenate Caged NO donor Alfa Aesar
Phenylm ethylsulphonyl fluoride Serine protease inhibitor Roche
Raloxifene eNOS stimulator Sigma Aldrich
Scopolamine General muscarinic antagonist Tocris Cookson
SNX-482 R-type Ca2+ channel antagonist Tocris Cookson
Sotalol General P antagonist Tocris Cookson
Superoxide dism utase (SOD) Superoxide scavenger Sigma Aldrich
Tum our Necrosis Factor alpha eNOS stimulator Promega
Tetrodotoxin (TTX) Na+ channel blocker Sigma Aldrich
Urate N 0 2 scavenger Sigma Aldrich
Vinyl L-NIO nNOS inhibitor Alexis Biochemicals
W ortm annin PI3-K inhibitor Sigma Aldrich
Table 2.1: Pharmacological compounds utilised, including their biological actions and
source.
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2.2 Hippocam pal slice preparation
Hippocampal slices were prepared from 6  to 8 -week-old male Sprague-Dawley rats 
(Charles River, Margate, UK). The animals were killed humanely according to the 
Scientific Procedures (1986) Act by way of stunning followed by cervical dislocation 
and decapitation. The brain was rapidly removed, the hippocampus dissected out 
(figure 2.1), and placed in cold ( 0 - 4  °C) artificial cerebrospinal fluid (ACSF) of the 
following composition (in mM): NaCl 124, KC1 3, NaH2P0 4  1.25, MgSC>4 1, 
NaHCC>3 26, CaC^ 2, D-glucose 10, equilibrated with 95 % O2  and 5 % CO2 . 
Transverse slices (400 pm thick) were cut using a Vibrotome ® Series 100 Sectioning 
system (Technical Products International Inc, St Louis, USA), and maintained in an 
interface holding chamber containing ACSF at room temperature (22 -  24 °C) for at 
least 1 h before use.
Figure 2.1: Line drawing illustrating the location of the hippocampus within the rat brain
(Johnson & Amaral, 1998).
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2.3 E lectrop h ysio log ica l record in gs from  h ip p ocam p al slices
Extracellular recordings of field excitatory postsynaptic potentials (fEPSPs) were 
made from the stratum radiatum of the CA1 area of the hippocampus following 
electrical stimulation (baseline frequency = 0.033 Hz) of the Schaffer Collateral- 
commissural pathway. Field EPSPs were made at either at room temperature or at 30 
°C in a submerged recording chamber. Figure 2.2 illustrates (a) the position of the 
stimulating (Harvard apparatus Ltd, Kent, UK) and recording electrodes (typical 
pipette resistance 2 - 4  MD), and (b) the resultant synaptic response following 
stimulation. Slope measurements were made by linear regression (pClamp6 /8 ) during 
the initial linear phase of each evoked fEPSP (20 -  50 % of the peak), and the values 
were normalized relative to the mean values obtained within the first 1 0  or 15 min of 
recording in the absence of any treatment.
a
S t im u la t in g
e l e c t r o d e
R e c o r d in g
e l e c t r o d e
■; v . 2  1
i___
Fibre Volley
0.5 mV
pEPSP
Stimulus
Figure 2.2: Stimulation and response of CA1 pyramidal neurons.
(a) Nissl-stained horizontal section through the rat hippocampus. The position of the 
recording and stimulating electrodes are indicated. The subiculum (S), presubiculum (PrS), 
parasubiculum (PaS) and entorhinal cortex (EC) are also illustrated (Adapted from Johnson 
& Amaral, 1998). (b) Synaptic response in the CA1 stratum radiatum in response to 
stimulation of the Schaffer collaterals. Population excitatory post synaptic potential (pEPSP). 
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2.4 cGMP measurement
Hippocampal slices were allowed to recover in carbogenated ACSF maintained in a 
shaking water bath for 1 - 2 h before use (at room temperature or 30 °C). The slices 
were then transferred to a fresh solution containing the non-specific PDE inhibitor 3- 
isobutyl-l-methylxanthine (IBMX; 1 mM) or the PDE2 inhibitor erythro-9-(2- 
hydroxy-3-nonyl)-adenine hydrochloride (EHNA; 300 pM) for 15 min. At the end of 
the exposure the slices were removed, inactivated by immersion in boiling hypotonic 
inactivation buffer (50 mM Tris, 4 mM EDTA, pH 7.4) for a minimum of 5 min, and 
homogenized by sonication.
The protein content of each sample was determined using the bicinchoninic 
acid (BCA) method (Pierce Rockford, IL, USA) with bovine serum albumin as 
standard. The assay is based on the reduction of Cu2+ to Cu+ in the presence of protein 
under alkaline conditions. 1 0  pi aliquots (in triplicate) of either standards or samples 
were dispensed into a 96-well plate followed by 200 pi of the BCA reagent. The 
plates were incubated at 37 °C for 30 min, and the absorbance measured at 562 nm 
using a Spectra max 250 spectrometer (Molecular Devices, California, USA).
The remaining samples were centrifuged at 10,000 g for 5 min at 4 °C to pellet 
the debris, and the cGMP content of the supernatant was determined by 
radioimmunoassay, based on a commercially available kit (Amersham Pharmacia 
Biotech, Hertfordshire, UK). Results are expressed as mean cGMP content/mg 
protein ± S.E.M.
2.5 Genotypic determination of transgenic mice
2.5.1 DNA Extraction
Approximately 1 cm of mouse tail was removed and added to 500 pi of lysis buffer of 
the following composition: 0.1 M Tris-HCl pH 8.5, 5 mM EDTA, 0.2 % SDS, 0.2 M 
NaCl, and 100 pg/ml proteinase K. The tails were incubated overnight at 55 °C to 
digest the protein. The digested tail mix was vortexed for 1 min, then centrifuged at 
14,000 g for 10 min at room temperature. The supernatant was decanted into a fresh 
eppendorf, and 500 pi isopropenol was added. Each eppendorf was slowly inverted 
several times until a white precipitate was observed (deoxyribonucleic acid; DNA), 
then centrifuged for 2 min at 14,000 g. The supernatant was removed, and the pellet 
was washed twice with 500 pi 70 % EtOH. The pellet was left to dry at 37 °C
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overnight, then re-suspended in 100 pi ddthO. The DNA was stored at - 20 °C until 
use.
2.5.2 Polymerase chain reaction (PCR)
The genotype of each sample was determined by the PCR technique of DNA 
amplification. PCR amplifications were carried out using the Promega PCR system 
according to the manufacturer’s recommendations. In summary, 25 pi reactions were 
set up in 200 pi PCR tubes with 1 pi of each primer (Sigma Genosys; table 2.2), 200 
pM PCR nucleotide mix (dNTPs; Promega), 0.75 U of Taq DNA Polymerase 
(Promega), 1 X PCR buffer (Promega) and 1 pi of mouse genomic DNA (purified as 
in 2.5.1). The optimum MgCb concentration was determined using increasing MgCl2 
concentrations from 0 to 4 mM to be 1.5 mM.
PRIMER Sequence 5-3’ Concentration
eNOS-FOR GGTGTTTGGCTGCCGATGC 2 pmol/pl
eNOS-REV GCACAGCAC AC GGT GAAC C 2 pmol/pl
NEO-FOR GCATAC GC TTGAT CCGGC TAC C 1.5 pmol/pl
NEO-REV GAAGGC GATGC GC TGC GAATC 1.5 pmol/pl
Table 2.2: Primers used fo r  PCR determination o f  mouse genotype.
Samples were briefly vortexed and PCR reactions were carried out in a 
thermocycler machine (MWG-Biotech Primus 96 plus). Samples were denatured at 94 
°C for 5 min, followed by 35 cycles of PCR: melting the template at 94 °C for 1 min, 
annealing at 55 °C for 1 min and extending the DNA segment at 72 °C for 1 min. This 
was followed by 7 min at 72 °C in order to allow extension of DNA fragments to be 
completed. All runs included a negative control, where instead of mouse genomic 
DNA ddH2 0  was used. Positive control DNA (wild type DNA) was also included in 
all PCR amplification runs. PCR products were stored at 4 °C until further use.
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2.5.3 Agarose gel electrophoresis
DNA fragments were separated by electrophoresis on 1.5 % agarose gels. Agarose 
gels were prepared by melting 1.5 g of agrose (Invitrogen) in 100 ml of Tris-Acetate- 
EDTA (TAE) buffer (containing 0.8 mM Tris, 20 pM ethylenediaminetetraacetic acid 
(EDTA), pH 8.0, 1.1 % (v/v) glacial acetic acid) in a microwave until the agarose was 
melted. Ethidium bromide (2.5 pi/100 ml; Sigma Aldrich) was added to the molten 
gels and mixed. Gels were poured into the casting trays of a horizontal electrophoresis 
tank (Wide mini-sub ® cell GT; Bio-Rad) with the appropriate combs inserted. Gels 
were allowed to set and TAE buffer was added to cover the gel.
10 pi of 1 kb Plus DNA ladder (Invitrogen) was added to 16.7 pi gel loading 
dye ( 6  X concentrate; Type 1; Sigma Aldrich) and 72.3 pi dcfflhO. DNA ladder/dye 
mix (5 pi) was loaded into the first well in each gel using a micropipette. DNA 
samples (13.5 pi) were mixed with 1.5 pi of gel loading buffer (10 X loading dye; 
0.42 % xylene cyanol FF (Sigma Aldrich), 50 % glycerol) and then loaded into the 
remaining wells. For each experiment, positive and negative controls were always 
run. Agarose gels were electrophoresed at a constant voltage of 100 V for 30 -  45 
min. Gels were stopped when the bromophenol blue and the xylene cyanol dyes had 
separated ~ 1 -  2 cm. DNA bands were visualized under UV light using Chemi- 
imager4400 v 5.1.
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Regulation of the NMDA receptor by nitric oxide
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3.1 Introduction
The NMDA receptor has been extensively studies during the past decade because of 
its implication in many physiological processes. Physiological activation of NMDA 
receptors, and the subsequent Ca2+ entry into neurones, has been associated with 
critical processes as diverse as neuronal development, mediation of excitatory 
neurotransmission and synaptic plasticity. However, excessive activation of the 
NMDA receptor leads to altered Ca homeostasis, and can be shown to contribute to 
neuronal cell death in a variety of acute and chronic neurological disorders including 
epilepsy, stroke and head trauma (Choi, 1988; Meldrum & Garthwaite, 1990; Kohr et 
al, 1993). Precise regulation of NMDA receptor activity is therefore critical to normal 
brain function, as well as to the avoidance of neuronal damage and death; accordingly 
there are several endogenous mechanisms for receptor modulation (Dingledine et al., 
1999). Given the well-established involvement of the NMDA receptor in the 
generation of NO in response to activation of the NMDA receptor (as described in the 
general discussion; 1.3), it therefore followed that NO may be a potential contender 
for its modulation.
The best-known pathway for NO signal transduction is through NO-activated 
GC, whose activation results in the intracellular accumulation of cGMP (Denninger & 
Marietta, 1999; Friebe & Koesling, 2003). As described in the general introduction 
(section 1.5), subsequent binding of cGMP to protein kinases, ion channels, PDEs, 
and other proteins translates NO signals into long- and short-term functional 
alterations. Of these targets cGK provides the broadest means of controlling ion- 
channel function, with virtually every type of ion channel containing cGK consensus 
phosphorylation sites (White et al., 1999).
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An alternative route for NO signal transduction that has been perceived to be 
of widespread importance is the chemical modification of protein function by the 
transfer of the NO moiety to protein thiol groups (Ahem et al., 2002, Stamler et al., 
2001). The NMDA receptor, present in most brain synapses, is a classical example of 
a protein allegedly regulated by S-nitrosation (Stamler et al., 2001; Ahem et al., 2002; 
Lipton et al., 2002), the result of which being an inhibition of receptor function that 
reverses only slowly (Choi et al, 2000), if at all (Murphy & Bliss, 1999). Figure 3.1 
summarizes the actions of NO in the CNS.
NO-generating cell Target cell
Biological
EffectsnNOS
GMP
Glu =|> 
(NMDA)
NO-S
Figure 3.1: Actions of NO in the CNS.
The best-known pathway by which NO acts is via activation of NO-activated GC. An alternate 
pathway by which NO has been proposed to act is via the S-nitrosation of thiol groups at 
cysteine residues, however the mechanism by which this may occur is unclear.
Although the transfer of the NO-moiety to protein thiol groups is commonly 
referred to as S-nitrosy/ation, the correct term for this process is S-nitrosation 
(Koppenol, 2002). Transnitrosation refers to the transfer of bound NO from one thiol 
group to another (including the reversible blockade of critical thiol groups in 
enzymes; equation 3.1).
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S-nitrosation
F^SNO + R?SH * '  R2SNO + R ^H
Equation 3.1: Mechanism for S-nitrosation.
Transfer of bound NO from one thiol group to another, with R being protein or peptide in
nature.
In contrast, S-nitrosy/ation refers to the direct action of NO that is either a 
radical, cation or ligand (equation 3.2). Whilst it is often stated that thiols represent a 
biological target for NO, the chemical reactivity of NO indicates that this is not the 
case. Ground-state NO exists in the so-called triplet state, which is of a lower 
electronic energy than the excited singlet state. NO in the triplet state contains two 
unpaired electrons which have parallel spins, a characteristic that, according to 
physical chemistry, does not allow them to react with most molecules. Thus, ground 
state (or triplet) NO is not very reactive towards most organic compounds. There is 
also the very common myth that S'-nitrosothiols may be formed by reversible 
association of nitric oxide and thiol. The reality is that the direct reaction between NO 
and thiols is in fact a very slow oxidation that yields thiol disulphide and nitroxyl 
anion (equation 3.2).
S-nitrosylation
NO" + RSH X ► RSNO + H+
NO- + 2RSH --------► RSSR + 2NO" + H +
Equation 3.2: Mechanism for S-nitrosylation.
Direct reaction between NO and RSH is a very slow oxidation that yields thiol 
disulphide and the nitroxyl anion
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NMDA receptors are composed of at least four subunits surrounding a central, 
water-filled pore. Functional NMDA receptors contain both NR1 and NR2 subunits, 
those containing the NR2a subunit being preferentially susceptible to S-nitrosation. 
Site-directed mutagenesis on the NR2a subunit has identified a cysteine residue (Cys 
399) that is critical for this modification (Choi et al, 2000). Functionally, the 
inhibitory effect of NO has been viewed either a negative feedback mechanism 
serving to protect against neuronal damage that can result from over-activation of 
NMDA receptors, or as a device that regulates the susceptibility of synapses to 
undergo plastic changes (Lei et al, 1992; Manzoni et al, 1992; Murphy & Bliss, 
1999).
Despite the status accorded by some commentators to S-nitrosation as a 
physiological regulatory mechanism (Stamler et al, 2001; Ahem et al, 2002; Lipton 
et al, 2002), numerous fundamental issues remain outstanding. For example, without 
a catalyst, NO cannot simply attach to thiol groups (Hogg, 2002), so it is unclear how 
such a chemical modification would occur. Also, many of the experiments leading to 
the idea that NMDA receptors are regulated by NO have relied on the indirect 
measurement of changes in cytosolic free Ca2+ (Lei et al, 1992; Manzoni et al, 1992; 
Tanaka et al, 1993; Choi et al, 2000), which could be affected by NO independently 
of any action on the NMDA receptor (Hoyt et al, 1992). Finally, and most 
importantly, there have been very few studies that have examined the effect of NO on 
NMDA receptors in their normal synaptic location, the exception being those of 
Murphy et a l (1994) and Murphy & Bliss (1999) who found that photolysis of a 
caged NO derivative caused an enduring inhibition of NMDA receptor function in 
CA1 hippocampal synapses and, hence, of LTP.
The aim of the present study, therefore, was to test some of the primary 
predictions of the hypothesis that NO regulates NMDA receptor function in central 
synapses. The role of endogenous and exogenous NO in synaptic function will be 
investigated on native or cloned NMDA receptors, in acute rat hippocampal slices and 
HEK-293 cells respectively. This will then be discussed in relation to the potential 
physiological role of NO in the regulation of NMDA receptor function.
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3.2 Methods
3.2.1 Tissue preparation
Hippocampal slices were prepared as described in chapter 2 (2.2).
3.2.2 Electrophysiological recordings
Extracellular recordings of field excitatory postsynaptic potentials (fEPSPs) were 
made from the stratum radiatum of the CA1 area of the hippocampus following 
electrical stimulation (baseline frequency = 0.033 Hz) of the Schaffer collateral- 
commissural pathway at room temperature (~ 24 °C). NMDA receptor-mediated 
responses were isolated pharmacologically using nominally Mg2+-free ACSF 
containing 10 pM 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) to block AMPA 
receptors. D(-)-2-amino-5-phosphonopentanoate (D-AP5) was added to confirm that 
the responses were NMDA receptor-mediated. AMPA receptor-mediated responses 
were obtained in normal ACSF. Photolysis of caged NO (potassium 
pentachloronitrosylruthenate, K2 Ru(NO)C1s; Alfa Aesar, Karlsruhe, Germany) was 
performed using the 1 ms discharge from a xenon arc bulb (Zeiss) transmitted through 
a fibre optic, and filtered with a UG11 filter (270 -  370 nm). Stock solutions of the 
NONOate NO donor, diethylamine/NO adduct (DEA/NO) were made up in 10 mM 
NaOH and diluted at least 1:100 into the ACSF solution. Separate slices were used for 
each DEA/NO concentration tested. Slope measurements were made during the initial 
linear phase of each evoked potential (20 - 50% of the peak), and the values were 
normalised relative to the mean values obtained within the first 1 0  or 15 min of 
recording in the absence of any treatment.
Whole-cell current-clamp recordings were made from CA1 hippocampal cells 
at room temperature using an Axoclamp 2A (Axon Instrument, Foster city, CA). 
Typical pipette resistance was 2 - 4  MQ. Pipette solutions contained (in mM): 
KMeS04 150, KC1 10, HEPES 10, NaCl 4, Mg2ATP 4. The pH was adjusted to 7.4 
and the osmolarity to 280 - 290 mOsm/1. NMDA receptor-mediated responses were
isolated using ACSF containing 10 pM CNQX and 50 pM picrotoxin. Some
2+experiments (n = 2) were carried out in the nominal absence of extracellular Mg 
with the membrane potential being held at -80 mV by current injection through the 
recording electrode; in others (n = 2) normal extracellular Mg was used and the 
membrane potential was held at -60 mV. A short current pulse was included in every 
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trace to ensure correct adjustment of bridge balance. Slope measurements were made 
during the initial linear phase (20 -  50 %) of each evoked potential and the values 
were normalised relative to the mean values obtained within the first 1 0  min of 
recording in the absence of any treatment.
All data are presented as the means ± S.E.M.
3.2.3 cGMP measurement
cGMP accumulation was determined by radioimmunoassay as described in chapter 2 
(2.4).
3.2.4 Cell Culture
Human embryonic kidney 293 cells (HEK-293 cells; European Collection of Cell 
Cultures, CAMR, Salisbury, ECACC No. 85120602) were grown in Dulbecco’s 
modified eagles medium (DMEM), containing 10 % fetal bovine serum and 100 U/ml 
of both penicillin and streptomycin, at 37 °C in a 5 % CO2 incubator. Exponentially 
growing cells were plated onto 9 mm diameter coverslips 24 h prior to transfection. 
HEK-293 cells were transfected with a mixture of plasmids containing the NR1 
(provided by Dr. R. Shoepfer, University College London, UK) and NR2a (from Dr. 
P. Seeburg, Heidelberg, Germany) subunits of the NMDA receptor, and green 
fluorescent protein (Clontech, USA) to allow visualisation of the transfected cells. 
Transfections were performed using Effectene Transfection Reagent (Qiagen Ltd, 
UK) following the manufacturer’s instructions. Approximately 76 % of cells 
expressing green fluorescent protein also expressed functional NMDA receptors. 
Following transfection, 500 pM ketamine was added to the DMEM culture medium 
to reduce glutamate-mediated cell toxicity. Studies on the recombinantly expressed 
receptors were performed two days after transfection, which gave optimal transient 
expression of the proteins.
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3.2.5 Whole cell electrophysiology
Transfected HEK-293 cells were studied at room temperature. The recording chamber 
was mounted on an inverted microscope (Zeiss), and was continuously perfused with 
extracellular solution containing (in mM): NaCl 135, KC1 5.4, CaCl2  1.8 glycine 0.01, 
HEPES 5. The pH was adjusted to 7.25 with NaOH and osmolarity was maintained at 
280 - 300 mOsm/1 with sucrose. Whole-cell voltage clamp recordings were made 
from green fluorescent protein-positive cells using an Axopatch ID (Axon 
Instrument, Foster city, CA) after capacitance and series resistance compensation. 
Typical pipette resistance was 3 - 6  MO. Patch pipette solutions contained (in mM): 
CsCl 140, MgCl2  1, EGTA 10, HEPES 10, Mg-ATP 4, pH 7.25 (CsOH) and 
osmolarity 280 -  300 mOsm/1 (adjusted with sucrose).
Immediately after establishing the whole-cell configuration, short (100 ms) 
pressure pulses of glutamate (100 pM dissolved in external solution) were applied 
with a Picospritzer (Picospritzer IID, General Valve Corporation; New Jersey, USA) 
every 20 s. Glutamate was used at a concentration of 100 pM to ensure maximal 
activation of NMDA receptor, as the steady-state for glutamate binding to the NMDA 
receptor has an EC5 0 of 1.7 pM, and is saturated at 10 pM (Nahum-Levy et al., 2001). 
Photolysis of caged NO was performed by illuminating a -100 pm diameter circle 
surrounding the cell of interest using a mercury vapour 50 W bulb (Osram, UK) 
filtered with the UG11 filter used in the slice experiments (see above). Data 
acquisition and analysis were with pClamp6  or pClamp8  (Axon Instruments, CA, 
USA).
3.2.6 NO measurement
NO concentrations were measured using an electrochemical probe (ISO-NO; World 
Precision Instruments, Stevenage, UK) under the same experimental conditions used 
to record currents from the HEK-293 cells.
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3.3 Results
3.3.1 Effect of endogenous NO on NMDA receptor-mediated synaptic 
transmission
Electrophysiological recordings of pharmacologically-isolated NMDA receptor- 
mediated fEPSPs were made from the CA1 region of adult rat hippocampal slices in 
order to test initially the prediction that manipulating the levels of endogenous NO 
influences synaptic NMDA receptor function. The excitatory synapses here express 
the NR2a receptor subunit (Steigerwald et al, 2000) which is preferentially 
susceptible to S-nitrosation (Choi et al., 2000) and the experiments were conducted at 
room temperature to be compatible with previous data (Lei et al., 1992; Murphy et 
al., 1994; Murphy & Bliss, 1999; Choi et al., 2000). Under conditions of low 
frequency stimulation (0.033 Hz) the fEPSPs were reasonably stable (figure 3.4), 
indicating that repetitive NMDA receptor activation and the presumed accompanying 
NO formation did not cause the progressive rundown predicted for a slowly- 
reversible or irreversible inhibition of NMDA receptors (Lei et al., 1992; Murphy et 
al., 1994; Murphy & Bliss, 1999; Choi et al., 2000). To boost the production of 
endogenous NO, the NO synthase substrate L-arginine was perfused in a 
concentration (100 pM) found to enhance NMDA receptor-evoked NO formation 
maximally in rat hippocampal slices (East & Garthwaite, 1991). The fEPSPs were not 
significantly reduced (figure 3.2). Maximal inhibition of NO synthase with the 
analogue L-NNA (100 pM; East & Garthwaite, 1991) also had no significant effect 
(figure 3.2).
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Figure 3.2: Effect of endogenous NO on NMDA-receptor-mediated synaptic transmission
in the CA1 region of the hippocampus in vitro. No significant change in the initial slope of 
the NMDA receptor-mediatedfEPSPs was seen on application of 100 pM L-arginine or 100 
pM L-NNA (20 min exposure; n = 4) in presence of 10 pM  CNQX. Subsequent addition of 
100 pM D-AP5 confirmed that the response was NMDA receptor-mediated. The inset shows 
representative traces taken at the times indicated by the letters.
3.3.2 Effect of exogenous NO on hippocam pal synaptic transm ission
The negative results obtained on attempting to manipulate endogenous NO levels 
prompted tests of the effects of delivering NO exogenously. For this purpose, we used 
the NONOate DEA/NO, which releases authentic NO with predictable kinetics 
(Keefer et al., 1996) and which has been shown to be able to substitute for 
endogenous NO in the induction of hippocampal synaptic plasticity (Bon & 
Garthwaite, 2001a; Bon & Garthwaite, 2003). To gauge the concentrations of 
DEA/NO that could be regarded as physiological, the range activating the NO- 
activated GC receptors in hippocampal slices was determined. Based on the ensuing 
accumulation of cGMP, the EC5 0 was 1.4 pM and maximal activation occurred at 10 
pM DEA/NO (figure 3.3). These results are very similar to those obtained previously 
at 30 °C (Bon & Garthwaite, 2001a).
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Figure 3.3: Concentration-response curve for DEA/NO on cGMP levels in adult rat 
hippocampal slices (2 min exposure; n = 6).
As NO-activated GC forms a complex with the NMDA receptor in the 
hippocampus (Russworm et al., 2001), free NO should have access to the two 
proteins with equal ease. However in electrophysiological experiments, applications 
of up to 10 pM DEA/NO had no significant effect on NMDA receptor-mediated 
fEPSPs (data not shown). Even concentrations up to 300 pM produced no detectable 
change (figure 3.4). However, upon further increasing the concentration to 1 mM, the 
fEPSPs were significantly reduced but recovered fully on washout (figure 3.5b). The 
inhibition was non-specific, however, because the same DEA/NO concentration 
caused a similar depression of synaptic AMPA receptor-mediated fEPSPs (figure 
3.5a). Such a depression has been observed previously in hippocampal slices and is 
attributable to the effects of metabolic stress caused by the inhibition of mitochondrial 
respiration by NO (Bon & Garthwaite, 2001a).
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Figure 3.4: Effect o f 2 minute application of300juMDEA/NO on the NMDA receptor-
mediated fEPSPs (n = 4).
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Figure 3.5: Comparison o f the effects on AMPA- and NMDA-mediated synaptic responses 
following the application o f 1 mM DEA/NO. Non-specific depression of both (a) AMPA- and 
(b) NMDA-mediated fEPSPs following exposure to 1 mM DEA/NO in the same slice 
preparation (2 min DEA/NO application; n -  4).
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To check the validity of the field potential recordings, whole-cell recordings 
of the NMDA receptor-mediated EPSP were carried out. Addition of 300 pM 
DEA/NO had no significant effect (figure 3.6), confirming the initial findings.
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Figure 3.6: Action o f300 pM  DEA/NO on NMDA receptor-mediated EPSPs recorded 
using the whole-cell technique (n =  4). The insets show representative traces from an 
experiment carried out in the presence of 1 mM Mg2* (membrane potential, -60 mV), taken at
the times indicated by the letters.
The lack of any selective effect of DEA/NO even in high concentration 
appears at odds with previous reports showing profound, selective, and apparently 
irreversible block of NMDA receptor function in the same synapses by release of NO 
from a caged derivative (potassium pentachloronitrosylruthenate) using a focused 
beam of UV light (Murphy et al, 1994; Murphy & Bliss, 1999). On repeating this 
experiment, we confirmed the result: perfusion of 500 pM caged NO itself had no 
effect but a subsequent flash of UV light (also without effect on its own) caused an 
almost complete block of the fEPSPs within 2 min (94 ± 3 %; n = 4) that showed little 
sign of recovery during at least 10 min (figure 3.7).
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Figure 3.7:Effect o f photolysis o f caged NO on NMDA receptor-mediated synaptic 
transmission. No significant change in the initial slope of the NMDA receptor-mediated 
fEPSPs was observed following either perfusion o f500 juM Caged NO alone or by a 1 ms UV 
flash. Application of the UVflash in the presence o f500 juM Caged NO depressed NMDA 
receptor-mediatedfEPSP by 94 ± 3 % (mean ± S.E.M.; n = 4). The inset shows representative 
traces taken at the times indicated by the letters.
3.3.3 Studies on heterologously expressed NMDA receptors
One explanation for the discrepant results obtained with the two different methods of 
applying NO could be that the NO needs to be delivered rapidly and in high 
concentrations in order to be able to influence the NMDA receptors, which would be 
the case with photolysis of the caged NO (Murphy et al., 1994) but not with bath 
application of DEA/NO. To address this and other possibilities under more controlled 
conditions, whole-cell recordings were made from HEK-293 cells co-transfected with 
the NR1 and NR2a NMDA receptor subunits. When exposed to brief pulses of 
glutamate (100 pM, 100 ms) at regular 20 s intervals, current responses were 
reasonably stable for at least 20 min. For uncaging NO, space limitations of the 
recording apparatus precluded use of the flash gun used in the earlier slice 
experiments and so UV light from the microscope was used instead.
Similar to findings in slices, caged NO or UV light exposure on their own had 
no effect, but a combination of the two resulted in a slow-onset and apparently
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Figure 3.8: Effect ofphotolysis o f500 pM  caged NO by exposure to UV light from the 
microscope on NMDA receptor currents. No significant change on NMDA receptor currents 
was observedfollowing individual exposure of HEK-293 cells transfected with NMDA 
receptor subunits to 500 pM caged NO or UV light. Application of UV light in the presence of 
500 pM Caged NO depressed NMDA receptor currents by 53 ± 3 % (n = 5). Boxed region 
represents duration of UV light. The inset shows representative traces taken at the times
indicated by the letters.
irreversible depression of whole-cell currents (figure 3.8). A relatively prolonged 
light exposure (routinely 1 min) was needed to produce this effect and the amplitude 
of the depression (about 50 %) was less than found in slices (about 90 %), 
presumably because the UV light was of relatively low intensity and/or the released 
NO, or other substances, were being continuously washed out by the flow of the 
perfusing solution ( 2  chamber volumes/min).
In contrast to these findings, exposure to DEA/NO (100 nM or 100 pM for 9
min) had no significant effect (figure 3.9). The corresponding NO concentrations in
the recording chamber were measured using an electrochemical probe. At 100 nM
DEA/NO, NO rose gradually to reach 32 ± 5 nM (n = 3) after 9 min (see figure 3.10a
for representative trace). With 100 pM DEA/NO, a plateau NO concentration of 5.1 ±
0.1 pM (n = 3) was achieved within 2 min (figure 3.10b). It was not possible to
perform similar recordings in experiments with caged NO because the probe
responded markedly to UV light alone (not illustrated) and, unfortunately, the carbon- 
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based device used earlier (Murphy et al., 1994) is no longer available. Nevertheless, 
the steady-state NO concentration with 100 pM DEA/NO in our experiments was the 
same as that estimated to be sufficient, when released from caged NO, to give a near- 
complete block of NMDA receptor-mediated fEPSPs in hippocampal slices (Murphy 
etal., 1994).
Hence, the use of UV light may be the critical variable. In accordance with 
this possibility, when the same UV light exposure used for uncaging was paired with 
NO provided by 100 pM DEA/NO, a depression of the NMDA receptor-mediated 
currents was observed (figure 3.9). The magnitude and time-course of the depression 
were similar to those observed when caged NO was used (figure 3.10). At the reduced 
DEA/NO concentration of 100 nM, UV exposure had no effect, showing that the 
effect is NO concentration-dependent and also not simply attributable to repeated 
exposure of the cells to UV light alone.
UV light can cause the production of many different types of reactive radicals 
in cells (Tyrrell & Keyse, 1990) some of which could combine with NO to form 
chemicals capable of yielding species able to nitrosate thiols. An obvious candidate 
was peroxynitrite, which is formed at diffusion-controlled rates from NO and 
superoxide ions, and which breaks down to yield NO2  radicals that can act as 
nitrosating agents (Beckman & Koppenol, 1996; Hogg, 2002). A high concentration 
of superoxide dismutase (1000 U/ml; Beckman & Koppenol, 1996), however, did not 
prevent the inhibition of NMDA receptor currents brought about by the combination 
of UV light and caged NO (figure 3.11a). Further increasing the concentration of 
SOD to 10 000 U/ml had an adverse effect on the health of the HEK-293 cells. A 
powerful scavenger of NO2 , urate (300 pM; Ford et al., 2002), also failed to prevent 
the depression of NMDA receptor currents (figure 3.1 lb).
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Figure 3.9: Combined effect o f DEA/NO and UV light on NMDA receptor currents.
Application of DEA/NO (100 nM or 100 pM) on its own had no effect, whereas delivery of UV 
light in the presence of 100 pM DEA/NO, but not 100 nM DEA/NO, resulted in depression of 
NMDA receptor currents by 35 ± 7  % (mean ± S.E.M.; n = 4) in HEK-293 cells transfected 
with the NMDA receptor subunits. Boxed region represents duration of UV light. The inset 
shows representative traces taken at the times indicated by the letters.
40
30
20
Sf3
O 10z
0
-10
3
O
12
Time (min)
100
DEA/NO Hb6
4
2
0
0 4 8 12
Figure 3.10: Representative recording of NO concentration profde on addition o f (a) 100
nM or (b) 100 pM  DEA/NO. Oxyhaemoglobin (Hb; 50 pM) was added at the times indicated 
by the arrows to zero the NO concentration.
16
100 nM
DEA/NO
3. Regulation of the NMDA receptor by nitric oxide
coo
c
0i_I—Do
2
2*.
CD
0
a.
1 2 0  - 
1 0 0  - 
80 
60 
40 
20 
0
1 2 0
1 0 0
80
60
40
20
0
Caged N O  
( 5 0 0  pM )
+ SOD
o 1 2 3 4 5 6 7
Caged N O  
( 5 0 0  pM )
D-AP5 
(100 pM)
*
+ urate
• • • • • •
 1 *“
8 10
Time (min)
Figure 3.11: Effect of radical scavengers on the depression o f glutamate-evoked currents 
induced by the combination o f UV light and NO on HEK-293 cells co-transfected with the 
NR1 and NR2a subunits o f the NMDA receptor. No effect of application of (a) 1000 U/ml 
superoxide dismutase or (b) 300 pM urate on the inhibition of NMDA receptor currents by the 
delivery of UV light in the presence o f500 pM caged NO (n = 3 - 4). Dashed boxes indicate
the duration of UV exposure.
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3.4 Discussion
Despite a voluminous literature, and its depiction by some authors as fact (Stamler et 
a l, 2001; Ahem et al., 2002; Lipton et al, 2002), the hypothesis that endogenously- 
generated NO acts as a feedback regulator of NMDA receptor function in synapses 
has not been critically examined. Indeed, there does not seem to have been a previous 
study that explicitly tested the hypothesis.
Contrary to predictions, we found that manipulations that should enhance or 
depress endogenous NO formation had no observable effect on fEPSPs mediated by 
NMDA receptors, even though the receptors were of a molecular composition 
supposedly susceptible to chemical modification by (S-nitrosation. Furthermore, 
exposure of hippocampal slices to the authentic NO donor DEA/NO in concentrations 
30-fold higher than those needed to maximally activate NO-activated GC, also failed 
to influence the fEPSPs. It could be argued that exogenous NO cannot access the two 
proteins equally but, given that the predominant NO receptor in the hippocampus (the 
a2pl isoform) is anchored to proteins that also bind NMDA receptors (Russwurm et 
al., 2001), this explanation is difficult to sustain. In addition, much lower DEA/NO 
concentrations (those in the range that elevate cGMP levels) were found to be 
effective in substituting for endogenous NO in hippocampal synaptic plasticity (Bon 
& Garthwaite, 2001a; Bon & Garthwaite, 2003).
Only at a very high DEA/NO concentration (1 mM) were the fEPSPs reduced 
but this effect was readily reversible and also non-selective, since AMPA receptor- 
mediated fEPSPs were similarly reduced. Such a transient depression of hippocampal 
synaptic transmission has been observed previously with high concentrations of 
DEA/NO and other donors (Bohme et al, 1991; Boulton et al., 1994; Bon & 
Garthwaite, 2001b), and can be explained by a presynaptic action of adenosine 
(Broome et al, 1994) which is released as a consequence of the metabolic stress 
imposed on the cells when the NO concentration rises high enough (a few hundred 
nanomolar) to inhibit mitochondrial respiration (Bon & Garthwaite, 2001a). That a 
higher DEA/NO concentration than before was required for this effect (c.f. Bon & 
Garthwaite, 2001a) is explained by the rate of NO release from the donor (and 
therefore the resulting NO concentrations) being lower at the lower temperature used 
in the present experiments (Keefer et al., 1996).
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The only evidence that exogenous NO can inhibit synaptic NMDA receptors 
came from experiments in which NO was released from a caged derivative by UV 
light (Murphy et al, 1994; Murphy & Bliss, 1999) and we were able to confirm this 
finding. On closer examination using transfected cells, however, it transpired that NO 
itself was not responsible but the combination of NO and UV light. Unfortunately the 
same experiment could not also be performed on slices with UV light from the 
flashlamp because the requisite NO concentrations (low micromolar) would 
inevitably have led to a profound non-specific synaptic depression through inhibition 
of mitochondrial respiration. Being of unlikely physiological significance, the 
mechanism of NMDA receptor block by NO and UV light was not pursued in detail, 
except that tests for an involvement of peroxynitrite proved to be negative. 
Nevertheless, the long duration of the resulting block of receptor activity would be 
consistent with NMDA receptor S-nitrosation (Lei et al., 1992; Choi et ah, 2000) and 
there are a number of alternative ways through which this could be achieved. For 
example, light exposure similar to that used to uncage NO (namely UVA light of 
wavelength 300 - 350 nm) causes the formation of various reactive radicals and 
singlet oxygen which could result in the formation of thiyl radicals, to which NO can 
bind directly, forming a nitrosothiol (Tyrrell & Keyse, 1990; Beckman & Koppenol, 
1996; Dillon et al., 1999; Hogg, 2002). This could occur on the NMDA receptor 
itself, or on low molecular weight thiols (e.g. glutathione) that could then nitrosate 
thiol groups on the receptor by a transnitrosation reaction.
The negative findings with NO itself, together with the results indicating that 
the block of NMDA receptors resulting from uncaging NO with UV light is 
artifactual, demand an appraisal of the other evidence that NO regulates NMDA 
receptors.
First, iS-nitrosated NMDA receptors and a collection of other proteins have 
been found in brain homogenates subjected to prolonged chemical treatment, the 
modification being reduced in tissue from animals lacking neuronal NO synthase 
(Jaffrey at al, 2001). It is unclear if the proteins were S-nitrosated in vivo, however. 
Among other possible explanations of the result is that post-mortem acidosis leads to 
the formation of the S-nitroso compounds from the combination of nitrite (whose 
levels are expected to reflect NO synthase activity; Lauer et ah, 2001) and thiols 
(Tsikas et al, 2001).
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Second, in the earlier work (Lei et al, 1992; Manzoni et al, 1992; Choi et al,
2000), administration of NO relied largely on the use of donors such as sodium 
nitroprusside, nitroglycerine, S-nitrosocysteine and 3-morpholino-sydnonimine (SIN- 
1 ), which are now considered problematic because of their intrinsic chemical 
reactivity and/or because they release reactive species in addition to NO (Feelisch, 
1998).
Third, much of the data relied on the use of fluorescent Ca2+ imaging to 
monitor NMDA receptor function indirectly (Lei et al, 1992; Manzoni et al, 1992; 
Tanaka et al, 1993; Choi et al, 2000). Apart from cytosolic Ca2+ being susceptible to 
independent regulation by NO (Hoyt et al, 1992) the fluorophore used in all cases 
was fura-2, whose use necessitates repeatedly exposing the cells to UVA light at 
similar wavelengths (340 - 380 nm) used to uncage NO. This raises the possibility 
that a similar artifactual block of NMDA receptors occurred in experiments of this 
type.
Finally, there have been direct patch electrode recordings of the effect of NO 
on NMDA receptor-mediated currents. The first of these (Manzoni et al, 1992) used 
mainly the compound SIN-1 to deliver NO and found that, in contrast with the 
supposed S'-nitrosation reaction (Lei et al, 1992; Choi et al, 2000), the block of 
NMDA-evoked currents in striatal neurones had a rapid onset and was readily 
reversible. The same result has recently been obtained using cell lines transfected 
with NR1/NR2A and exposed to SIN-1 (Gbadegesin et al, 1999; Aizenman & 
Potthoff, 1999). Mutational analysis suggested a mechanism distinct from thiol 
modification (Aizenman & Potthoff, 1999), consistent with an interaction between 
NO and a metal binding site on the receptor (Fagni et al, 1995). SIN-1 is problematic 
because it releases both NO and superoxide (leading to peroxynitrite formation; 
Feelisch, 1989, 1998) and when the experiments were repeated with NONOate 
donors, which release authentic NO, one study found that NMDA receptor-mediated 
currents were increased (Gbadegesin et al, 1999) whereas another found that they 
were decreased (Aizenman & Potthoff, 1999). These opposite effects, together with 
the lack of significant change in either direction observed in our experiments, cannot 
readily be explained by differences in the applied NO concentration: direct 
measurement (present study and Gbadegesin et al, 1999) or calculation from the half­
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lives of the NONOates (Schmidt et al., 1997; Aizenman & Potthoff, 1999) indicate 
that concentrations in the low micromolar range were applied in all cases.
Regardless of the reason for the variable effects of NONOates on 
heterologously-expressed receptors, the biological relevance of the resulting 
micromolar NO concentrations is highly questionable. These concentrations are about 
1000-fold higher than are needed to activate NO-activated GC receptors half- 
maximally (Griffiths & Garthwaite, 2001; Bellamy et al, 2002), they would cause 
almost complete inhibition of mitochondrial respiration in vivo (Brown, 1999; 
Bellamy et al., 2002), and they are 100- to 1000-fold higher than the NO 
concentrations found following NMDA receptor activation in intact brain tissue (Lin 
et al, 1996; Griffiths et al, 2002).
Overall, the previous indirect evidence that NO affects NMDA receptor 
function is questionable and this, together with the additional direct evidence 
presented here, places the hypothesis that NO regulates the functioning of synaptic 
NMDA receptors in serious doubt.
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Chapter 4 
Mechanisms of basal NO synthesis in the hippocampus
h-----------------------------------------------------------------------------------------------------------
4.1 Introduction
4.1.1 NO/cGMP signal transduction pathway
The NO/cGMP signal transduction pathway is thought to play an important role 
during synaptic plasticity, being involved in LTD in the cerebellum and striatum, and 
in LTP in the hippocampus and cerebral cortex (for more details see general 
introduction; 1.6.3). In cerebellar and striatal LTD, NO appears to be generated either 
presynaptically or in intemeurons, and to exert its action postsynaptically. In contrast, 
NO is synthesised postsynaptically in cortical and hippocampal LTP, and is believed 
to act as a retrograde messenger on presynaptic terminals, although postsynaptic 
actions of NO in the hippocampus have also been reported (Ko & Kelly, 1999; Lu et 
al., 1999).
In the CA1 region of the hippocampus, LTP is induced by brief tetanic 
stimulation of afferent glutamatergic fibers, and typically exhibits a form of LTP that 
critically depends on postsynaptic activation of the NMDA receptor (Bliss & 
Collingridge, 1993). As described in the general introduction (section 1.2), NMDA 
receptors are physically coupled to nNOS via PSD-95 (Brenman et al., 1996a;
•jt
Christopherson et al., 1999), an arrangement that allows the influx of Ca into the 
postsynaptic cell to couple to NO formation. In the previous chapter the proposed 
regulation of the NMDA receptor by NO was discussed, and determined to be of 
questionable physiological relevance.
The NMDA receptor/NO/cGMP pathway has been well-characterised in the 
cerebellum, where robust cGMP responses to excitatory amino acids and relatively 
low PDE activity facilitate the monitoring of cGMP production. However the pathway 
has not been as well-described in the hippocampus, which is surprising considering 
the importance of excitatory amino acid circuits in a number of physiological 
(learning and memory) and pathophysiological conditions (epilepsy, stroke, head 
trauma).
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Localisation studies have revealed NMDA receptors to be abundantly 
expressed in the hippocampus, with particular prominence in the stratum radiatum 
(Monaghan et al., 1984). nNOS staining is found to be largely confined to a 
subpopulation of GABA-containing intemeurons in the stratum oriens and stratum 
radiatum (Bredt et al., 1991; Valschanoff et al., 1993; Lumme et al., 2000), whereas 
when weak fixation protocols are followed staining can also be identified in CA1 
pyramidal cells (Endoh et al., 1994; Wendland et al., 1994; Blackshaw et al., 2003). 
In the case of NO-activated GC, the principal mediator of NO signal transduction, its 
distribution has been localised by in situ hybridisation to the pyramidal layers of CA1 
- CA3 and to the granule layer of dentate gyrus (Matsuoka et al., 1992; Burgunder & 
Cheung, 1994), whilst cGMP immunostaining can be detected uniformly throughout 
the hippocampus, with the pyramidal and granule cells exhibiting the most intense 
signal (Southam & Garthwaite, 1993). Interestingly, recent light and electron 
microscopy studies reveal NO-activated GC to associate with nNOS at subpopulations 
of synapses in the hippocampus (De Vente et al, 1998; Burette et al., 2002): nNOS 
accumulation is observed at the postsynaptic density of asymmetric axospinous 
synapses, whereas NO-activated GC concentrates close to the plasma membrane in 
presynaptic axon terminals. Furthermore, the anatomical relationship between 
presynaptic NO-activated GC and postsynaptic nNOS is spatially precise; although 
only a modest fraction of synapses express either nNOS or NO-activated GC, NOS- 
positive post synaptic densities are usually postsynaptic to NO-activated GC-positive 
axon terminals and vice versa (Burette et al., 2002). These studies provide 
neuroanatomical support for the hypothesis that NO can act as a synapse-specific 
retrograde messenger in a subpopulation of synapses in the CA1 region of the 
hippocampus. However, it must also be noted that, in contrast to the above studies, a 
recent immunohistochemical study failed to find significant co-localization of nNOS 
and NO-activated GC in the hippocampus (Ding et al., 2004).
Electrophysiological investigations additionally provide support for the 
retrograde messenger hypothesis: application of exogenous NO, timed to coincide 
with weak tetanic stimulation of afferent fibers, elicited an NMDA receptor- 
independent persistent potentiation of hippocampal synaptic transmission that 
occluded LTP (Zhuo et al., 1993, 1994; Malen & Chapman, 1997; Bon & Garthwaite, 
2003). Furthermore, recent observations by Bon & Garthwaite (2003) indicate that
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LTP requires both a tonic NO level and a phasic NO signal arising from tetanic 
stimulation, and that the post-tetanus time window during which NO is required is <
15 min (Haley et a l, 1992; Bon & Garthwaite, 2003). Figure 4.1 is a schematic 
diagram which illustrates the current understanding of the requirement for NO during 
LTP.
• NO burst
Tonic NO
►
Time
Figure 4.1 Schematic representation o f the requirement for NO during LTP.
Despite the importance of both a tonic NO level at the time of LTP induction 
lasting for < 15 min post LTP induction, and a phasic NO signal coinciding with LTP 
induction, the isoform of NOS responsible for NO production in the hippocampus has 
so far not been investigated. Measurements of cGMP reveal a biologically active level 
of NO to exist, even in unstimulated hippocampal slices, which is increased following 
tetanic stimulation (Chetkovich et al., 1993). However, in contrast to the relatively 
high cGMP levels observed in the cerebellum, cGMP levels in the hippocampus are 
low, partially as a consequence of high PDE activity (DeVente & Steinbusch, 1992). 
Therefore, in order to study endogenous NO production in the hippocampus, using 
cGMP as an index, studies must be carried out in the presence of a PDE inhibitor such 
as IBMX, and an enhancer of NO-activated GC in order to sensitise NO-activated GC
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towards NO, thereby increasing the cGMP accumulation resulting from any given 
stimulus.
4.1.2 Enhancers of NO-activated GC
The main mechanism of physiological activation and pharmacological inhibition of 
NO-activated GC is via changes in the state of the enzyme’s haem-moiety; however, 
other regulatory mechanisms are also known to exist. YC-1 (3-(5'-hydroxymethyl- 
2'fiiryl)-l-benzyl indazole) is recognized as an activator of NO-activated GC, and 
whilst the precise mechanism by which YC-1 exerts its actions is not yet clear, the 
proposed mechanism of action is through the binding of YC-1 to an allosteric site 
within NO-activated GC, which acts to increase the catalytic rate and sensitises the 
enzyme towards NO and CO (Ko et al., 1994; Hoenicka et al., 1999). Kinetic and 
equilibria investigations of NO-activated GC in the presence of YC-1 has led to a 
mechanistic model, which attributes a crucial role to the proximal bond that connects 
the haem iron to histidine-105 residue of the p-subunit of NO-activated GC (Zhao & 
Marietta, 1997; Zhao et al., 1998a), but also requires the protein control of the distal 
environment (Kharitonov et al., 1999). In addition it has been put forward that there is 
an intramolecular sixth ligand of the haem, which oscillates on and off the sixth 
coordinate, thereby conferring a certain degree of ligand specificity (Hobbs, 1997). 
The direct binding of NO-activated GC activators to this site has been proposed to 
block this intramolecular binding site, and thereby strengthen the binding of NO to the 
enzyme. YC-1 has been shown to inhibit platelet aggregation via the elevation of 
cGMP levels leading to VASP phosphorylation (Wu et al., 1995, 1997; Friebe et al. 
1998; Becker et al., 2000), and to relax pre-contracted aortic rings (Mulsch et al, 
1997).
Recently a new allosteric compound, BAY 41-2272, has been described
which is a pyrazolopyridine derivative able to stimulate NO-activated GC directly via
an NO-independent, but a haem-dependent mechanism, and affects the activity of
NO-activated GC in a manner similar to YC-1 (Straub et al., 2001; Stasch et al.,
2001). However, in contrast to YC-1, BAY 41-2272 exhibits a distinctly higher
potency, of about two orders of magnitude, and does not appear to inhibit PDE
activity in concentrations up to 10‘ 5 M (Stasch et al., 2001), thereby offering
significantly greater selectivity. BAY 41-2272 has been found to be a potent
vasodilator of aortic rings in vitro, and in vivo exhibits antiplatelet activity, reduces 
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mean arterial blood pressure in normal and hypertensive rats, and increases survival 
rates in a low-NO rat model of hypertension (Stasch et al., 2001; Straub et al., 2001). 
Figure 4.2 compares the structure of YC-1 and BAY 41-2272, highlighting the 
similarities in their structures.
Figure 4.2: Structure o f (a) YC-1 and (b) BAY 41-2272. The common backbone between the
compounds is highlighted in red.
Photoaffinity labeling studies reveal that both compounds bind to the N- 
terminal region of the a-subunit in close proximity to two cysteine residues (aCys 238 
and aCys 243), which highlights a unique, allosteric regulatory site on NO-activated 
GC distinct from the NO-binding site (Stasch et al., 2001; Becker et al., 2001).
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4.1.3 Aim
The aim of the present study was to investigate the endogenous production of NO in 
the hippocampus. Initially the isoform of NOS responsible for the basal levels of NO 
was studied by examination of cGMP accumulation in adult hippocampal slices in the 
presence of a PDE inhibitor to prevent the breakdown of cGMP, and BAY 41-2272 to 
sensitize the enzyme towards NO (as depicted in figure 4.3).
Nitric Oxide
L-arginine
cGMP
BAY 41-2272
EHNA
GMP
Figure 4.3: NO synthesis and breakdown in the CNS. 
Points ofpharmacological regulation of this pathway are marked.
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4.2 Methods
4.2.1 Hippocampal tissue preparation
Hippocampal slices were prepared as described in chapter 2 (2.2).
4.2.2 Aortic ring preparation
Aortic rings were prepared from 6  to 8 -week-old male Sprague-Dawley rats (Charles 
River, Margate, UK). The animals were killed humanely according to Home Office 
regulations by way of stunning followed by cervical dislocation. The thoracic portions 
of rat aortas were rapidly removed from the animals and immediately immersed in 
cold ( 0 - 4  °C) ACSF solution, equilibrated with 95 % O2  and 5 % CO2 . Thoracic 
aortic portions were gently cleaned of adhering perivascular connective tissue and 
blood was gently flushed out. Aortic rings were then cut into ~ 3 mm segments with a 
razor blade, and maintained in carbogenated ACSF solution. Typically 6  rings were 
obtained from each aorta, 5 or 6  rats were used for each experiment, and the rings 
were randomly divided into groups before incubation.
4.2.3 cGMP measurement
Hippocampal slices or aortic rings were allowed to recover in carbogenated ACSF 
maintained in a shaking water bath at 30 °C for at least 1 - 2 h before use. 
Hippocampal slices or aortic rings were then transferred to a fresh solution containing 
the general PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX; 1 mM) or the PDE2 
inhibitor erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride (EHNA; 300 pM) for 
15 min, before being exposed to either the enhancer of NO-activated GC, BAY 41- 
2272 for 5 min, or to NMDA for 2 min. All pharmacological agonists/antagonists 
were present for the same period as the PDE inhibitor except for wortmannin, 
raloxifene and LY294002, in which the slices were pre-incubated for 30 min, 15 min, 
and 10 min respectively, prior to PDE inhibition in accordance with previous studies 
(Simoncini et al, 2000; Simoncini et al., 2002a; Isenovic et al., 2002). At the end of 
the exposure the hippocampal slices or aortic rings were removed, inactivated by 
immersion in boiling hypotonic inactivation buffer for a minimum of 5 min, and 
homogenized by sonication.
The protein content and cGMP accumulation were determined as described in 
chapter 2 (2.4).
88
4. Mechanisms of basal NO synthesis in the hippocampus
_l---------------------------------------------------------------------------------------------------------------------------
4.2.4 Western blotting
Mouse DNA was prepared as described in chapter 2 (2.5.1), of which 15 pi was 
combined with 5 pi loading dye of the following composition: 100 mM Tris-HCl (pH
6 .8 ), 4 % (w/v) SDS, 0.2 % (w/v) bromophenol blue, 20 % (v/v) glycerol, and 10 % 
(v/v) (3-mercaptoethanol. Samples were heated to 100 °C for 5 min, and then separated 
by electrophoresis on a 10 % SDS-PAGE gel at 200 mV for 45 min. Proteins were 
then transferred to nitrocellulose membrane (Hybond ECL; Amersham Biosciences, 
Buckinghamshire, UK) and blocked for 2 h at room temperature in 5 % (w/v) non-fat 
milk made up in PBST buffer of the following composition: 80 mM Na2HPC>4 , 20 
mM NaH2 PC>4 , 100 mM NaCl, and 0.1 % (v/v) Tween 20. Membranes were incubated 
with the primary anti-eNOS antibody (1:2000 dilution made up in PBST; BD 
Biosciences, Oxford, UK) overnight at 4 °C. The membranes were washed 3 times in 
PBST to remove unbound antibodies before being incubated in the anti-mouse- 
horseradish peroxidase-conjugated secondary antibody (1:4000 dilution made up in 
PBST; DAKO, Ely, Cambridgeshire, UK) for 1 hr at room temperature. A final 
triplicate wash was performed in PBST to remove unbound secondary antibody, and 
then protein bands were visualised using an enhanced chemiluminescence kit (ECL 
Plus; Amersham Biosciences, Buckinghamshire, UK) according to the manufacturer’s 
protocol.
4.2.5 Resin preparation
The amino acids arginine and citrulline can be separated according to their different 
charges. The resin AG 50W X 8  resin (Biorad) binds positively charged species, 
including arginine. The resin was fully hydrated by washing 4 times with an excess of 
1 M NaOH, and then washing in distilled water until the effluent pH was < 8 . The 
resin was made up to a 50 % (v/v) packed resin slurry with 1 mM EDTA in 20 mM 
pH 7.2 HEPES buffer by ‘eye’. This resin was kept stirring prior to the addition to 
samples to ensure that a constant volume of buffer and resin was added. The 
efficiency of arginine binding to the resin was tested by counting the radioactive 
content of the 14C-arginine standards before and after incubation with the resin slurry.
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4.2.6 NOS homogenate assay
Hippocampal tissue was added to extraction buffer (EB buffer), maintained at 4 °C, of 
the following composition: 20 mM HEPES, 1 mM EDTA, 320 mM sucrose, and in 
the presence of a protease inhibitor cocktail (Roche 1 873 580). 10 mg/ml 
phenylmethylsulphonyl fluoride (PMSF) was then added, the mixture sonicated, and 
the homogenate protein content determined as described in chapter 2 (2.4).
The NOS activity of each enzyme extract was determined by the conversion of 
radiolabelled arginine to citrulline (Knowles & Salter, 1998). Briefly, 20 pi of enzyme 
extract was added to 230 pi 20 mM HEPES, pH 7.4 containing 50 mM valine, 1 mM 
DTT, 0.2 mM CaCl2 , 1 mM MgCl2 , 1 mM L-citrulline, 100 pM NADPH, 10 pM 
BH4 , 80 U/ml CaM, 1 pM FAD, 1 pM FMN and 19 pM L-arginine, 0.1 pM 1 4C- 
arginine. Valine is included in this mixture at such high concentrations to limit 
arginase activity in the absence of more selective inhibitors. In control reactions 1 
mM EGTA was also included. The incubation mix was kept at 37 °C for 20 minutes, 
and then the reaction terminated by the addition of 750 pi resin slurry and mixing 
thoroughly. After the resin had settled, 300 pi of the supernatant was taken and added 
to scintillant, and the radioactive content was determined. The arginine content was 
expressed as pmol arginine/mg protein.
4.2.7 Data Analysis
All data are presented as the mean ± S.E.M; concentration response data were fitted 
with the logistic function on Origin 6.1 (equation 4.1). Differences between 
experimental results were analysed using SPSS and GraphPad Instat software utilizing 
a one-way or two-way ANOVA with Tukey’s post-hoc test; P values of < 0.05 were 
regarded as significant.
y  =
A 1 -  A;
1 + x 0l
°)
+  A
Equation 4.1: Origin logistic function. Where x = concentration of drug; xo =  centre point 
on curve; p  = power; A} — initial y  value; A2 =  final y  value; y  =  cGMP level.
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4.3 Results
4.3.1 Pharmacological discrimination between eNOS and nNOS activity
4.3.1.1 nNOS inhibition
Although there are numerous estimations in the literature regarding the potency of the 
various NOS inhibitors, a direct comparison is difficult owing to the use of various 
assay systems, assay conditions and species. As nNOS forms a complex with the 
NMDA receptor in the hippocampus (Brenman et a l, 1996a), NMDA was used as a 
positive control for nNOS-induced NO production (and thereby nNOS-induced cGMP 
accumulation) in hippocampal slices. Incubation of slices with increasing 
concentrations of NMDA resulted in a concentration-dependent increase in cGMP 
levels which was maximal at 100 pM, with an EC5 0  of 10 pM NMDA (figure 4.4). 
These results are very similar to those obtained previously (East & Garthwaite, 1991).
Incubation of slices with 100 pM NMDA in the presence of increasing 
concentrations of three different nNOS inhibitors, L-VNIO, NPA or 1400W, resulted 
in a concentration-dependent decrease in cGMP levels with IC5 0  values of 0.003 pM 
(figure 4.5a), 0.03 pM (figure 4.5b), and 0.03 pM (figure 4.5c) respectively. It must 
be noted that for the purpose of fitting the data in figure 4.5 with the logistic function, 
the control cGMP level (i.e. cGMP level with no antagonist present) is shown as le ' 8 
pM. These results reveal the nNOS inhibitors to be more potent than observed in 
previous studies (Table 4.2; Boer et al., 2000; Cooper et al., 2000).
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Figure 4.4: Concentration-response curve fo r NMDA on cGMP levels in adult rat 
hippocampal slices (2 min exposure; n = 5).
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Figure 4.5: Effect of nNOS inhibitors on NMDA-stimulated cGMP levels in adult rat 
hippocampal slices in presence of IBMX.
A concentration dependent decrease in cGMP levels was observed in the presence of 
increasing concentrations of (a) L-VNIO, (b) NPA, and (c) 1400W (n = 5).
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4.3.1.2 eNOS inhibition
Due to the fact that eNOS activity is essential for the maintenance of blood flow and 
blood pressure, and that there is no known therapeutic benefit of eNOS inhibition, 
little effort has been directed towards the production of NOS inhibitors which are 
selective for eNOS over nNOS. Two compounds frequently used to inhibit eNOS are 
wortmannin and LY294002, both of which reduce eNOS activity via an indirect 
action on PI3-K. Similarly to nNOS, a positive control for eNOS-generated NO is 
required in order to investigate the potencies of these compounds on eNOS-induced 
cGMP accumulation in hippocampal slices. Raloxifene, a selective oestrogen receptor 
modulator, has been shown to acutely stimulate NO synthesis, an effect that is 
associated with improved endothelium-dependent relaxation (Figtree et al, 1999; 
Simoncini & Genazzani, 2000; Simoncini et al, 2002a,b; Wassmann et al, 2002). 
However, incubation of hippocampal slices with increasing concentrations of 
raloxifene did not result in an increase in cGMP levels (figure 4.6).
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Figure 4.6: Effect of raloxifene on cGMP accumulation in adult rat hippocampal slices.
A concentration-dependent decrease in cGMP levels was observed in the presence of 
increasing concentrations of raloxifene (30 min exposure; n = 5). 1 mM IBMXwas applied to 
the slices for the final 15 min of incubation with raloxifene.
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In a further attempt to find a positive control for the actions of wortmannin 
and LY294002, slices were incubated with two alternative compounds at a 
concentration previously found to stimulate eNOS activity: tumour necrosis factor 
alpha (TNFa; Barsacchi et al., 2003) and bradykinin (Harris et al., 2001). However, 
no significant change in cGMP accumulation was observed when hippocampal slices 
were exposed to either TNFa (figure 4.7a) or bradykinin (figure 4.7b). Furthermore, 
no significant change in cGMP levels was observed in the presence of wortmannin or 
LY294002 and TNFa, whereas wortmannin was found to significantly inhibit basal 
cGMP accumulation in the presence of bradykinin.
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Figure 4.7: Effect of TNFa and bradykinin on cGMP accumulation in adult rat 
hippocampal slices. No significant change in cGMP accumulation was seen on application of 
(a) 50 ng/ml TNFa or (b) 1 pM bradykinin (15 min exposure; n = 5). *P < 0.05 vs. IBMX 
control; one-way ANOVA with Tukey’spost-hoc test.
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When interpreting the results with raloxifene, TNFa, and bradykinin, it must 
be taken into account that the cGMP levels involved are at the boundary of detection 
and therefore absolute values are unlikely to be trustworthy. It must also be noted that 
they are the result of single experiments which were not investigated further given 
that no significant difference in cGMP accumulation was noted in their presence.
4.3.2 Effect of NOS inhibition on cGMP accumulation in presence of IBMX
4.3.2.1 Measurement of BAY 41-2272-stimulated cGMP production
The effect of BAY 41-2272 on cGMP levels in rat hippocampal slices was measured 
in the presence of the general PDE inhibitor, IBMX (figure 4.8). In the absence of 
BAY 41-2272, the cGMP content of the hippocampal slice was determined to be 2.9 ± 
0.7 pmol cGMP/mg protein. Incubation of slices with increasing concentrations of 
BAY 41-2272 resulted in a concentration-dependent increase of cGMP levels. Based 
on the ensuing accumulation of cGMP, the EC5 0  for BAY 41-2272 was 10 pM (figure
4.8). To gauge the proportion of the cGMP response that could be regarded as NO- 
dependent, slices were incubated with increasing concentrations of BAY 41-2272 in 
the presence of the general NOS inhibitor, L-NNA (100 pM). Incubation with L-NNA 
prevented the increase in cGMP levels produced by BAY 41-2272, although a 
residual increase in NOS-insensitive cGMP levels can be observed at the highest 
concentration of BAY 41-2272. This residual increase is presumably attributable to 
the direct activation of NO-activated GC by BAY 41-2272. 30 pM BAY 41-2272 
resulted in almost maximal stimulation of NO-activated GC whilst having a relatively 
small NO-insensitive component, and therefore this concentration was used in all 
subsequent experiments.
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Figure 4.8: Concentration-response curve for BAY 41-2272 on cGMP levels in adult rat 
hippocampal slices. A concentration- dependent increase in cGMP levels was observed on 
application of BAY 41-2272 (5 min exposure) which was significantly inhibited in the 
presence of 100 pM L-NNA (n = 6).
4.3.2.2 Effect o f different NO S inhibitors in rat hippocam pal slices
No significant difference in basal cGMP levels was observed in the presence or 
absence of the general NOS inhibitor, L-NNA (100 pM). However, incubation with 
30 pM BAY 41-2272, a concentration of BAY 41-2272 previously found to enhance 
NO-dependent cGMP formation, resulted in a ~ 10-fold increase in cGMP levels 
(figure 4.9). This increase was inhibited by 100 pM L-NNA to a cGMP level not 
significantly different to that obtained following incubation with L-NNA in the 
absence of BAY 41-2272, confirming that endogenous NO production was 
responsible for the increased level of cGMP. In contrast, no significant effect on NO- 
dependent cGMP production was observed by the application of the NMDA 
antagonist, D-AP5 (100 pM). This suggests that endogenous NO production in the 
hippocampus is NOS-dependent, but NMDA receptor-independent.
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Figure 4.9: Endogenous NOS activity in adult rat hippocampal slices.
Slices were incubated in the presence of 1 mM IBMX for 15 min; no significant change in 
cGMP levels was observed in the presence of L-NNA (100 pM). Incubation with BAY 41-2272 
(5 min exposure 30 pM) resulted in an increase of cGMP accumulation which was inhibited 
by L-NNA (100 pM), but was unaffected by D-AP5 (100 pM; n = 5). *P < 0.05 vs. BAY41- 
2272- treated slices; one-way ANOVA with Tukey’s post-hoc test.
The finding that basal NO-dependent cGMP levels were NMDA receptor-
independent indicates that the nNOS isoform may play little or no role in basal NO
production in the hippocampus. In order to investigate this matter further, and to
determine which isoform of NOS may be responsible, hippocampal slices were
exposed to different NOS inhibitors in the presence of BAY 41-2272. In accordance
with previous observations, application of 30 pM BAY 41-2272 resulted in an
increase in cGMP accumulation. This increase was significantly reduced by ~ 25 %
following incubation with L-VNIO (0.1 pM), 1400W (1 pM), or NPA (1 pM; figure
4.10). Concentrations of L-VNIO, 1400W and NPA were chosen that produced > 80
% inhibition of nNOS activity, but that were not supramaximal so as to avoid
potential inhibition of eNOS activity since all three compounds are also known to
inhibit eNOS activity, albeit with a lower potency (Boer et al., 2000; Zhang et al.,
1997). As 1400W is a more potent inhibitor of iNOS than nNOS (Boer et al., 2000;
Young et al., 2000), application of 1400W is additionally a control for the
contribution of iNOS to endogenous NO levels. Two different general NOS inhibitors 
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(L-NIO and L-NNA) significantly inhibited cGMP accumulation, confirming the NO- 
dependence of the cGMP levels. Although there is no control for the action of 
wortmannin or LY294002 on eNOS activity, the presence of LY294002 or 
wortmannin produced a significant decrease in cGMP levels (figure 4.10). Taken 
together, these results suggest that both eNOS and nNOS may contribute towards 
basal NO production in rat hippocampal slices.
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Figure 4.10: Effect of different NOS inhibitors on cGMP levels in adult rat hippocampal
slices. Incubation of slices with nNOS inhibitors (L-VNIO, 0.1pM; 1400W, 1 pM; NPA, 1 pM) 
resulted in the reduction of cGMP levels by ~ 25 %. Application of 100 pM L-NNA or 100 L- 
NIO almost completely inhibited cGMP accumulation, whereas 1 pM wortmannin and 50 pM  
LY294002 reduced cGMP levels by up to 50 % (n = 5). *P < 0.05 vs. BAY 41-2272 treated 
slices; one-way AN OVA with Tukey’s post-hoc test.
4.3.3 Effect of neurotransmitter inhibitors on cGMP accumulation in rat 
hippocampal slices
Pharmacological agents were used to investigate potential mechanisms which may 
contribute to changes in cGMP levels in hippocampal slices under resting conditions. 
Slices were incubated in ACSF containing 1 mM IBMX for 15 min in the presence or 
absence of a cocktail containing 2 - 3  pharmacological antagonists. Initially, various 
antagonist cocktails were used in order to detect any mechanisms worthy of further 
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study. The increase in cGMP production observed following 5 min exposure to BAY 
41-2272 was reduced by the AMPA antagonists, CNQX and NBQX, the voltage- 
gated Na+ channel inhibitor, tetrodotoxin (TTX), a cocktail of the a  and P 
adrenoreceptor antagonists, nicergoline and sotalol, and by the NO-activated GC 
inhibitor, ODQ (figure 4.11a). No significant effect on cGMP accumulation was 
observed upon incubation with the mGluR antagonist, MCPG, a cocktail containing 
the GABAa antagonist, picrotoxin and the muscarinic antagonist, atropine, a cocktail 
containing the opioid antagonist, naloxone, the adenosine antagonist, DPCPX and the 
cannabinoid antagonist, AM 251, a cocktail containing the muscarinic antagonist, 
scopolamine and the nicotinic antagonist, benzoquinonium, or a cocktail containing 
the dopamine antagonist, AJ-76, and the serotonin antagonist, methysergide (figure 
4.11a). Table 4.1 summarises all the pharmacological agents utilised in figure 4.11, 
including their respective concentrations and the pharmacological actions attributed to 
them.
In order to further explore which mechanisms may contribute to resting 
endogenous cGMP levels in the rodent hippocampus, slices were incubated with the 
individual pharmacological agents that looked promising when present as part of a 
cocktail. In addition, the adenosine and cannabinoid antagonists, DPCPX and AM 251 
respectively, were also tested to ensure that a change in cGMP levels was not masked 
by possible opposing results of the individual compounds. When rat hippocampal 
slices were incubated with individual antagonists, the increase in cGMP production 
induced by 5 min exposure to BAY 41-2272 was reduced by incubation with TTX, 
CNQX, AM 251, DPCPX, sotalol or in the absence of external Ca2+ (Ca2+-free ACSF 
containing the Ca2+ chelator, EGTA (1 mM; figure 4.11b). No significant effect on 
cGMP accumulation was observed in the presence of nicergoline. These results 
suggest that resting cGMP levels in the hippocampus may be influenced by Na+ 
channels, AMPA receptors, cannabinoid receptors, adenosine receptors, p
*7*4-adrenoreceptors, and is partially dependent on external Ca .
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Figure 4.11: Effect o f pharmacological agents on cGMP levels in adult rat hippocampal
slices. Incubation of slices in ACSF containing IBMX (ImM) and BAY 41-2272 (30 pM) in the 
absence or presence of a variety ofpharmacological agents: CNQX (100 pM), NBQX (100 
pM), TTX (1 pM), MCPG (1 mM), picrotoxin (100 pM), atropine (1 pM), naloxone (10 pM), 
DPCPX (0.1 pM), AM251 (2 pM), nicergoline (50 pM), sotalol (100 nM), scopolamine (50 
pM), benzoquinonium (100 nM), AJ-76 (10 pM), methysergide (100 nM), ODQ (1 pM) and 
EGTA (1 mM). *P < 0.05 vs. BAY 41-2272 treated slices; one-way ANOVA with Tukey’s post-
hoc test.
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A gen t
C on cen tra tion
P h arm acolog ica l
A ction
R eferen ce
CNQX 100 pM AMPA/kainate antagonist Blake et al., 1989 Yamada et al., 1989
NBQX 100 pM Non-NMDA antagonist Goldstein & Litwin, 1993 Cronberg et al., 2004
TTX 1 pM Na channel blocker Kaneda et al., 1989 Kononenko et al., 2004
MCPG 1 mM mGluR antagonist Frenguelli et al., 1993 Davies et al., 1995
Picrotoxin 100 pM GABA A antagonist Chevaleyre & Castillo, 2004
Atropine 1 pM mAChR antagonist Imbrogno et al., 2003
Naloxone 10 pM Opioid antagonist Dunwiddie et al., 1982
DPCPX 0.1 pM Adenosine A 1 antagonist Alzheimer et al, 1991
AM 251 2 pM Cannabinoid CB1 antagonist Gately et al., 1996
Nicergoline 50 pM a antagonist Heitzera/., 1986 Takahashi et al., 1990
Sotalol 100 nM P antagonist Imbrogno et al., 2003
Scopolamine 50 pM Muscarinic antagonist Shibata et al., 1992 Shinoura et al., 2002
Benzoquinonium 100 nM Nicotinic antagonist Pereira et al., 1993 Yeoman et al., 1993
AJ-76 10 pM Dopamine D2 antagonist Gifford & Johnson, 1993
Methysergide 10 pM 5HT1/5HT2 antagonist Ge & Barnes, 1996 Tuladhar et al., 1996
Table 4.1: Pharmacological agents included in antagonist cocktails.
4.3.4 cGMP levels in rat hippocampal slices after incubation with different 
NOS inhibitors in presence of EHNA
One explanation for the numerous pharmacological antagonists which result in the 
inhibition of cGMP accumulation may be due to the fact that IBMX is not a “clean” 
compound: in addition to its action as a non-specific PDE inhibitor, IBMX is also 
known to act as an antagonist of adenosine receptors (Choi et al, 1988), a well- 
established modulator of synaptic transmission and neuronal excitability in the CNS 
(Dunwiddie & Fredholm, 1989; Greene & Haas, 1991). A second possible 
explanation relates to the fact that IBMX acts as a non-specific PDE inhibitor, 
preventing the breakdown of cAMP as well as cGMP. Various studies find that cross­
talk arises between the cAMP and cGMP signalling pathways capable of cross­
modulation of each other’s synthesis, degradation and actions (Vigne et al., 1994; 
Suvama & O’Donnell, 2002). Therefore the fact that IBMX inhibits the breakdown of 
both cAMP and cGMP may also potentially complicate the interpretation of 
biochemical results.
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In order to address this possibility, cGMP accumulation experiments were 
repeated using the selective PDE2 inhibitor, EHNA. PDE2 exhibits strong expression 
in neurons of the hippocampus (Repaske et al, 1993), and although it is able to 
degrade both cAMP and cGMP with similar Km and Kd in vitro (Martins et al, 1982), 
studies carried out on cortical neurons and hippocampal slices indicate that PDE2 
inhibition selectively increases only cGMP levels (Suvama & O’Donnell, 2002; Boess 
et al, 2004).
4.3.4.1 Optimisation of EHNA concentration in presence of BAY 41-2272
In order to determine the optimum concentration of EHNA required for PDE2 
inhibition, cGMP accumulation was determined in hippocampal slices following 
exposure to BAY 41-2272. Exposure of hippocampal slices to 30 pM BAY 41-2272 
(5 min) in the presence of increasing concentrations of EHNA resulted in a 
concentration dependent increase in cGMP levels (figure 4.12). Over the 
concentration range investigated, the increase in cGMP accumulation did not reach a 
maximum, an observation consistent with previous findings (van Staveren et al, 
2001). A concentration of 300 pM EHNA produced roughly equivalent cGMP 
accumulation to that observed with IBMX (figure 4.4), and therefore this 
concentration was used in all subsequent experiments.
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Figure 4.12: Concentration-response curve for EHNA on cGMP levels in adult rat 
hippocampal slices. (15 min exposure; n = 5).
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4.3.4.2 Selectivity of nNOS inhibitors on cGMP accumulation
To check the validity of the control experiments obtained in the presence of IBMX, 
cGMP accumulation was measured in response to 2 min exposure to NMDA in the 
presence of EHNA (300 pM). Similar to observations in the presence of IBMX, 
incubation of slices with increasing concentrations of NMDA resulted in a 
concentration-dependent increase of cGMP levels which was maximal at 100 pM, 
with an E C 50 of ~ 10 pM NMDA (figure 4.13).
As previous estimations for the nNOS inhibitor IC5 0  values were obtained in 
the presence of IBMX, the potencies of the nNOS inhibitors in the presence of EHNA 
were tested. Incubation of slices with 100 pM NMDA in the presence of increasing 
concentrations of L-VNIO and 1400W, resulted in a concentration-dependent 
decrease in cGMP levels with IC5 0  values of 0.01 pM (figure 4.14a), and 0.01 pM 
(figure 4.14b), respectively. Similarly to results obtained in the presence of IBMX, for 
the purpose of fitting the data in figure 4.14 with the logistic function, the control 
cGMP level (i.e. cGMP level with no antagonist present) is shown as le ' 9  pM. These 
results reveal the potencies of L-VNIO and 1400W for nNOS inhibition to be very 
similar whether in the presence of IBMX or EHNA.
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Figure 4.13: Concentration-response curve for NMDA-stimulaled cGMP levels in adult rat 
hippocampal slices in presence of EHNA (2 min exposure to NMDA; n =  5).
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In order to test the selectivity of the inhibitors for nNOS over eNOS at the 
concentrations used in all subsequent experiments, their action on cGMP 
accumulation was observed in rat hippocampal slices following NMDA activation 
(nNOS), and in aortic rings following ACh stimulation (eNOS). Incubation of 
hippocampal slices with 100 pM NMDA resulted in a ~ 10-fold increase in cGMP 
levels, which was inhibited by the presence of 1 pM 1400W, 1 pM NPA or 0.1 pM L- 
VNIO (figure 4.15a). This confirms that NO-generation from nNOS is predominantly 
inhibited at these concentrations.
In contrast, incubation of aortic rings with 10 pM ACh resulted in a ~ 12-fold 
increase in cGMP levels which was not significantly affected by the presence of 1 pM 
1400W, 1 pM NPA or 0.1 pM L-VNIO (Figure 4.15b). However, this increase was 
prevented by 100 pM L-NNA, confirming that endogenous NO production was 
responsible for the increased level of cGMP. Therefore these results indicate that at 
the concentrations applied, 1400W, NPA and L-VNIO are all selective inhibitors for 
the nNOS over the eNOS isoform.
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Figure 4.14: Effect o f nNOS inhibitors on NMDA-stimulated cGMP levels in adult rat 
hippocampal slices in presence o f EHNA.
A concentration dependent decrease in cGMP levels was observed in the presence of 
increasing concentrations of (a) L-VNIO, and (b) 1400W (n = 5).
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Figure 4.15: Selectivity o f nNOS inhibitors.
(a) Adult rat hippocampal slices were incubated in the presence o f300 pM EHNA for 15 min. 
Application of BAY 41-2272 (30 pM; 5 min exposure) resulted in an increase in cGMP 
accumulation which was inhibited by 1400W (1 pM), NPA (1 pM) or L-VNIO (0.1 pM). (b) 
Adult rat aortic rings were incubated in the presence of 1 mM IBMX for 15 min. ACh (10 pM;
1 min exposure) resulted in an increase in cGMP accumulation which was prevented by L- 
NNA (100 pM). No significant change in cGMP levels was observed in the presence of1400W 
(1 pM), NPA (1 pM) or L-VNIO (0.1 pM). *P < 0.05 vs. NMDA or ACh treated slices (n = 5); 
one-way AN OVA with Tukey’s post-hoc test.
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4.3.4.3 Effect of different NOS inhibitors on cGMP accumulation in rat 
hippocampal slices
To determine the isoform of NOS responsible for endogenous NO production in the 
hippocampus, slices were exposed to different NOS inhibitors in the presence of BAY 
41-2272. The increase in cGMP accumulation following exposure to BAY 41-2272 
was not significantly reduced following incubation with L-VNIO, 1400W or NPA at 
concentrations inhibiting the majority of nNOS activity (figure 4.16a). Given the 
evidence that 1400W is a more potent inhibitor of iNOS than nNOS (Boer et al., 
2000; Young et al., 2000; Garvey et al., 1997), application of 1400W is additionally a 
control for the contribution of iNOS to endogenous NO levels in the hippocampus. 
Additionally, no significant effect on cGMP accumulation was observed in the 
presence of D-AP5. In contrast, the presence of L-NIO, L-NNA or ODQ produced 
almost complete inhibition of cGMP production, confirming the NO-dependence of 
the cGMP levels (figure 4.16a).
In order to explore the involvement of eNOS in endogenous NO production in 
the hippocampus, slices were exposed to wortmannin or LY294002, both in the
 ^I I
presence, and in the absence, of Ca . In  zero Ca conditions, the experiment was
2~bcarried out in the absence of Ca from the ACSF solution, and in the presence of the 
Ca2+-chelator, EGTA. Application of 30 pM BAY 41-2272 resulted in an increase in 
cGMP accumulation which was significantly inhibited by both wortmannin and 
LY294002 (figure 4.16b; F = 7; d.f. = 2, 63; P = 0.002), and by the absence of 
external Ca2+ (F = 39; d.f. = 1, 63; P < 0.001), as analysed using two-way ANOVA 
with Tukey’s post-hoc test. Furthermore the effect of the inhibitors was found to be 
dependent on whether Ca2+ is present or not (F = 5; d.f. = 2, 63; P = 0.011): that is, 
both wortmannin and LY294002 significantly inhibit BAY 41-2272-stimulated cGMP 
accumulation in the presence of Ca2+, whereas they have no significant effect on 
cGMP levels when compared to the zero Ca2+BAY 41-2272 control (figure 4.16b).
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Figure 4.16: Effect o f different NOS inhibitors on cGMP levels in adult rat hippocampal
slices. Application of BAY 41-2272 (30 pM; 5 min exposure) resulted in an increase in cGMP 
accumulation which was (a) not significantly inhibited by the presence of nNOS inhibitors (L- 
VNIO, 0.1 pM; 1400W, 1 pM; NPA, 1 pM) or D-AP5, but was significantly decreased by 
application of 100 pM  L-NNA or 100 pM L-NIO. *P < 0.05 BAY 41-2272 treated slices (n — 
5); one-way ANOVA with Tukey’spost-hoc test, (b) Incubation with wortmannin (1 pM; 45 
min exposure) or LY294002 (20 pM; 25 min exposure) significantly reduced BAY 41-2272- 
stimulated cGMP accumulation, both in the presence and absence of external Ca2+, when 
compared with BAY 41-2272 treated slices in the presence of Cd2+. *P < 0.05 BAY 41-2272 
treated slices (n = 8 -14); one-way ANOVA with Tukey’s post-hoc test.
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The inconclusive results for the involvement of eNOS in endogenous NO 
levels obtained on application of wortmannin and LY294002 prompted tests of these 
compounds on rat aortic rings which generate NO following eNOS activation. As 
observed previously, 1 min exposure to ACh (10 pM) resulted in ~ 10-fold increase in 
cGMP accumulation (figure 4.17). This increase was not significantly changed by 
incubation with either wortmannin or LY294002, which indicates both compounds do 
not effectively inhibit NO generation from ACh-activated eNOS in rat aorta.
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Figure 4.17: Effect o f wortmannin and LY294002 on cGMP levels in adult rat aortic rings.
Application of ACh (10 pM; 1 min exposure) resulted in an increase in cGMP accumulation 
which was not significantly reduced by LY294002 (20 pM) or wortmannin (1 pM). Subsequent 
addition of 100 pML-NNA confirmed that the cGMP accumulation was NOS-mediated.
*P < 0.05 vs. ACh treated slices (n = 5); one-way ANOVA with Tukey’s post-hoc test.
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4.3.4.4 Effect of different NOS inhibitors on cGMP accumulation in mouse 
hippocampal slices
The absence of selective eNOS inhibitors prevents the direct testing of the 
contribution that eNOS plays in generating endogenous cGMP production in the rat 
hippocampus. Therefore, in order to explore the contribution of eNOS towards tonic 
levels of NO in the hippocampus, cGMP levels were analysed in hippocampal slices 
obtained from 8  - 12 week old eNOS knockout (Huang et al., 1995a) or wild type 
(129SV/C57BL/6) mice. In order to check NOS isoform expression in the wild type 
and eNOS knockout mice, western blot analysis was carried out on hippocampal 
slices from both wild type and eNOS knockout animals. eNOS protein expression in 
wild type animals, and conversely its absence in eNOS knockout mice, was 
confirmed. In contrast, there was no obvious difference in nNOS protein expression 
levels between the two groups of animals (figure 4.18). Additionally, no significant 
iNOS expression was observed in either wild type or eNOS knockout mouse 
hippocampal slices (figure 4.18). These results indicate that there is no significant 
compensation in either nNOS or iNOS expression levels in eNOS knockout mice, 
although the possibility that there might be subtle changes in expression levels cannot 
be ruled out.
iNOS nN O S eN O S
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Figure 4.18: Western blot analysis o f NOS protein in wild type and eNOS knockout mouse
hippocampus.
No difference in iNOS or nNOS expression was observed between wild type (WT) and eNOS 
knockout (KO) hippocampal slices. The absence of eNOS expression in eNOS knockout 
animals was also confirmed. Arrows indicate position of NOS protein.
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In order to investigate the possibility that iNOS is up-regulated within eNOS 
knockout mice, functional NOS activity within the mouse hippocampus was 
determined by means of the conversion of radio-labelled arginine to citrulline. 
Comparison of wild type and eNOS knockout hippocampal slices by means of two- 
way ANOVA analysis with a Tukey’s post-hoc test, however, revealed no significant 
difference in NOS activity (F = 0.02; d.f. = 1, 79; P = 0.885; figure 4.19). Slices were 
incubated in carbogenated ACSF for 1 -  2 hr in a shaking waterbath at 30 °C to be 
consistent with the biochemical studies. No significant difference was also observed 
when the hippocampus was removed, the two ends removed, and then immediately 
frozen, crushed and sonicated without any incubation (F = 4; d.f. = 1, 79; P = 0.06; 
figure 4.19). In contrast, when nNOS and eNOS activity was prevented by the 
removal of Ca2+ (which is obligatory for eNOS and nNOS activity) using the Ca2+ 
chelator, EGTA, the conversion of arginine to citrulline was almost completely 
inhibited (F = 227; d.f. = 1, 79; P < 0.001). This condition presumably reflects no 
significant change in iNOS activity between wild type and eNOS knockout 
hippocampi, since iNOS activity is Ca2+-independent.
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Figure 4.19: NOS activity in wild type and eNOS knockout mouse hippocampus.
No significant difference in NOS activity was observed between wild type (WT) and eNOS 
knockout (KO) hippocampi (n = 5). Incubated slices: 400 pm hippocampal slices incubated 
for 1 - 2 hr at 30 °C in a shaking waterbath, frozen, crushed and sonicated. Crushed 
hippocampus: fresh hippocampi were frozen immediately, crushed and sonicated. *P < 0.05 
vs. WT controls; one-way ANOVA with Tukey’s post-hoc test.
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Following validation of the eNOS knockout model, the contribution of eNOS 
towards basal NO production was explored by analysis of cGMP levels in 
hippocampal slices obtained from eNOS knockout or wild type mice in the presence 
of EHNA. Both experiments were run side-by-side and using the same solutions to 
ensure directly comparable results. Similar to the findings in the rat hippocampus, 5 
min exposure to BAY 41-2272 resulted in an increase in cGMP production in the 
mouse hippocampus (figure 4.20). In wild type mice the increase in cGMP 
accumulation was not significantly changed by nNOS inhibition (1400W, NPA, and 
L-VNIO) or NMDA receptor inhibition (D-AP5), whereas incubation with general 
NOS inhibitors (L-NNA and L-NIO) or ODQ resulted in significant reduction in 
cGMP levels (figure 4.20a).
The increase in cGMP accumulation observed in eNOS knockout mice 
following 5 min exposure to BAY 41-2272 was not significantly changed by 
incubation with 1400W, NPA, L-VNIO, L-NIO, L-NNA or D-AP5 (figure 4.20b). 
However, the increase in cGMP level was significantly decreased by the application 
of ODQ, although to a lesser degree than observed in wild type animals. Comparison 
of cGMP levels between eNOS knockout and wild type animals by means of two-way 
ANOVA analysis with a Tukey’s post-hoc test confirmed a significant effect of 
genotype on cGMP accumulation in the mouse hippocampus (F = 12; d.f. = 1, 264; P 
=  0 .01).
The finding that neither general NOS inhibition nor NO-activated GC 
inhibition produces a more that a 50 % block of cGMP production indicates that there 
is a reduction in NO-dependent cGMP production in mice deficient in eNOS (from ~ 
20 to ~ 10 pmol cGMP/mg protein). One possible explanation for the difference 
observed between wild type and eNOS knockout animals could be that NOS 
inhibitors are not as potent on mouse tissue as on rat tissue. To address this possibility 
the range of 1400W concentrations which inhibit NMDA-stimulated cGMP 
accumulation was determined. Incubation of hippocampal slices with increasing 
concentrations of 1400W resulted in a concentration-dependent decrease in cGMP 
levels which was maximal at 5 pM, with an I C 50 of 0.2 pM 1400W (figure 4.21a).
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Figure 4.20: Effect o f NOS inhibition on cGMP levels in adult mouse hippocampal slices 
in the presence o f EHNA. Incubation of slices with nNOS inhibitors (1400W, 1 pM; NPA, 1 
pM; L-VNIO, I pM), or D-AP5 (100 pM) had no significant effect on cGMP accumulation in 
(a) wild type and (b) eNOS knockout animals. General NOS inhibitors (L-NNA, L-NIO; 100 
pM) significantly reduced cGMP levels in wild type animals, but had no significant effect in 
eNOS knockout animals. Incubation with ODQ resulted in a significant reduction in cGMP 
levels in both wild type and eNOS knockout mice. *P < 0.05 vs. BAY 41-2272 treated slices (n 
= 15); one-way ANOVA with Tukey’s post-hoc test.
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In order to investigate the potencies of the remaining nNOS inhibitors, wild 
type hippocampal slices were incubated with 100 pM NMDA which resulted in a ~ 
10-fold increase in cGMP levels which was significantly inhibited by the presence of 
1 pM 1400W, 1 pM NPA, 0.1 pM L-VNIO or 100 pM L-NNA (figure 4.21b). This 
indicates that the NOS inhibitors are similarly potent in both rat and mouse tissue.
[1400W] (jiM)
100 pM NMDA
Figure 4.21: Effect o f nNOS inhibitors on cGMP accumulation in adult mouse 
hippocampal slices in presence o f EHNA. (a) A concentration dependent decrease in cGMP 
levels was observed in the presence of increasing concentrations of1400W. (b) Application of 
NMDA (100 pM; 2 min exposure) resulted in an increase in cGMP accumulation which was 
inhibited by incubation with L-VNIO (0.1 pM), NPA (1 pM), 1400W (1 pM) or L-NNA (100 
pM). *P < 0.05 vs. NMDA treated slices (n = 5); one-way ANOVA with Tukey’s post-hoc test.
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4.3.5 Effect of neurotransmitter inhibitors on cGMP accumulation in rat 
hippocampal slices in presence of EHNA
In order to investigate the validity of the numerous pharmacological compounds 
which resulted in a reduction in cGMP accumulation when incubated in the presence 
of IBMX, hippocampal slices were incubated in ACSF containing 300 pM EHNA for 
15 min in the presence or absence of the following compounds. As observed 
previously, 5 min exposure to BAY 41-2272 resulted in an increase in cGMP 
production in the hippocampus. This increase was significantly reduced by the 
adrenoreceptor antagonists, nicergoline and sotalol, and by the NO-activated GC 
inhibitor, ODQ (figure 4.22). This result suggests that endogenous NO levels in the 
hippocampus may be influenced by adrenoreceptors, although this line of 
investigation was not pursued any further given the relatively small effects
45 30 pM BAY 41-2272
£  40 -<D
Figure 4.22: Effect o f pharmacological agents on cGMP levels in adult rat hippocampal 
slices in presence o f EHNA (n = 10). Incubation of slices in ACSF containing EHNA (300 
pM) and BAY 41-2272 (30 pM) in the absence (control) or presence of a variety of 
pharmacological agents: CNQX (100 pM), TTX (1 pM), AM251 (2 pM), DPCPX (0.1 pM), 
Nicergoline (50 pM), Sotalol (100 nM), D-AP5 (100 pM), and ODQ (1 pM). *P < 0.05 vs. 
BAY 41-2272 treated slices; one-way ANOVA with Tukey’s post-hoc test.
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In contrast to the results obtained in the presence of IBMX, no effect on cGMP 
accumulation was noted following incubation with CNQX, TTX, AM 251, or DPCPX 
in the presence of EHNA (figure 4.22). The much “cleaner” result profile obtained in 
the presence of EHNA suggest that the numerous pharmacological antagonists which 
resulted in the inhibition of cGMP accumulation in the presence of IBMX may have 
been down to non-specific effects influenced by either the inhibition of cAMP 
breakdown or by the action of IBMX on adenosine receptors.
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4.4 Discussion
Given the importance of the NO/cGMP pathway in hippocampal synaptic plasticity, it 
is surprising that the isoform of NOS responsible for tonic NO production in the 
hippocampus has so far not been investigated. The object of the present study was 
therefore to investigate the basal production of NO in the hippocampus using cGMP 
levels as an indicator.
Potency and selectivity o f  NOS inhibitors
Several studies have measured the potency and selectivity of various nNOS inhibitors, 
however, a direct comparison is difficult due to the use of various assay systems, 
assay conditions and species (Nakane et al., 1995; Wolff et al., 1998). For example 
different groups utilised different concentrations of arginine in their assay systems: 10 
pM (Cowart et al., 1998); 70 pM (Hagen e ta l, 1998); 0.1 pM (W o lffs  al, 1998). As 
a great proportion of the NOS inhibitors are arginine-competitive, the resultant IC5 0  
values are directly dependent on the arginine concentration used in the respective 
assay system. Table 4.2 summarises the reported potencies of two general NOS 
inhibitors (L-NNA and L-NIO), and three nNOS inhibitors (L-VNIO, 1400W and 
NPA).
As an added complication, the majority of investigations into the potency of 
these compounds on different NOS isoforms have so far been carried out on isolated 
enzymes, which may not reflect their potencies at the cellular level. Therefore we 
decided to re-evaluate the inhibitory potencies of three reported nNOS inhibitors on 
hippocampal slice tissue. A lower potency for nNOS inhibition was predicted in tissue 
as opposed to isolated enzyme as a result of cell permeability and/or intracellular 
metabolism of the inhibitor. However, IC50 values of approximately 0.003 pM, 0.03 
pM, and 0.03 pM were obtained for L-VNIO, 1400W, and NPA, respectively, in the 
presence of IBMX. Very similar IC50 values of approximately 0.01 pM and 0.01 pM 
were also determined for L-VNIO and 1400W, respectively, in the presence of 
EHNA.
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IC 50(hM ) selectiv ity
C om pound nN O S eN O S iN O S eN O S /n N O S R eference
L-NNA
0.03 0.08 1.5 3 Boer et al., 2000
0.02 0.03 13 1.5 Cooper et al., 2000
L-NIO
0.5 0.63 0.25 1 Boer et al., 2000
1.7 3.9 3.9 2 R eese / al., 1990
L-VNIO
0.5 1.4 0.7 3 Boer et al., 2000
0.1 12 60 120 BabuA. Griffith, 1998
1400W
2.5 2.5 0.13 10 Boer et al., 2000
7.3 1000 0.23 130 Young et al., 2000
2 50 0.007 25 Garvey et al., 1997
NPA
0.085 2 209 24 Cooper et al., 2000
0.057 8.5 180 149 Zhang et al., 1997
Table 4.2: Potency and selectivity o f NOS inhibitors on the purified enzymes.
Surprisingly these results reveal all three nNOS inhibitors to be more potent in 
hippocampal tissue than in isolated enzymes, indicating that the compounds appear to 
have no difficulty in permeating the cell membrane and acting on intracellular NOS. 
The explanation for the apparent increased potency compared to the literature data, 
however, is unclear. One possibility relates to the concentration of arginine present in 
the assay system, since most of the compounds are arginine-competitive, and IC50 
values are directly dependent on the arginine concentration used in the respective 
assay system.
Additionally, it must also be noted that the concentration-response curves 
observed for 1400W and NPA are very shallow (i.e. inhibition occurring over ~ 6 log 
units) in the presence of IBMX, although, again, the explanation for this is unclear. It 
is possible that this reflects a permeability problem across the cell membrane,
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especially given that NPA and 1400W do not appear to completely inhibit cGMP 
accumulation, even at the highest concentration applied. However, this scenario seems 
unlikely as a more ‘normal-shaped’ concentration-response curve was obtained for 
1400W in the presence of EHNA. Interestingly, the concentration-response curve for 
L-VNIO was found to be consistent between the IBMX and EHNA conditions, and 
also to be very similar between 1400W and L-VNIO in the presence of EHNA. This 
finding implies that the shallow concentration-response curves observed in the 
presence of IBMX may be more likely to be related to the presence of IBMX, as 
opposed to a characteristic trait of the respective inhibitor.
Overall, all three inhibitors were determined to be selective for the nNOS 
isoform over the eNOS isoform, as concentrations which inhibit the majority of nNOS 
activity resulted in no significant change in cGMP accumulation in rat aortic rings 
(which generate NO from the eNOS isoform). Unfortunately, a positive control for the 
action of these inhibitors on eNOS-induced cGMP accumulation in hippocampal 
slices was not attained. Three compounds previously found to stimulate eNOS activity 
(raloxifene, TNFa, and bradykinin; Harris et al., 2001; Simoncini et al, 2002a,b; 
Barsacchi et al., 2003) were found to have no significant effect on basal cGMP levels 
in the hippocampal slice preparation, although it must be noted that the cGMP levels 
involved are at the boundary of detection and therefore absolute values are unlikely to 
be trustworthy. Taken together, these data identify three selective nNOS inhibitors 
that are able to inhibit the bulk of nNOS activity at concentrations which spare the 
eNOS isoform.
Effect o f  NOS inhibition in the hippocampus
The isoform of NOS responsible for basal levels of NO in the hippocampus was
studied by examination of the cGMP accumulation in adult hippocampal slices
following incubation with a PDE inhibitor to prevent breakdown of cGMP, and BAY
41-2272 to inhibit the dissociation of NO from NO-activated GC. To our knowledge,
this is the first study to investigate the specific isoform of NOS involved in the tonic
production of NO in the hippocampus. Selective inhibition of nNOS was found to
have little or no effect on cGMP accumulation, either in the presence of IBMX or
EHNA. As 1400W is considered to have a higher potency for iNOS than nNOS (Boer
et al, 2000; Young et al, 2000), incubation with 1400W additionally acts as a control
for the contribution of iNOS to endogenous NO levels. In contrast, general NOS 
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inhibition almost completely abolished cGMP accumulation confirming the NO- 
dependence of the cGMP levels. Therefore the assumption from these results, by 
process of elimination, is that eNOS is likely to be responsible for tonic NO 
production in the hippocampus. Unfortunately, this hypothesis cannot be tested 
pharmacologically as, to date, there are no selective eNOS inhibitors.
Control experiments carried out on rat aortic rings (which generate NO from 
eNOS) demonstrate very little inhibition of ACh-induced cGMP accumulation 
following exposure to either LY294002 or wortmannin. This finding is consistent 
with the observation by Kobayashi and colleagues (2004) that pre-treatment of aortic 
strips with LY294002, or an Akt inhibitor, had no significant effect on ACh-induced 
cGMP accumulation. The explanation for this result relates to the mechanism of 
ACh-induced NO generation in the aorta. It has been demonstrated that activation of 
eNOS by various agonists, including ACh and bradykinin, is mediated primarily by 
elevation in intracellular free Ca2+ concentration (Forstermann et al, 1991; Knowles 
& Moncada, 1994; Moncada et a l, 1991). However, several stimuli, such as shear 
stress and PI3-K, have also been found to activate NO production in a Ca2+- 
independent manner (section 1.2.3). As well as activating of the PI3-K/Akt pathway 
(Kitayama et al, 2000), tyrosine kinase has also recently been shown to modulate 
ACh-induced dilation of the rat basilar artery in-vivo (Kitazono et al., 1998). Tyrosine 
kinase exerts its effects via IP3 receptors (Jayaraman et al, 1996) with the consequent 
release of Ca from intracellular stores. Given that both LY294002 and wortmannin 
are inhibitors of PI3-K, (with little or no inhibitory effects on phosphatidylinositol-4- 
kinase, PKC, or tyrosine kinase: Powis et al, 1994; Vlahos et al, 1994) it is likely 
that the lack of inhibitory action of these two compounds on ACh-induced cGMP
*y 1
accumulation may be a reflection of their lack of inhibition of intracellular free Ca 
levels, and their lack of inhibition of eNOS.
The specificity of LY294002 and wortmannin as PI3-K inhibitors may also go
some way towards explaining the minimal inhibition of cGMP accumulation in the
presence of these compounds on BAY 41-2272-stimulated hippocampal slices. That
is, if basal production of NO in the hippocampus is regulated by a combination of
intracellular Ca2+ levels and phosphorylation, then inhibition of PI3-K by LY294004
or wortmannin would only remove one regulatory pathway, leaving the others intact
to stimulate eNOS activation. Therefore inhibition of PI3-K would not be expected to 
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completely inhibit eNOS activity. Furthermore, of particular relevance to this current 
study, is a recent report by Kitayama and colleagues (2000) which suggested that PI3- 
K may not be involved in the basal production of NO in-vivo, despite its potential 
action in ACh-induced NO production.
Given the fact that there are no selective eNOS inhibitors available, the 
isoform of NOS responsible for basal NO levels was then explored in a different way, 
by investigation of cGMP levels in hippocampal slices obtained from mice deficient 
in eNOS. It would be predicted that if  eNOS was responsible for tonic NO production 
in the hippocampus, basal cGMP production would be either reduced or non-existent 
in eNOS knockout mice. However, surprisingly, basal cGMP production was found to 
be similar between wild type and eNOS knockout hippocampal slices. This finding is 
also in contrast to various studies which report higher cGMP content in vessels from 
wild type mice when compared to their eNOS knockout counterparts (Brandes et al, 
2000; Hussain et al., 2001; Li et al, 2001). One possible explanation for this 
observation may be tissue-specific variation in cGMP levels, especially given that 
PDE expression varies between tissues, and that none of the previous studies were 
carried out in the hippocampus. Another potential explanation could be that as basal 
cGMP levels are so low in the hippocampus without sensitising NO-activated GC to 
NO, the previously reported differences between the two groups of mice may reflect 
natural variation within a population, as opposed to any real difference. By inhibiting 
the dissociation of NO from NO-activated GC with BAY 41-2272, the effect is an 
increased sensitivity of the enzyme to NO which allows small changes in endogenous 
NO production to be reflected by larger differences in cGMP accumulation.
Predictably, wild type hippocampal slices were found to exhibit very similar 
BAY 41-2272-stimulated cGMP responses following NOS inhibition to those 
observed in the rat: no effect upon nNOS or iNOS inhibition, and almost complete 
inhibition of cGMP accumulation in the presence of general NOS inhibitors. In 
contrast, in the presence of EHNA there was a marked reduction in NOS-dependent 
cGMP production in eNOS-deficient mice. The lack of effect of L-NNA and L-NIO 
argues against a role for other NOS isoforms in the production of cGMP, instead 
suggesting an alternative compensatory mechanism for the absence of eNOS in 
mutant mice. Consistent with this idea is the demonstration of cross-talk between 
NO-activated GC and pGC systems (Hussain et al, 2001). NO-deficient vessels 
(human internal mammary artery; wild type aorta in presence of NOS inhibitors;
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eNOS knockout aorta) have been demonstrated to exhibit increased sensitivity to 
atrial natriuretic peptide (ANP); conversely pre-treatment of vessels with an excess of 
NO reduces their responsiveness to ANP. Additionally, treatment of rat renal 
glomeruli with L-NAME leads to an increase in the activity and sensitivity of the 
ANP-dependent pGC system (Lewko et al, 1997). Evidence for compensatory 
mechanisms other than NOS upregulation also arises from studies exploring cardiac 
function. Cardiac cGMP levels were found to be the same in eNOS knockout and 
wild type mice (Gyurko et al., 2000). However, higher expression levels of ANP are 
observed in eNOS-deficient animals which appear to provide a mechanism capable of 
maintaining basal cGMP levels in the absence of eNOS. This is consistent with the 
finding that ANP injected intravenously into L-NNA-treated wild type mice is also 
found to restore ventricular relaxation (Gyurko et al, 2000).
Given that ODQ is selective for NO-activated GC over pGC (Garthwaite et 
al, 1995b), it would therefore be predicted that if pGC activity could account for the 
cGMP accumulation observed in eNOS knockout mice, ODQ would have no effect on 
cGMP accumulation in these animals. However, in apparent contrast to this 
supposition, ODQ still produced significant inhibition (~ 50 %) of BAY 41-2272- 
stimulated cGMP production in the absence of eNOS. This finding implies that there 
is an NO-activated GC component of cGMP accumulation that remains in eNOS 
knockout animals, although the origin of these levels is a mystery, especially given 
that general NOS inhibitors have no significant effect on cGMP accumulation in these 
animals. The most likely explanation is that there is a minor contribution from nNOS 
to tonic NO levels in the hippocampus that is too small (with the current n values) to 
be registered as significant with nNOS inhibitors, especially when used at sub 
maximal concentrations, as is the case in the present study. In support of this there are 
various reports which find that eNOS-deficient mice exhibit an increased sensitivity 
towards exogenous NO (Hussain et a l, 1999, 2001; Waldron et al, 1999; Brandes et 
al, 2000), indicating that if  nNOS does make a small contribution to tonic NO levels, 
the relevant contribution would be amplified in the knockout animal. A second 
possibility is that in the presence of BAY 41-2272, the endogenous level of CO may 
be sufficient to give a small degree of GC activation in eNOS knockout animals 
(given that BAY 41-2272 has been reported to sensitise NO-activated GC towards 
CO; Martin et al, 2005). A third possibility, although unlikely, is that there may be
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another, currently undiscovered, source of NO in the hippocampus (distinct from 
eNOS, nNOS, and iNOS) capable of activating NO-activated GC in the hippocampus.
It is also important to note another unexpected observation made in eNOS 
knockout mice: BAY 41-2272 retained its activity in the hippocampus of eNOS- 
deficient animals. Consistent with this Hussain and colleagues (1999) found YC-1 to 
be equipotent between wild type and eNOS knockout animals. At first glance these 
finding appears to imply that a source of basal NO is present in the hippocampus in 
the absence of eNOS, although the origin of this source is unclear. It is more probable, 
however, that the explanation for this activity lies in a combination of different 
factors. One possibility, as mentioned previously, is that nNOS may play a minor role 
in tonic NO production that is too small to be registered as significant in the current 
study. A second possibility is that iNOS may be upregulated in eNOS knockout 
animals as previously reported by Li and colleagues (Li et al, 2001). However, no 
obvious compensation in either iNOS or nNOS protein expression was observed 
between wild type and eNOS knockout hippocampal slices, although subtle changes 
in expression levels cannot be ruled out. Additionally no significant change in iNOS 
activity was noted between the two groups of animals. These findings are consistent 
with the lack of effect of iNOS and nNOS inhibitors in eNOS-deficient hippocampal 
slices. Another possibility is that a proportion of the cGMP accumulation may be NO- 
independent, especially given that BAY 41-2272 can exert a small NO-independent 
increase in NO-activated GC activity at the concentration of BAY 41-2272 used in the 
current study. Other potential explanations also include upregulation of NO-activated 
GC, and/or altered PDE activity in eNOS-deficient mice (Hussain et al, 1999, 2001).
Taken together, these findings support the hypothesis that eNOS is responsible 
for the basal levels of NO in the hippocampus, and that in eNOS-deficient mice there 
may be an increased importance of pGC in the maintenance of cGMP levels, which 
may be able to compensate, at least in part, for the absence of eNOS. In support of 
this proposal is the recent demonstration that basal cGMP-staining appears to be 
restricted to astrocytes in the presence (and absence) of EHNA, although it must also 
be noted that this astrocytic staining was only observed in the mouse, and that it was 
not inhibited by NOS or NO-activated GC inhibitors indicating that this staining may 
be non-specific. Following incubation with BAY 41-2272, there was an increase in 
staining of astrocytes, blood vessel walls and in varicose fibres (van Staveren et al,
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2004), although the relevance of the astrocytic staining is uncertain given that it was 
not inhibited by a NOS inhibitor.
Possible mechanism underlying endogenous NO production
The complementary question addressed in the present study concerned the mechanism 
responsible for maintaining basal NO production in the hippocampus. Exposure to the 
NMDA receptor antagonist D-AP5 was observed to have no effect on cGMP 
accumulation, indicating that tonic NO production in the hippocampus is independent 
of the NMDA receptor. This finding is consistent with the assumption that basal 
levels of NO result from eNOS activation, which is most likely present in endothelial 
cells as opposed to neurons (where the NMDA receptors are located). Evidence for 
tonic NO generated independently of NMDA receptors additionally comes from data 
on hippocampal and striatal slices demonstrating that most of the basal cGMP 
(augmented by a PDE inhibitor) was sustained by NOS but not by NMDA receptors 
(Chetkovich et al., 1993; Griffiths et ah, 2002).
Investigation of the potential mechanisms contributing to endogenous NO 
production revealed a discrepancy between the results achieved with IBMX and 
EHNA. In the presence of IBMX a decrease in cGMP accumulation was observed 
following exposure to the voltage-gated Na+ channel inhibitor TTX, the AMPA 
antagonist CNQX, the cannabinoid antagonist AM 251, the adenosine antagonist 
DPCPX, and the p adrenergic antagonist sotalol. These data is in partial agreement 
with a previous study, also carried out in the presence of IBMX, which observed an 
inhibition of cGMP accumulation in the striatum by TTX, but not by the AMPA 
antagonist NBQX (Griffiths et al, 2002). In contrast, when hippocampal slices were 
incubated with EHNA, the only significant reduction in cGMP levels was observed 
with a (nicergoline) and p (sotalol) adrenoreceptor antagonists. This result indicates 
that endogenous NO levels in the hippocampus may be influenced by 
adrenoreceptors, although this line of investigation was not pursued any further given 
the relatively small effect.
This experiment highlights a distinct difference in cGMP accumulation
between that observed in the presence of IBMX or EHNA. One feasible explanation
for this difference may be due to the fact that IBMX is not a “clean” compound: in
addition to its action as a non-specific PDE inhibitor, IBMX is also known to act as an
antagonist of adenosine receptors (Choi et al., 1988). Adenosine is a well-established 
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modulator of synaptic transmission and neuronal excitability in the ClSIS (Dunwiddie 
& Fredholm, 1989; Greene & Haas, 1991), typically acting through the presynaptic 
A l receptor to decrease neuronal firing via suppression of glutamate release (Fowler 
et al., 1999; Mitchell et al., 1993, Wu & Saggau, 1994). Given that adenosine release 
results in the decrease of neuronal excitability, conversely the presence of IBMX 
(which inhibits the adenosine receptor) leads to an increase in neuronal firing. It is 
also relevant to note that EHNA is an inhibitor of adenosine deaminase (Sattin & Rail, 
1970), and therefore potentially may also influence adenosine levels in the 
hippocampus. However, a recent study by Suvama & O’Donnell (2002) demonstrated 
that neither adenosine nor an adenosine deaminase inhibitor mimicked the effect of 
EHNA on cGMP accumulation, therefore indicating that EHNA's inhibition of PDE2, 
and not its effects on adenosine metabolism, mediates its effects on cGMP 
concentration in the hippocampus.
A second possible explanation for the difference in cGMP accumulation
relates to the PDE isoform inhibited: IBMX is a general PDE inhibitor, whereas
EHNA is a selective PDE2 inhibitor. To date, several PDE isoforms have been
localised in the rat hippocampus. In situ hybridisation and immunohistochemical
studies demonstrate the presence of PDE1, PDE2, PDE3, and PDE4 in this brain
region of the rat (Furuyama et al., 1994; Ludvig et al., 1991; Reinhardt & Bondy,
1996; Repaske et al., 1993), although recent studies indicate that other PDE isoforms
may also be present (such as PDE5 and PDE9; van Staveren et al., 2004). Recent
evidence finds no effect of PDE1 or PDE3 inhibition on cGMP accumulation in the
hippocampus (van Staveren et al., 2001; Suvama & O’Donnell, 2002), whereas PDE4
is a cAMP-specific PDE (general introduction; 1.5.1) and therefore inhibition of this
isoform is of little benefit to the current study. In contrast, PDE2 is a cGMP-activated
PDE which is able to degrade both cGMP and cAMP with similar Km and Vmax in
vitro (Martins et al., 1982), although studies carried out on cortical neurons and
hippocampal slices indicate that PDE2 inhibition selectively increases only cGMP
levels (Suvama & O’Donnell, 2002; Boess et al., 2004). The rationale for this is most
likely due to the presence of several other cAMP metabolising enzymes, including
PDE4, in these cells. Therefore in the presence of EHNA it is likely that cGMP
breakdown would be inhibited, whilst leaving cAMP levels relatively free to vary as
per usual. However in contrast, IBMX would prevent the breakdown of both cAMP
and cGMP. Various studies have found that cross-talk arises between the cAMP and 
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cGMP signalling pathways capable of modulation of each other’s synthesis, 
degradation and actions (Vigne et al., 1994; Suvama & O’Donnell, 2002). 
Furthermore, a recent study by Lu and colleagues (Lu et al., 2004) demonstrated that 
increased levels of cAMP leads to increased glutamate release, and the homeostatic 
release of adenosine. The authors postulated that this may provide an important 
negative feedback modulation of neuronal excitability, by which increases of neuronal 
activity are dampened by the release of adenosine following activation of glutamate 
receptors.
Overall, it seems likely that the interpretation of biochemical results obtained 
in the presence of IBMX may be complicated by effects of adenosine release and/or 
increased levels of both cGMP and cAMP. This indicates that the results obtained in 
the presence of EHNA may provide a more accurate reflection of cGMP responses. 
This finding highlights the importance of the choice of PDE inhibitor when cyclic 
nucleotide levels are studied in complex tissues.
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Involvement of calcium channels in basal NO production in
the hippocampus
-i------------------------------------------------------------------------------------------------------------
5.1 Introduction
As described in the general introduction (section 1.2), both constitutive isoforms of 
NOS have an absolute requirement for Ca2+ for their activation. Whilst Ca2+ entry via 
the NMDA receptor following synaptic activation may be sufficient to activate nNOS 
phasically, it cannot account for the continued presence of Ca2+ required to sustain
94-tonic NO production in the hippocampus. The majority of Ca entry into the cell is 
mediated by voltage-gated Ca2+ channels, whose entry then triggers a range of cellular
*y I  ^i
responses such as the regulation o f Ca -dependent second messenger cascades, Ca 
release from cytoplasmic stores, and gene expression (Dolmetsch et al., 2001).
I
Excitable tissues express a multitude of voltage-gated Ca channels, each of 
which are associated with specialized physiological roles. Based on both their 
pharmacological and biophysical profiles, voltage-dependent Ca2+ channels can be 
classified into T-, L-, N-, P-, Q-, and R- types. Both structurally and functionally the
I
primary division is between low voltage-activated (LVA) T-type Ca channels which 
typically activate at fairly negative potentials (-70 mV to -50 mV), and high voltage- 
activated (HVA) channels which activate at more positive membrane potentials and
 ^I
include L-, N-, P-, Q-, and R-types. HVA Ca channels are crucial for muscle 
contraction and neurotransmitter release, whereas LVA tend to be involved in the 
generation of repetitive electrical activity.
In the CNS, different types of HVA Ca channels serve specialized cellular 
functions, and exhibit varying subcellular distributions. For example, L-type Ca 
channels are typically confined to cell bodies (Hell et al., 1993) where they are likely 
to regulate Ca2+-dependent enzymes and gene expression. N- and P/Q- type calcium 
channels show highest expression levels at presynaptic terminals and are directly 
coupled to neurotransmitter release (Wheeler et al., 1994; Westenbroek et al, 1992,
1995). R-type Ca2+ channels are expressed on proximal dendrites and may, in some 
neurons, participate in neurotransmitter release (Hanson & Smith, 2002). T-type Ca2+ 
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channels are expressed in a variety of different cell types where they are typically 
involved in shaping the action potential, and in controlling patterns of repetitive firing 
(Ertel et al, 2000). Table 5.1 summarises the various voltage-gated Ca2+ channels, 
their tissue localization, and their respective inhibitors.
a
subunit
Alternative Name/ 
Splice variants Channel type Primary tissue Inhibitor
1A Cav2.1aCav2.1b
P- and/or Q- 
(purkinje) Brain, cochlea, pituitary
co-aga IVA, to-CTx 
MVIIC
IB Cay2.2aCav2.2b
N-
(neuron) Brain, nervous system
to-CTx GVIA, cd-CTx 
MVIIC
1C
Cav1.2a
Cavl.2b
Cav1.2c
L-
(large)
Heart 
Smooth muscle 
Brain, heart, pituitary, adrenal
Nifedipine
ID Cav1.3 L- Brain, pancreas, kidney, ovary, cochlea Nifedipine
IE
Cav2.3a
Cav2.3b
R-
(resistant)
Brain, cochlea, retina, heart, 
pituitary 
Brain, cochlea, retina
SNX-482, Nickel
IF Cav1.4 ? Retina ?
1G Cav3.1 T-(transient) Brain, Nervous system Mibefradil, Nickel
1H Cav3.2 T- Brain, heart, kidney, liver Mibefradil, Nickel
11 Cav3.3 T- Brain Mibefradil, Nickel
IS Cavl.l L- Skeletal muscle Nifedipine
Table 5.1: Classification o f voltage-gated Ca2* channels: 
channel type, primary localization and their respective inhibitors.
Given the diverse roles of voltage-gated Ca2+ channels in synaptic function, 
and the fact that Ca2+ influx as a result of NMDA receptor activation cannot account 
for sustained Ca2+ levels required for tonic NO production, it seems conceivable that 
voltage-gated Ca2+ channels may play an important role in basal NO production in the 
hippocampus. The aim of the current study was to investigate the role of voltage- 
gated Ca2+ channels in maintaining the Ca2+ levels required for NOS activity.
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5.2 Methods
5.2.1 Hippocampal tissue preparation
Hippocampal slices were prepared as described in chapter 2 (2.2).
5.2.2 cGMP measurement
Hippocampal slices were allowed to recover in carbogenated ACSF maintained in a 
shaking water bath at 30 °C for at least 1 - 2 h before use. Hippocampal slices were 
then transferred to a fresh solution containing the general PDE inhibitor 3-isobutyl-1- 
methylxanthine (IBMX; 1 mM) or the PDE2 inhibitor erythro-9-(2-hydroxy-3-nonyl)- 
adenine hydrochloride (EHNA; 300 pM) for 15 min, before being exposed to the 
enhancer of NO-activated GC, BAY 41-2272 for 5 min. At the end of the exposure 
the hippocampal slices were removed, inactivated by immersion in boiling hypotonic 
inactivation buffer for a minimum of 5 min, and homogenized by sonication.
The protein content and cGMP accumulation were determined as described in 
chapter 2 (2.4).
5.2.3 Data Analysis
All data are presented as the mean ± S.E.M; differences between experimental results 
were analysed using SPSS and/or GraphPad Instat software by way of a one-way or 
two-way ANOVA with Tukey’s post-hoc test; P values of < 0.05 were regarded as 
significant.
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5.3 Results
5.3.1 Effect of calcium channel inhibitors on cGMP accumulation in rat 
hippocampal slices in presence of EHNA
As discussed in the general introduction (section 1.2), both constitutive isoforms of 
NOS exhibit Ca2+-dependence. To investigate the Ca2+-dependence of cGMP 
accumulation, hippocampal slices were initially incubated with the general Ca2+ 
channel inhibitor, cadmium. The increase in cGMP accumulation observed following 
5 min exposure to BAY 41-2272 was significantly reduced by the presence of 
cadmium (figure 5.1).
To determine which subtype of voltage-gated Ca2+ channel may contribute to 
basal endogenous cGMP production in the rodent hippocampus, slices were incubated
2"bwith the Ca channel inhibitors for each of the subtypes. The increase in cGMP 
accumulation observed following 5 min exposure to BAY 41-2272 was significantly 
reduced by incubation with nickel (Ni2+; R-/T-type Ca2+ channel inhibitor; Soong et 
ah, 1993), mibefradil (T-type Ca2+ channel inhibitor; Martin et al, 2000), and to a 
lesser degree w-conotoxin GVIA (co-CTx-GVIA; N-type Ca2+ channel inhibitor; 
Wheeler et al, 1994) (figure 5.1). No significant effect on cGMP levels was observed 
in the presence of nifedipine (L-type Ca2+ channel inhibitor; Creba & Karobath, 
1986), co-conotoxin MVIIC (co-CTx-MVIIC; N-/P/Q-type Ca2+ channel inhibitor; 
Wheeler et al., 1994), co-agatoxin IVA (P/Q-type Ca2+ channel inhibitor; Randall & 
Tsien, 1995) or SNX-482 (R-type Ca2+ channel inhibitor; Newcomb et al., 1998) 
(figure 5.1).
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Figure 5.1: Effect of subtype-selective Ctf*-channel inhibitors on cGMP levels in rat 
hippocampal slices. Incubation of hippocampal slices in cadmium (200 juM), nickel (50 pM), 
mibefradil (3 pM) and CTx-GVIA (1 pM) resulted in a significant inhibition of cGMP 
accumulation. No significant change in cGMP level was observed in the presence of 
nifedipine (20 pM), CTx-MVIIC (500 nM), co- agatoxin (100 nM) or SNX-482 (100 nM).
*P < 0.05 vs. BAY 41-2272 treated slices (n = 5 - 10); one-way ANOVA with Tukey’s post-
hoc test.
5.3.2 Effect of zero calcium on cGM P accumulation in rat hippocam pal slices in 
presence o f EHNA
The almost complete inhibition of cGMP production in the presence of cadmium (~ 
90 %) appears at odds with only ~ 50 % reduction observed in Ca -free ACSF 
(chapter 4; figure 4.16b). One explanation could be that as NO-activated GC usually
9-1- iexists in a state of inhibition by Ca (Kazerounian et al., 2002), Ca -free ACSF may 
result in disinhibition of the cyclase as internal Ca2+ would be reduced, which would 
not be the case for cadmium as internal Ca2+ would remain untouched and only Ca2+ 
uptake would be prevented. To address this possibility hippocampal slices were 
incubated in nickel and cadmium both in the presence, and absence, of Ca in the 
external ACSF medium. In accordance with results obtained previously, incubation in 
nickel, cadmium or Ca2+-free ACSF all produced a significant reduction in cGMP 
accumulation (figure 5.2). Additionally the presence of nickel and cadmium resulted 
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in a significant reduction in cGMP levels to that observed in Ca2+-ffee ACSF. In 
contrast, incubation of hippocampal slices with cadmium or nickel resulted in no 
significant reduction in cGMP accumulation in Ca2+-free ACSF when compared to the 
BAY 41-2272 control in the presence of Ca2+.
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Figure 5.2: Effect of zero calcium on cGMP accumulation in rat hippocampal slices. 
Incubation of slices in zero calcium (1 mM EOTA), cadmium (200 pM) or nickel (50 pM) 
significantly reduced cGMP accumulation. Application of cadmium or nickel in the absence 
of calcium prevented this reduction. . *P < 0.05 vs. BAY 41-2272 treated slices (n = 5); one­
way ANOVA with Tukey'spost-hoc test.
Comparison of cGMP levels by means of two-way ANOVA analysis with a 
Tukey’s post-hoc test confirmed cadmium and nickel significantly inhibit cGMP 
levels (F = 20; d.f. = 2, 30; P < 0.001), and also reveal a significant interaction to exist 
between the presence or absence of external Ca2+ and the effect of cadmium and 
nickel (F = 64; d.f. = 2, 30; P < 0.001). That is, both cadmium and nickel significantly 
inhibited BAY 41-2272-stimulated cGMP accumulation in the presence of Ca2+, 
whereas they had no significant effect on cGMP levels in the absence of external 
Ca2+.
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These results indicate that the discrepancy observed between Ca -free ACSF 
and incubation with cadmium could be explained by disinhibition of the cyclase. In
 ^i
order to test this hypothesis a concentration-response curve was carried out in Ca - 
free ACSF, the prediction being that there would be an enhancement of the cGMP 
response to DEA/NO in the absence of Ca in the external medium if the cyclase was 
disinhibited. However, the EC50 for cGMP accumulation was not found to be 
significantly different between the two conditions: 1.4 pM DEA/NO in the presence 
of Ca2+ and 1.1 pM DEA/NO when Ca2+ was excluded from the ACSF solution 
(figure 5.3). Interestingly there is a significant increase in the sensitivity of the 
cyclase to low DEA/NO concentrations (1 pM DEA/NO; P < 0.05). It must also be 
noted that there is a significant reduction in basal cGMP levels in zero Ca2+, which is 
likely be related to the calcium dependence of basal NOS activity.
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Figure 5.3: Concentration-response curve for DEA/NO on cGMP levels in adult rat 
hippocampal slices in presence and absence of Ca2+ (2 min exposure; n -  5). Experiments
carried out in presence of EHNA.
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5.4 Discussion
The current study addressed a complementary question to that investigated in chapter 
4; given the absolute requirement for Ca of both the constitutive forms of NOS, 
what is the involvement of voltage-gated Ca2+ channels in the basal production of NO 
in the hippocampus?
Firstly we investigated the effect of selective inhibition of individual subtypes 
of voltage-gated Ca2+ channel on basal cGMP production in the hippocampus. 
Inhibition of L-type, P/Q-type and R-type Ca channels were found to have no effect
I
on cGMP accumulation, and only a small inhibition resulted from N-type Ca 
channels inhibition. In contrast, basal cGMP levels were significantly inhibited by 
nickel (50 pM) or mibeffadil (3 pM). At this concentration nickel is known to inhibit 
both R-type and T-type Ca2+ channels (Zamponi et al, 1996; Tottene et al, 1996), 
although at higher concentrations (such as in the hundred micromolar range), nickel
74-additionally blocks transiently expressed N-type, L-type and P/Q-type Ca channels 
(Zamponi et al, 1996) and capacitative Ca2+ channels (Zweifach & Lewis, 1993,
1996). Mibeffadil on the other hand is an L-type and T-type antagonist (Massie,
 ^i
1997), although an effect mediated via L-type Ca channels can be discounted since a 
selective L-type antagonist, nifedipine, had no effect on cGMP accumulation. There is 
also evidence that mibeffadil is an N-type antagonist (Bezprozvanny & Tsien, 1995; 
Gothert & Molderings, 1997; Van der Lee et al, 2000), R-type antagonist (Randall & 
Tsien, 1997) and that it can inhibit neuronal Na+ channels (Eller et al, 2000). 
However, these effects can also be excluded since both the Na+ channel inhibitor 
TTX, and selective R- and N-type Ca2+ channel inhibitors had little or no effect. Our 
findings therefore suggest that the majority of basal NO production in the
7+hippocampus is likely to be mediated via T-type Ca channels.
T-type Ca2+ channels are expressed throughout the body, including in nervous
tissue, heart, kidney, smooth muscle, sperm, and in many endocrine organs (for
•  • 2 1review see Perez-Reyes, 2003). To date, three different isoforms of T-type Ca
channels have been shown to exist, each of which exhibits a distinct tissue 
distribution. Many regions of the brain have been found to express more than one of 
these isoforms; interestingly all three isoforms are present in hippocampal pyramidal 
neurons (Talley et al., 1999). Of particular relevance to the current study is the
74*demonstration of T-type Ca channels on microvascular endothelial cells of the
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bovine adrenal medulla (Bossu et a l, 1989; Vinet & Vargas, 1999) and from rat brain 
(Delpiano & Altura, 1996). Furthermore, these channels exhibit a window current; 
that is they display a large overlap between the curves describing their inactivation 
and activation which effectively allows them to support a maintained current under 
steady state conditions (Hughes et al., 1999; Jones, 2003). Sustained Ca2+ entry 
through T-type channels has been implicated in secretion from adrenal glomerulosa 
cells (Cohen et al, 1988), and pacemaker potentials in sino-atrial node cells 
(Hagiwara et al, 1988;Nilius, 1986).
These findings represent an plausible mechanism by which sustained Ca2+ 
entry may occur into the cell under resting conditions, which would then be available 
to activate the endothelial isoform of NOS (presumably present in endothelial cells) 
and consequently generate tonic NO levels. Consistent with this idea are studies 
which find mice lacking in T-type Ca channels to exhibit constitutively constricted 
coronary arterioles and focal myocardial fibrosis (Chen et al, 2003). These mice 
demonstrate a normal contractile response; however, their NO-mediated relaxation 
appears to be defective. Also of possible relevance is the observation that a low 
concentration of nickel is able to prevent the relaxation of coronary arteries (Chen et 
al, 2003), as well as inhibit the induction of LTP in the hippocampal CA1 pyramidal 
cells (Magee & Johnston, 1997).
It is important to note that a second putative mechanism of Ca entry into 
endothelial cells has also been suggested in the literature: via transient receptor 
potential (TRP) channels. Although not investigated in this study, one member of the 
TRP family (TRPV4) has been found to be highly expressed in endothelial cells 
(Wissenbach et al, 2000) and are thought to be constitutively open in endothelial cells 
at body temperature, thereby potentially contributing to the maintenance of a steady- 
state Ca2+ concentration (Giiler et al, 2002; Nilius et al, 2003). Furthermore, mice 
lacking TRPV4 exhibit an inhibition of endothelium NO-dependent vasorelaxation 
(Freichel et al., 2001). However, given that 50 pM nickel resulted in an inhibition of 
basal cGMP production, and that this concentration of nickel is not thought to inhibit 
TRPV4 channels (Golovina et al, 2001), our findings indicate that TRPV4 channels 
do not contribute to any great extent towards basal NO production in the 
hippocampus. Nevertheless, it would be interesting to explore the relative 
concentrations of Ca2+ entry mediated by T-type Ca2+ channels as opposed to TRPV4 
channels.
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The second part of the study investigated the surprising observation that 
cGMP accumulation was almost completely inhibited by the general voltage-gated
2"b • • •Ca -channel inhibitor, cadmium, whilst only ~ 50 % reduction in cGMP levels was
2+
observed in Ca -free ACSF. The most likely explanation for this discrepancy relates 
to the discovery that NO-activated GC usually exists in a state of inhibition by Ca2+ 
(Kazerounian et a l, 2002). In the Ca2+-free ACSF condition, the internal Ca2+ 
available in the cell would be reduced, thereby disinhibiting the cyclase, whereas in 
the case of cadmium only Ca2+ uptake would be prevented, with internal Ca2+ levels 
remaining intact. Therefore, in contrast to Ca2+-free ACSF, exposure to cadmium 
would leave the state of the cyclase unchanged. Consistent with this idea is the 
observation that incubation of hippocampal slices with cadmium or nickel 
significantly inhibited BAY 41-2272-stimulated cGMP accumulation in the presence
2 j
of Ca , whereas they had no significant effect on cGMP levels in the absence of
2_j_  ^ _
external Ca . The latter condition is likely to represent the lowest concentration of
 ^I  ^j
internal Ca of all the conditions tested, given that Ca uptake would be prevented 
in addition to initially reduced levels of internal Ca2+. Therefore maximal 
disinihibition of the cyclase would be predicted in the latter condition when compared 
with either Ca2+-free ACSF, cadmium or nickel alone. Our results also demonstrated 
that, although the cGMP concentration-response curve was not significantly changed
94- •by the presence or absence of Ca in the external ACSF solution, there was a 
significant increase in sensitivity of the cyclase to low DEA/NO concentrations (1 
pM DEA/NO; P < 0.05). Additionally, there was a significant reduction in basal 
cGMP levels in zero Ca2+ conditions, which is likely to reflect the calcium 
dependence of basal NOS activity.
 ^I
Overall, the data here indicates that T-type Ca channels may play an 
important role in maintaining a steady influx of Ca2+ into the cell which is capable of 
sustaining eNOS activation.
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6.1 Introduction
LTP is a form of synaptic plasticity in which synaptic transmission is enhanced for 
hours, days or even weeks, and is widely considered to be the cellular correlate for 
learning and memory. In the CA1 region of the hippocampus LTP is induced by brief 
tetanic stimulation of afferent glutamatergic fibres, and typically exhibits a form of 
LTP that critically depends on postsynaptic activation of the NMDA receptor with the 
consequent influx of Ca2+ into the postsynaptic cell (Bliss & Collingridge, 1993). 
With the exception of mossy fiber-CA3 synapses, LTP induction is NMDA receptor 
dependent in all regions of the hippocampus, although one form of LTP has also been 
reported in CA1 that can be induced without activation of the NMDA receptor 
(Grover & Teyler, 1990). In this instance, exposure to high external Ca 
concentrations induced a NMDA receptor-independent LTP, presumably facilitated 
by Ca2+ influx through voltage-gated Ca2+ channels. In both situations, Ca2+ entry into 
the post-synaptic cell results in a cascade of intracellular events culminating in the 
enhancement of synaptic transmission (Madison & Malenka, 1991; Malenka et al., 
1991; Chittajallu et al, 1998).
LTP is conventionally separated into two distinct phases: induction and 
expression. The induction of LTP relates to the sequence of events taking place during 
and shortly following a brief period of high frequency stimulation (HFS). This phase 
generally lasts for ~ 1 min following tetanus (Bortolotto et al, 2001), and is widely
I
thought to reflect NMDA receptor activation, and the consequent influx of Ca into 
the postsynaptic cell. The expression of LTP can be further subdivided into early-LTP 
and late-LTP, based on their sensitivity to protein synthesis inhibitors. Early-LTP lasts 
~ 1 hr, and is generally considered to be resistant to protein synthesis. In contrast, 
late-LTP lasts for > 3 hr, and is dependent on protein and mRNA synthesis (Frey et 
al, 1993; Huang & Kandel, 1994; Abel et al, 1997).
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Several theories exist as to how specific synapses are strengthened and 
weakened following activity, although it now seems clear that both pre- and 
postsynaptic changes contribute to hippocampal LTP. Postsynaptic changes include 
increased AMP A receptor density (Edwards, 1995), whereas evidence for a 
presynaptic change came from the finding that there was an enhanced release of 
glutamate from presynaptic terminals, correlating with LTP (Dolphin et al., 1982; 
Williams et al., 1989; Larkman et al., 1995). Given the well-established postsynaptic 
involvement of the NMDA receptor in LTP induction, it therefore followed that a 
presynaptic modification would require a retrograde signalling system from the 
postsynaptic terminal to the presynaptic cell. Several molecules were suggested as 
candidates for diffusible messengers including arachidonic acid (Williams et al., 
1989), NO (Gaily et al., 1990), carbon monoxide (Zhuo et al., 1993) and platelet- 
activating factor (Kato et al., 1994).
Amongst these candidates NO received the most attention, given that NO was 
synthesized in neurons following NMDA receptor activation, facilitated by the 
physical coupling of nNOS to the NMDA receptor via PSD-95 (Brenman et al., 
1996a; Christopherson et al., 1999), an arrangement that allows the influx of Ca2+ in 
the post-synaptic cell to couple to NO formation. The first studies to implicate NO in 
the establishment of LTP appeared in 1991 (Bohme et al., 1991; Schuman & 
Madison, 1991), although subsequent experiments designed to test this hypothesis 
have yielded very controversial results. Table 6.1 summarises the major studies 
investigating the effect of NOS inhibition on hippocampal LTP: some authors 
demonstrate either a partial or complete block of LTP, whereas other groups report no 
effect at all of NOS inhibition. Various groups also report that agents which bind NO, 
such as haemoglobin (to absorb NO in the extracellular space), prevent the induction 
of LTP (O’Dell et al., 1991; Schuman & Madison, 1991; Bon et al., 1992; Haley et 
al, 1992), indicating that NO must leave the postsynaptic cell to function.
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Study L T P  p ro to co l B a sa l
S tim u la tio n
T e m p S p e c ie s T im e  o f  
re co r d in g
A g e  o f  
a n im a l
omplete Inhibition
Bohme et al, 1991 2 x 100 Hz 0.2 Hz 32 °C Rat 60 min 140-200 g
O’Dell et al., 1991 2 x 100 Hz 0.02 Hz 24 °C Guinea Pig 75 min -
Schuman & Madison, 1991 4-5 x 100 Hz 0.033 Hz 22 °C Rat 70 min -
Bon et al., 1992 2 x 100 Hz 0.2 Hz 32 °C Rat 60 min 150-200 g
Haley et al., 1992 10 x 100 Hz 0.067 Hz 22 °C Rat 60 min _
Doyle et al., 1996 1-3 x 100 Hz 0.033 Hz In vivo Rat 60 min 250-350 g
Zhuo et al., 1999 1 x 100 Hz 0.02 Hz 30 °C Rat 60 min 4-6 weeks
artial Inhibition
Chetkovich et al., 1993 3 x 100 Hz 0.1 Hz 32 °C Rat 60 min ~ 125 g
Muslehe/a/., 1993 Theta burst 0.067 Hz 35 °C Rat 40 min 150-200 g
Boulton et al., 1995 1 x 100 Hz 0.033 Hz 24 or 29 °C Rat 60 min 4-6 weeks
Kleppisch et al., 1999 Theta Burst 0.067 Hz 27.5 °C Mouse 60 min -
to inhibition
Bannerman et al., 1994 3 x 100 Hz 0.1 Hz In vivo Rat 60 min 250-450 g
Cummings et al., 1994 4 x 100 Hz 0.1 Hz 25-29 °C Rat 50 min 12-18 days
Inhibition under certain 
conditions
iribkoff & Lum-Ragan, 1992 Various 0.016 Hz 32 °C Rat 60 min 1-3 months
Chetkovich et al., 1993 Various 0.1 Hz 32 °C Rat 60 min ~ 125 g
Haley et al., 1993 Various 0.033 Hz 31 °C Rat 60 min 100-200 g
Williams et al., 1993a,b 6 x 100 Hz 0.033 Hz 24 or 29 °C Rat 60 min Young (5-7 
weeks) or old 
(4-6 months)
.uni-Ragan & Gribkoff, 1993 Various 0.02 Hz 32-34 °C Rat 60 min 75-100 g
Table 6.1: Effect o f NOS inhibition on hippocampal LTP.
- ‘ indicates age of animal unknown
As research has progressed it has become clear that LTP can be established by 
multiple independent effector mechanisms, some of which are NO-dependent and 
some of which are NO-independent. It also appears the stimulation protocol utilized is 
of utmost importance in determining the pathway by which LTP is established. For 
example, a weak tetanic stimulation that is alone insufficient to induce LTP can 
enhance synaptic responses when timed to coincide with direct application of NO 
(Bon et al., 1992; Zhuo et a l, 1993; Bon & Garthwaite, 2003), whilst stronger HFS is 
able to induce forms of LTP that are insensitive to NOS inhibitors (Chetkovich et a l, 
1993; Haley et al., 1993; O’Dell et al., 1994). Furthermore, in contrast to the 
inhibitory effect of NOS inhibition, exposure of hippocampal slices to NO donors 
(such as sodium nitroprusside (SNP), hydroxylamine or DEA/NO) result in a long- 
lasting enhancement of excitatory synaptic transmission that occludes LTP (Bohme et
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al, 1991; Bon et al, 1992; Bon & Garthwaite, 2001a,b). The NO-dependence of LTP 
has additionally been shown to be affected by various experimental conditions such as 
temperature, animal age, or even the particular strain of rat or mouse used in the 
study (Williams et al., 1993a; Holscher et al., 2002; Blackshaw et a l, 2003). It must, 
however, be noted that Boulton and colleagues (1995) failed to find a temperature- 
dependence of NO-dependent LTP.
Another point of controversy concerns the isoform of NOS which mediates the 
involvement of NO in LTP. Although both constitutive NOS isoforms are present in 
the hippocampus, their cellular locations are found to differ. In the adult hippocampus 
nNOS staining was originally thought to be largely confined to a subpopulation of 
GABA-containing intemeurons in the stratum oriens and stratum radiatum (Bredt et 
al, 1991; Valschanoff et a l, 1993; Lumme et al., 2000; Seress et al, 2002). However 
it is increasingly becoming clear that nNOS expression is also present in CA1-CA3 
pyramidal cells (Endoh et al, 1994; Wendland et al, 1994; Doyle & Slater, 1997; 
Blackshaw et al, 2003), and in dendritic spines (Burette et al, 2002) when obtained 
by weak fixation protocols. Some laboratories have failed to reproduce this finding, 
although this can likely be explained by the potential cross reactivity of the 
antibodies, the method of fixation, and the differing antibody incubation time required 
to stain intemeurons and pyramidal cells (see general introduction, 1.7.3, for more 
details).
In contrast, the majority of studies observe eNOS expression to be restricted to
the vascular endothelium (Seidel et al, 1997; Stanarius et al, 1997; Topel et al,
1998), although there are a couple of reports that eNOS may also be present in CA1
pyramidal neurons and/or in astroglia-like cells (Dinerman et al., 1994; Doyle &
Slater, 1997). One explanation for the difference in eNOS localisation may be the
species in which the study was carried out on: Doyle and Slater carried out their study
on human tissue, whereas the majority of the remaining studies were carried out on rat
tissue (with the exception of Blackshaw et al., (2003) who performed in situ
hybridization for eNOS in both mouse and human). It is also possible that some of the
astroglial eNOS visualised by Doyle and Slater may have been induced post mortem,
although there is other evidence that some astroglia may display both constitutive and
inducible forms of NOS (Murphy et al, 1993). Murphy and colleagues do not
distinguish whether the constitutive form of NOS in astrocytes is eNOS or nNOS.
With respect to the reported eNOS expression in pyramidal cells, the investigators 
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demonstrated elimination of staining with preabsorption using the peptide, and the 
absence of staining with pre-immune serum (Dinerman et al, 1994; O’Dell et al, 
1994). However, these types of controls do not rule out cross-reactivity with other 
proteins. More recent studies from the same group observe eNOS immunoreactivity 
and mRNA to be restricted to blood vessels in the brain (Demas et al, 1999), which is 
in agreement with other immunohistochemical evidence utilising a number of 
selective eNOS antibodies (Seidel et al., 1997; Stanarius et al., 1997; Topel et al.,
1998). Taken together, these findings indicate that the observations of eNOS 
expression in pyramidal cells are likely to be artifactual.
Ideally the isoform of NOS which mediates the involvement of NO in LTP 
would be investigated using selective inhibitors of nNOS and eNOS, however, as 
discussed in chapter 4, a selective eNOS inhibitor does not yet exist. Genetic NOS 
knockout models have therefore been exploited as the next best alternative. The nNOS 
knockout (-/-) mouse model was first reported in 1993 (Huang et a l, 1993), created 
by homologous recombination in embryonic stem cells by deletion of the first protein 
coding exon of nNOS. The deleted section of the codon contained the PDZ domain 
necessary for the association of nNOS to the NMDA receptor. Disruption of the 
nNOS gene resulted in elimination of 95 -  98 % of nNOS activity in the hippocampus 
in these mice, leaving only variant transcripts that lack the first exon and that are 
present at extremely low levels. The first study investigating LTP in these animals 
observed that nNOS -/- mice exhibited normal LTP (O’Dell et al, 1994), which was 
reduced by general NOS inhibition. This finding led the authors to suggest that 
another isoform of NOS may participate in LTP.
A couple of years later an eNOS knockout model was produced, where a
mutation was targeted to the NADPH ribose and adenine-binding sites of eNOS.
Enzymatic assay confirmed a lack of eNOS activity in these mice, and
immunohistochemistry found lack of eNOS expression in all tissues examined. LTP
was found to be normal in these mutant mice, although targeted deletion of both
nNOS and eNOS was demonstrated to result in the loss of LTP (Son et al, 1996). In
contrast, an independent group found that eNOS -/- mice lack NOS-inhibitor-sensitive
LTP, but exhibit NOS-inhibitor-insensitive LTP (Wilson et al, 1999). Both groups
used the same mouse construct (129SV/C57BL/6), the same targeting strategy, and
tested the mice at the same age so the explanation for the discrepancy is not
immediately apparent. However, one plausible explanation may be the stimulation 
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protocol used to induce LTP: Son et al. used 2 trains of 100 Hz at 1 s duration 
whereas Wilson et al. used 3 trains of 100 Hz at 0.1 s duration to induce LTP. This 
possibility will be addressed in the current work
A second strategy was also developed to target eNOS in the adult animal, 
adding support for the case that eNOS activity is important in LTP. Adult 
hippocampal slices infected with recombinant adenovirus vectors containing either a 
truncated eNOS (which lacks catalytic activity yet retains the NH2 -terminal sequence 
required for myristoylation) or an eNOS fused to a transmembrane protein (CD8), 
demonstrated that membrane-targeted eNOS is required for LTP, and its function 
cannot be compensated by nNOS (Kantor et al., 1996).
Although the evidence from the genetic models appears to indicate that the 
eNOS isoform mediates the majority of the involvement of NO in LTP, it is by no 
means conclusive. It is possible that genetic knockout animals are able to compensate 
with another subtype, whereas adult wild type animals could not. Another possibility 
that has so far also not been addressed is that nNOS and eNOS may both be required 
for differential functions in the induction and maintenance phases of LTP. In addition 
to being involved in the induction phase of LTP as a retrograde messenger, NO is also 
thought to contribute to the expression phase of LTP in the hippocampus which is 
dependent on protein and mRNA synthesis (Frey et al., 1993; Huang & Kandel, 1994; 
Nguyen et al., 1994). Accordingly, recent studies have demonstrated that NO 
contributes to late-phase LTP through the stimulation of postsynaptic NO-sensitive 
GC and cGK, which may act in parallel with the cAMP/PKA pathway to increase 
phosphorylation of the transcription factor CREB (Lu et al, 1999, 2002).
The aim of the present study was to investigate the requirement for NO in 
hippocampal LTP, focussing in particular on the isoform of NOS responsible. Initially 
we set out to investigate the effect of exogenous NO on synaptic transmission, 
however, we were unable to reproduce the previously reported rebound potentiation 
following bath application of DEA/NO. Subsequently the isoform of NOS which 
mediates the involvement of NO in LTP was explored using a combination of genetic 
and pharmacological techniques. In particular, the explanation for the apparent 
discrepancy between different laboratories in analogous studies on the deficit of LTP 
in eNOS-deficient mice will be discussed.
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6.2 M ethods
6.2.1 Endothelial NOS deficient mice
Mice homozygous for a mutation in eNOS (Huang et al, 1995) were crossed with 
wild type 129SV/C57BL/6 mice (Charles River, Margate, UK) to generate 
heterozygous mutant mice. Heterozygous mice from different litters were then mated, 
and the genotype of their offspring was determined as described below. Homozygous 
eNOS knockout mice and their control homozygous wild type littermates were 
selected for the study. Mice deficient in eNOS were viable, fertile, and 
indistinguishable from their wild type and heterozygous littermates in gross physical 
appearance.
6.2.2 Genotypic determination of transgenic mice
Mice from each litter were genotyped by PCR as described in chapter 2 (2.5) to 
confirm the presence or absence of the eNOS or NEO gene. The amplified products 
were electrophoresed in 1.5 % agrose gel with 2.5 pi/100 ml ethidium bromide, and 
DNA bands were visualised under UV light. Figure 6.1a demonstrates a representative 
agarose gel as visualised under UV light; figure 6.1b shows the same agarose gel as 
viewed under phase contrast to enhance the DNA bands. Heterozygotes were 
distinguished from their homozygote littermates by the presence of two DNA bands; 
homozygotes exhibited only one band. Positive and negative samples were always run 
on each gel.
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Figure 6.1: Genotyping of wild type and eNOS knockout mice.
(a) Agarose gel as visualised under UV light; (b) same agarose gel as viewed by phase- 
contrast. The columns in both represent: (i) DNA ladder; (ii) homozygous eNOS knockout 
mice; (iii) heterozygous mice; (iv) homozygous wild type mice; (v) negative control.
+ 142
6. Involvement of NO in LTP
H----------------------------------------------------------------------------------------------------------------------------
6.2.3 Tissue preparation
Hippocampal slices were prepared from either 6 to 8 week-old male Sprague-Dawley 
rats (Charles River, Margate, UK) or 8 - 12 week old male eNOS knockout (Huang et 
al, 1995) or male wild type mice (Charles River, Margate, UK or Harlan, Bicester, 
UK) as described in chapter 2 (2.2).
6.2.4 Electrophysiological recordings
Extracellular recordings of field excitatory postsynaptic potentials (fEPSPs) were 
made from the stratum radiatum of the CA1 area of the hippocampus following 
electrical stimulation (baseline frequency 0.033 Hz or 0.2 Hz) of the Schaffer 
collateral pathway at 30 °C. The strength of presynaptic stimulation was adjusted to 
evoke fEPSPs that were ~ 30 % of the maximum fEPSP slope. After recording stable 
baseline synaptic responses for at least 20 min, LTP was induced by either one train 
of 100 Hz stimulation ( I s  duration), or by three trains of 100 Hz stimulation (0.1 s 
duration) delivered 20 s apart at the test stimulation intensity. Stock solutions of the 
NONOate NO donor, diethylamine/NO adduct (DEA/NO) were made up in 10 mM 
NaOH and diluted at least 1:100 into the ACSF solution. Hippocampal slices to be 
tested in the presence of DEA/NO were incubated with DEA/NO for 5 min prior to 
and 10 min post tetanic stimulation. Both 1400W and L-VNIO were perfused for 15 
min prior to and 15 min post tetanic stimulation to be consistent with biochemical 
results obtained in chapter 4. L-NNA was present for the duration of the respective 
experiment. Experiments were carried out blind to the origin of the tissue. Slope 
measurements were made during the initial linear phase of each evoked potential (20 
-  50 % of the peak) and the values were normalised relative to the mean values 
obtained within the first 10 or 15 min of recording in the absence of any treatment. 
The fEPSPs are presented as a percentage of the baseline.
6.2.5 Data Analysis
All data are presented as the mean ± S.E.M. Differences between experimental results 
were analysed using a one-way ANOVA with Tukey’s post-hoc test; P values of < 
0.05 were regarded as significant.
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6.3 Results
6.3.1 Effect of NO donors on synaptic transmission
The effect of NO donors on synaptic transmission has been investigated by a number 
of different groups, although the majority of studies (Bohme et a l, 1991; Bon et al., 
1992; Boulton et al, 1994) have utilised NO donors such as SNP, hydroxylamine, or 
various nitrosothiols, all of which are now considered to be problematic because of 
their intrinsic chemical reactivity and/or because they release reactive species in 
addition to NO (Feelisch, 1998). More recently the effect of authentic NO (released 
from the NONOate DEA/NO) on synaptic transmission has been examined, and found 
to elicit an enduring potentiation of CA1 hippocampal neurotransmission that 
occludes tetanus-induced LTP (Bon & Garthwaite, 2001 a,b; Bon & Garthwaite, 
2002). This effect was found to be critically dependent on the frequency of synaptic 
transmission, occurring at 0.2 Hz but not at 0.033 Hz. However, on repetition of this 
experiment we could not reproduce all the findings obtained previously. In 
accordance with Bon & Garthwaite, 10 min perfusion of 300 pM DEA/NO resulted in 
a depression of synaptic transmission at 0.2 Hz that was reversible upon washout of 
NO. However, in contrast to the robust rebound potentiation observed by Bon & 
Garthwaite, the depression was followed by only minimal rebound potentiation 
(figure 6.2a). Subsequent tetanus-induced LTP (one train of 100 Hz; Is) however was 
found to be normal.
The explanation for this discrepancy is unclear. Checks were made by the 
authors in the previous study that NO was responsible for the effects observed; 
degraded DEA/NO had no effect on synaptic transmission, and a second NONOate, 
PAPA/NO, had the same effect as DEA/NO, albeit to a lesser degree (Bon & 
Garthwaite, 2001b). The same frequency of synaptic transmission (0.2 Hz), the same 
strength of presynaptic stimulation (~ 30 % of maximum fEPSP slope), and the same 
source of DEA/NO (Alexis Biochemicals), were used in both the current study and in 
previous reports. The source of DEA/NO was additionally tested from an alternative 
company (Sigma) with the same result. Similar observations were also made in both 
the rat (figure 6.2a) and the mouse (figure 6.2b) hippocampus, giving additional 
support to the validity of our results. Furthermore, various experiments carried out on 
the same electrophysiological set-up used to obtain the previous findings again 
resulted in only minimal rebound potentiation. Given that the explanation for the
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discrepancy still remained uncertain, the decision was made not to pursue this method 
of investigation any further.
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Figure 6.2: Effect o f DEA/NO on synaptic transmission at a basal frequency o f 0.2 Hz.
Comparison of effect of DEA/NO (300 pM; 10 min exposure) on (a) rat and (b) mouse 
synaptic transmission (n = 4). LTP was induced by one train of 100 Hz (1-s duration) at the 
time indicated by the arrow. Insets show representative traces taken at the times indicated by
the letters.
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6.3.2 Effect of weak tetanic stimulation on LTP in eNOS knockout mouse
hippocampal slices at 0.2 Hz baseline stimulation frequency
The inconclusive results obtained on attempting to induce rebound potentiation 
following application of exogenous NO prompted tests to investigate the role of 
endogenous NO in synaptic plasticity in the mouse hippocampus. Initial experiments 
were performed in order to address the apparent discrepancy in the deficit of LTP 
observed from eNOS knockout mice between different laboratories (Son et al, 1996; 
Wilson et al, 1999). The most plausible explanation for this difference relates to the 
stimulation protocol used to induce LTP, since relatively weak tetanic stimulation 
tends to favour NOS-dependent LTP, whilst stronger stimulation tends to favour 
NOS-independent LTP. In the present study we initially applied a relatively weak 
tetanic stimulation (one train at 100 Hz; 1 s duration), previously found to induce NO- 
dependent LTP in rat hippocampal slices (Bon & Garthwaite, 2003). LTP induced in 
“wild type” mice by this protocol produced a surprising result; only a relatively small 
PTP was observed, followed by a rapid decrease in EPSP slope which reversed to 
leave a long-lasting potentiation within 10 min (figure 6.3a). Furthermore, LTP in 
“wild type” hippocampal slices appeared insensitive to the presence of L-NNA (100 
j i M ) .  In contrast, eNOS -/- hippocampal slices exhibited a reduction in LTP compared 
to “wild type” animals at 80 min post tetanus (from 155 ± 14 % to 129 ± 3 %; figure 
6.3b). Exposure to L-NNA however did not further reduce LTP in eNOS-deficient 
slices.
It is important to note two fundamental differences between the two groups of 
animals. First, “wild type” animals appear to demonstrate a drifting baseline, whilst 
eNOS knockout animals have a stable baseline. Second, eNOS -/- slices reveal an 
apparently stable LTP, whereas “wild type” slices exhibit unstable LTP. The only 
apparent difference between the two groups of animals was that they were obtained 
from different sources: ‘"wild type” mice were bought from Harlan (Bicester, UK), 
whereas knockout mice were bred in-house (Wolfson Institute, UCL, UK). After 
further investigation it was realised that the supposedly “wild type” mice from Harlan 
contained a chromosomal deletion of the a-synuclein locus (Specht & Schoepfer, 
2001), an abundant presynaptic protein important in regulating presynaptic vesicular 
pools (Cabin et al, 2002), and in augmenting neurotransmitter release (Liu et al, 
2004). Harlan subsequently removed these mice from sale.
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Figure 6.3: LTP in CA1 region of the hippocampus in wild type and eNOS-deficient mice at 
0.2 Hz baseline frequency. LTP was induced by one train of 100 Hz (1 s duration) at the 
time indicated by the arrow. Insets show representative traces taken at the times indicated by
the letters.
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Given the finding that “wild type” mice obtained from Harlan contained an a- 
synuclein chromosomal deletion, mice homozygous for a deletion in eNOS were 
crossed with wild type mice of a similar background as used to generate the mutant: 
the eNOS knockout was produced in a 129SV/C57BL/6 background; however as 
Harlan was the only supplier of this particular cross, C57BL/6 mice were acquired 
from Charles River (Margate, UK). Heterozygous mice from different litters were 
then mated, and the resultant homozygous eNOS knockout mice and their control 
homozygous wild type counterparts were used in all further experiments.
Contrary to the instability observed previously, wild type mice from the new 
batch of animals exhibited a normal LTP profile with a stable baseline (figure 6.4). 
LTP was also found to be sensitive to NOS inhibition: that is treatment with L-NNA 
resulted in a gradually decaying potentiation such that by 80 min after tetanus the 
fEPSP slope was 131 ± 1 % of the baseline value, whereas in control slices it was 152 
± 2 % .  This reduction in LTP was found to be statistically significant (P < 0.05). In 
contrast, slices from eNOS -/- mice demonstrated a reduction in LTP which was not 
further reduced by exposure to L-NNA (figure 6.4). Interestingly, comparable 
potentiation was also observed in eNOS -/- slices 80 min post tetanus whether in the 
presence (126 ± 6 %) or absence (127 ± 2 %) of L-NNA, and in wild type slices 
exposed to L-NNA (131 ± 1 %). However, it must also be noted that the LTP profile 
differs between the two conditions.
Wild Type ACSF
eNOS knockout ACSF
—• — eNOS knockout l -NNA
Tim e (min)
Figure 6.4: LTP in control littermates of wild type and eNOS deficient mice at 0.2 Hz 
baseline frequency. LTP was induced by one train of 100 Hz (1 s duration) at the time 
indicated by the arrow (n = 5). Insets show representative traces taken at the times indicated
by the letters.
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6.3.3 Effect of tetanic stimulation on LTP in endothelial NOS knockout 
hippocampal slices at 0.033 Hz
It is widely recognised that the frequency at which electrophysiological experiments 
are undertaken is of great importance. Typically frequencies in the range of 1 -  3 Hz 
give rise to LTD, whereas stimulation in the 30 - 100 Hz range is required for LTP 
(Bliss & Collingridge, 1993). Varying stimulation frequencies have also been used in 
the literature to evoke baseline fEPSPs, the highest of which being 0.2 Hz (Bohme et 
al, 1991, 1993). However, recent studies indicate that long lasting plastic changes 
may occur in central synapses in normal animals at stimulation frequencies as low as 
0.2 Hz that do not occur at 0.033 Hz, such that potentiation results from exogenous 
NO paired with a weak tetanus at 0.2 Hz, but not at 0.033 Hz (Bon & Garthwaite, 
2001b). Furthermore this NO-triggered potentiation appears to share mechanisms in 
common with normal HFS-induced LTP; LTP was progressively occluded in 
proportion with the degree of prior NO-triggered potentiation, and the NO-triggered 
potentiation could be inhibited by NMDA receptor antagonists similar to HFS- 
induced LTP (Bon & Garthwaite, 2001a).
In order to explore the possibility that this phenomenon may be influencing 
the results obtained so far, the experiments were repeated at 0.033 Hz. Similar to 
observations at 0.2 Hz, a relatively weak tetanic stimulation (100 Hz; 1 s duration) 
was found to induce a robust LTP in wild type hippocampal slices that was NO- 
dependent (204 ± 11 %; figure 6.5a). Also consistent is the finding that eNOS -/- 
slices exhibit significantly reduced levels of LTP (154 ± 8 %; P < 0.05 vs. wild type 
control; figure 6.5b), which was not further reduced following exposure to L-NNA.
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Figure 6.5: LTP in CA1 region of the hippocampus in wild type and eNOS-deficient mice at 
0.033 Hz baseline frequency. LTP was induced by one train of 100 Hz (1 s duration) at the 
time indicated by the arrow. Insets show representative traces taken at the times indicated by
the letters.
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We then addressed why there is a discrepancy in the literature between the 
degree of LTP observed in eNOS-deficient mice in analogous studies. As the results 
in the present study lie between those observed previously (Son et al, 1996; Wilson et 
al, 1999), that is, only a partial deficit in LTP is observed in eNOS -/- mice, one 
plausible explanation may be the differing LTP induction protocols utilised: Son et a l 
used two trains of 100 Hz at 1 s duration, Wilson et a l used three trains of 100 Hz at 
0.1 s duration to induce LTP, whereas our induction protocol lies between the two 
(one train of 100 Hz; 1 s). To address this possibility we monitored the synaptic 
response of wild type and eNOS -/- hippocampal slices under the same LTP induction 
protocol as followed by Wilson et a l (1999). On repeating the experiment we 
confirmed that weak tetanic stimulation in wild type mice resulted in robust LTP of ~ 
150 % (figure 6.6a) that was NO-dependent. However, in contrast to the previous 
study, the LTP deficit observed in eNOS knockout mice was only partial (figure 
6.6b). Furthermore, the deficit in LTP observed in eNOS -/- slices (124 ± 3 %) is 
comparable to that observed in the presence of L-NNA (125 ± 3 %), indicating that 
the remaining portion of the LTP response is NO-independent. Interestingly, the first 
EPSP slope post tetanus is significantly reduced (P < 0.05) in eNOS -/- slices (170 ± 3 
%) when compared to their wild type counterparts (230 ± 1 5  %), whereas in the 
presence of L-NNA this reduction is not significant (197 ± 3 %; figure 6.6c).
We then enquired whether the deficit in LTP observed in eNOS knockout 
mice might be explained simply by the loss of tonic levels of NO, presumably 
generated from eNOS. If so, then pairing a low exogenous concentration of DEA/NO 
designed to mimic basal NO levels with tetanic stimulation might “rescue” LTP in 
eNOS knockout slices. We chose to apply DEA/NO at a concentration of 0.3 pM, 
which is just above threshold for raising cGMP levels in hippocampal slices (Bon & 
Garthwaite, 2001b) but has no effect on baseline fEPSPs elicited at 0.2 Hz (Bon & 
Garthwaite, 2001a). When the low DEA/NO concentration was perfused for a total of 
15 min, covering the period before, during and after weak tetanic stimulation, LTP 
was apparently restored in eNOS knockout hippocampal slices (148 ± 3 %; figure 
6.7). It must be noted, however, that although the degree of LTP observed in these 
slices did not significantly differ from the wild type (145 ± 6 %), the initial transient 
phase of LTP was not fully restored. Figure 6.8 confirms that 0.3 pM DEA/NO alone 
has no effect on LTP.
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Figure 6.6: LTP induced by three trains of 100 Hz; 0.1s; 20 s intertrain interval at 0.033 Hz 
baseline frequency. The tetanic stimulation was applied at the time indicated by the arrow. 
Insets show representative traces taken at the times indicated by the letters.
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Figure 6.7: Rescue of CA1 hippocampal LTP by pairing exogenous NO with weak tetanic 
stimulation at 0.033 Hz baseline frequency. Pairing of 0.3 pM DEA/NO with tetanus (three 
trains of 100 Hz; 0.1s; 20 s intertrain interval) restored LTP in eNOS knockout hippocampal 
slices. Insets show representative traces taken at the times indicated by the letters.
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Figure 6.8: Effect o f 0.3 pM  DEA/NO on hippocampal LTP with weak tetanic stimulation 
at 0.033 Hz baseline frequency. LTP was induced at the time indicated by the arrow. Insets 
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6.3.4 Effect of nNOS inhibition on LTP induction
Given the finding that eNOS knockout mice exhibit a deficit in LTP comparable to 
that observed in the presence of L-NNA, these data indicates that there is an 
involvement of eNOS in LTP in the CA1 region of the hippocampus; conversely the 
results also suggest there is little or no involvement of the nNOS isoform. To 
investigate this assumption, wild type hippocampal slices were treated with two 
selective nNOS inhibitors identified in chapter 4 (4.3.1.1). Hippocampal slices were 
exposed to 1400W and L-VNIO for a total of 30 min, starting 15 min prior to tetanic 
stimulation to be consistent with the biochemical results. Incubation with either 
1400W (figure 6.9a) or L-VNIO (figure 6.9b) resulted in a gradually decaying 
potentiation comparable to findings in the presence of L-NNA. That is, similar to 
findings with L-NNA (Boulton et ah, 1995; Lu et ah, 1999; Bon & Garthwaite, 2003), 
nNOS inhibition primarily appears to inhibit late-phase LTP. Additionally, the fact 
that two different nNOS inhibitors resulted in the same inhibition of late-phase LTP, 
indicates that the effect observed is attributable to their action on NO formation as 
opposed to any direct effect on protein synthesis or transcriptional/translational events 
associated with the maintenance of LTP.
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We then addressed whether it is possible to “rescue” the deficit in LTP 
observed following nNOS inhibition by pairing a low exogenous application of 
DEA/NO with tetanic stimulation. However, exposure to 0.3 pM DEA/NO for a total 
of 15 min before, during and after weak tetanic stimulation resulted in only a partial 
restoration of LTP (figure 6.10).
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Figure 6.10: Effect o f pairing exogenous NO with nNOS inhibition on LTP at 0.033 Hz 
baseline frequency. Pairing of 0.3 pM  DEA/NO with tetanus (three trains of 100 Hz; 0.1 s 
duration; 20 s intertrain interval) partially restored LTP in the presence of1400W. Insets 
show representative traces taken at the times indicated by the letters.
One possible explanation for the partial “rescue” of LTP is that nNOS would 
typically generate a higher NO concentration following tetanic stimulation than is 
present under basal conditions. To test this possibility we chose to apply DEA/NO at a 
concentration of 3 pM, a concentration likely to reflect the burst of NO generated as a 
consequence of NMDA receptor activation following tetanic stimulation (Bon & 
Garthwaite, 2003). When 3 pM DEA/NO was perfused for a total of 15 min before, 
during and after weak tetanic stimulation, LTP was apparently restored in 1400W- 
treated hippocampal slices (figure 6.11). The degree of LTP observed under these 
conditions was not significantly different from untreated wild type hippocampal 
slices. Furthermore, the initial transient phase of LTP was fully restored. Figure 6.12 
confirms that 3 pM DEA/NO alone has no effect on LTP.
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Figure 6.11: Effect o f pairing exogenous NO with nNOS inhibition on LTP at 0.033 Hz 
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6.4 Discussion
In this chapter we have investigated the requirement for NO in hippocampal LTP, 
focussing on the isoform of NOS responsible. Our findings indicate that both eNOS 
and nNOS contribute to hippocampal LTP, although we propose that they may 
possess distinct roles in either the early or late phase.
Unfortunately, initial control experiments carried out on “wild type” mice 
encountered difficulties both in maintaining stable synaptic transmission, and in 
obtaining a “normal” LTP profile in response to HFS. However, a plausible 
explanation for this finding was provided by the surprising discovery that C57BL/6 
inbred mice obtained from Harlan contained a chromosomal deletion of the a- 
synuclein locus which was not present in C57BL/6 mice obtained from Charles River 
(Specht & Schoepfer, 2001). a-synuclein is a presynaptic protein highly expressed in 
regions of the adult CNS that display synaptic plasticity (such as the hippocampus; 
Petersen et al, 1999), and has been found to be localised in the presynaptic terminal 
in close proximity to synaptic vesicles (Iwai et al, 1995). Analysis of mice lacking a- 
synuclein revealed a marked decrease in the pool of resting-reserve synaptic vesicles 
in these animals, although the quantity of docked vesicles appears normal (Cabin et 
al., 2002). This realisation was of vital importance to my work, as the synaptic 
response to a high frequency tetanus would typically exhaust not only the docked 
vesicles, but would also deplete the reserve pool of vesicles in the presynaptic cell. 
Therefore, given the fact that the reserve pool of vesicles necessary for LTP is 
depleted in mice which lack a-synuclein (such as in the mice obtained from Harlan), it 
would be expected that the ability of the synapse to undergo plastic changes would 
also be compromised. Consistent with this idea is a recent study which has shown that 
hippocampal LTP is associated with an increase in the number of a-synuclein clusters, 
and that mice deficient in a-synuclein exhibit reduced levels of hippocampal LTP (Liu 
et al, 2004). Of particular interest to our work is their finding that application of NO 
also increases the number of a-synuclein clusters in hippocampal neurons, indicating 
that a-synuclein may play an integral role between the generation of NO and 
presynaptic neurotransmitter release. Therefore, in light of the fact that a-synuclein is 
likely to play an important role in synaptic plasticity, and that “wild type” C57BL/6 
mice from Harlan are deficient in a-synuclein, we crossed eNOS knockout mice with
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C57BL/6 mice from another source (Charles River, UK) to generate eNOS mutant 
and wild type littermates which do not contain this deletion.
Attempts made to address the relative contribution of the nNOS and eNOS 
isoforms to hippocampal LTP via genetic manipulations have so far proved 
unsuccessful in clarifying the situation. Initial studies found that mice lacking both 
eNOS and nNOS demonstrated reduced LTP in the stratum radiatum of the 
hippocampus (Son et al, 1996), whereas animals which were mutant for only nNOS 
or eNOS exhibited normal or nearly normal LTP which was still sensitive to NOS 
inhibition (O’Dell et al, 1994; Son et al, 1996). In contrast, Wilson et al., (1999) 
observed that LTP induced by a weak tetanus was completely absent in both eNOS 
knockout mice and in the presence of L-NNA in wild type animals, whilst LTP 
induced by a stronger tetanus was unaffected. Furthermore, LTP induced by the 
stronger tetanus was found to be NO-independent, that is it was insensitive to NOS 
inhibition. Since the authors of the latter study observed a complete absence of LTP in 
eNOS knockout animals they concluded that NO-dependent LTP is mediated by 
eNOS alone, with little or no contribution to nNOS, although this prediction was not 
explicitly tested. Also consistent with their conclusion is a report from Kantor et a l 
(1996), which found that transfection of hippocampal slices with a recombinant 
retrovirus carrying a dominant-negative truncated non-functional eNOS blocked LTP 
in the stratum radiatum.
The results obtained in the present chapter allow us to address four important 
questions regarding the contribution of the nNOS and eNOS isoforms to the induction 
and expression of LTP in the rodent hippocampus. The first issue we addressed was 
whether eNOS or nNOS generates the NO required for LTP. In our experiments we 
found that, although mice deficient in eNOS exhibited a significant deficit in LTP as 
reported previously (Wilson et al, 1999), there was also a significant amount of 
residual LTP. However, no further reduction in LTP was observed in the presence of 
L-NNA, indicating that the residual component is NO-independent. Interestingly, it is 
the early phase of LTP that appears to be most affected in eNOS -/- slices when 
compared to their wild type counterparts (figure 6.13), although this does not seem to 
hinder the capacity of the hippocampus to maintain stable LTP, albeit to a lesser 
degree than in wild type animals.
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Figure 6.13: Effect o f eNOS knockout on EPSP slope immediately following tetanus.
LTP was induced by three trains of 100 Hz; 0.1 s; 20 s intertrain interval at 0.033 Hz basal 
stimulation frequency (n = 4 — 5). *P < 0.05 vs. wild type control EPSP slope; one-way
AN OVA with Tukey ’s post-hoc test.
Given the similar deficits in LTP in both the presence of L-NNA, and in eNOS 
knockout animals, it would be predicted that nNOS would play little or no 
contribution towards LTP. However, contrary to expectations, selective inhibition of 
nNOS by either 1400W or L-VNIO produced a gradually decaying potentiation 
comparable to findings in the presence of L-NNA. That is, similar to findings with L- 
NNA (Boulton et al, 1995; Lu et al., 1999; Bon & Garthwaite, 2003), nNOS 
inhibition primarily appears to affect the late-phase LTP. This result supports the 
growing body of evidence that NO, acting postsynaptically via the NO/cGMP/cGK 
pathway, contributes to CREB phosphorylation and late-phase LTP (Lu et al., 1999; 
Lu & Hawkins, 2002; Kleppisch et al., 2003). At first glance the involvement of 
nNOS in hippocampal LTP found in our work may appear at odds with the previous 
reports of normal LTP in nNOS -/- mice (O’Dell et al., 1994; Son et al., 1996). 
However, disruption of the nNOS gene only eliminates 95 - 98 % of nNOS activity 
(Huang et al., 1993). Two alternatively spliced isoforms of NOS, nNOSp and nNOSy, 
continue to be expressed in nNOS mutant mice (Putzke et al., 2000), and both have 
recently been identified in hippocampal pyramidal cells as well as in intemeurons 
(Blackshaw et al., 2003). Given that one of these alternatively spliced isoforms 
(nNOSP) has been found to be catalytically active in vivo (Eliasson et al., 1997), it is 
feasible that these alternative isoforms may provide an important physiological source
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of NO capable of compensating, at least in part, for the lack of nNOSa in mutant 
animals.
The results presented in this chapter clearly indicate that both eNOS and 
nNOS contribute to hippocampal LTP and, surprisingly, it appears that the absence of 
either isoform independently is sufficient to produce a deficit in LTP comparable to 
that found in the absence of both isoforms (as is the case in the presence of L-NNA; 
figure 6.14). Although this may initially appear to be a surprising conclusion given 
that ~ 98 % of the NOS activity in the hippocampus is due to nNOS, with eNOS 
activity only accounting for the remaining 2 % (Huang et al, 1993). However, it 
seems likely that the timing and localisation of NO may be more important than the 
net NOS activity, especially as our results indicate that the two NOS isoforms may 
possess distinct roles regarding their influence in either the early or late phase of LTP. 
One study examining the role of NO in cerebellar LTD has shown that LTD is only 
induced when Ca2+ transients coincide precisely with a rise in NO levels in the same 
Purkinje cell; LTD induction only permits a gap of < 10 ms between these two signals 
(Lev-Ram et al., 1997). It is very possible that a similar arrangement exists in the 
hippocampus which may govern the action of NO in LTP; that is selectively inhibiting 
only one NOS isoform could prevent the NO-dependent component of LTP to occur.
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Figure 6.14: Effect o f NOS inhibition on EPSP slope measured 80 min post tetanus.
LTP was induced by three trains o f 100 Hz; 0.1 s; 20 s intertrain interval at 0.033 Hz baseline 
frequency (n = 4 - 5). *P < 0.05 vs wild type control EPSP slope; one-way ANOVA with
Tukey ’s post-hoc test.
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The second issue we addressed was whether the strength of the tetanus could 
account for the discrepant results observed with regards to the degree of LTP in 
eNOS-deficient mice. A direct comparison between LTP studies is often hindered by 
the use of widely varying protocols to induce LTP; for example Son et al. (1996) used 
a tetanus of two trains of 100 Hz frequency with Is duration, whereas Wilson et al. 
(1999) used three trains of 100 Hz frequency with 0.1 s duration. In our experiments 
we found that although mice deficient in eNOS exhibited a pronounced deficit in 
LTP, a significant degree of LTP remained. However, no further reduction in LTP 
was observed in the presence of L-NNA, indicating that the residual component is 
NO-independent. We are uncertain why our results differ from both Wilson et al. 
(1999) and Son et al. (1996), especially since eNOS -/- mice in each case were 
constructed using the same mouse strains (129SV and C57BL/6), by the same strategy 
of targeting a mutation to the NADPH binding site of eNOS, and all mice were tested 
at roughly the same age (8 -1 2  weeks). One possible explanation lies in the different 
tetanus protocols used, since weak tetanus protocols tend to favour NO-dependent 
forms of LTP whereas stronger stimulations induce NO-independent forms of LTP. 
Why a stronger stimulation is able to bypass the requirement for NO is not yet clear. 
Stronger stimulation intensities presumably activate more fibres; by recruiting a larger 
number of glutamatergic afferents, a strong tetanus could depolarise the postsynaptic 
cell to a greater degree and thereby engage biochemical pathways which are not 
activated by weaker postsynaptic depolarisations. Alternatively, a stronger stimulus 
could recruit other types of afferents, such as aminergic fibres, which may lower the 
threshold for LTP induction. Consistent with the tetanus protocol being of utmost 
importance to induce NO-dependent LTP, Wilson et al. (1999) found that eNOS -/- 
mice displayed a deficit in LTP when induced by a weak tetanus (three trains of 100 
Hz with 0.1s duration at baseline stimulus intensity) but not by a stronger tetanus 
(three trains of 100 Hz with 0.1s duration at double baseline stimulus intensity). 
However, in our study we found that the weak stimulation protocol of Wilson et al. 
(1999) failed to abolish LTP in eNOS animals. This implies that the stimulation 
protocol alone is insufficient to entirely account for the discrepancy observed between 
groups.
A second possibility is that since our population of eNOS knockout mice
contain a slightly different background to those used in previous studies (i.e. a greater
degree of similarity to the C57BL/6 strain in our eNOS knockout) that this may 
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indicate different expression levels of nNOS, and thereby lead to varying degrees of 
NO-dependent LTP in the mutant mice. This supposition stems from the recent 
observation by Blackshaw et al., (2003) that nNOS expression is substantially higher 
in C57BL/6 than 129SV mice in the CA1 region of the hippocampus, although nNOS 
levels were indistinguishable between strains in all other regions tested.
Additionally, it is also worth noting that a difference in LTP was observed 
between the two tetanus protocols (1 train of 100 Hz, 1 s as opposed to 3 trains of 100 
Hz, 0.1 s) following NOS inhibition. Both early- and late-phase LTP was found to be 
reduced following NOS inhibition in the weaker stimulation protocol, whereas no 
difference in the early-phase was noted when a stronger tetanus was utilised. The 
most plausible explanation for this finding is that LTP induced by 100 Hz, 1 s may be 
less NO-dependent than LTP resulting from the weaker protocol. If this was the case, 
the stronger tetanus may mask the inhibition of the early-phase of LTP observed 
following weak tetanic stimulation in the absence of NOS activity.
The third issue we addressed was whether the deficit in NO-dependent LTP 
observed in eNOS -/- animals could be explained simply by the loss of NO generated 
from eNOS, the assumption being that eNOS is responsible for tonic NO production 
in the hippocampus (chapter 4). If this was the case, then pairing a low exogenous 
concentration of DEA/NO that restores basal NO levels should “rescue” the LTP 
deficit in eNOS knockout slices. Accordingly, 0.3 jxM DEA/NO restored LTP in 
eNOS knockout animals when paired with a weak tetanus, indicating that tonic NOS 
activity is required for LTP. This finding is in agreement with previous reports which 
found that LTP could be inhibited by general NOS inhibition for < 15 min post 
tetanus (Haley et al., 1992; Bon & Garthwaite, 2003). It must be noted however that 
although the degree of LTP observed in the “rescued” eNOS knockout slices did not 
significantly differ from that in the wild type, the initial transient phase of LTP was 
not fully restored (figure 5.12). The finding that the initial transient phase of LTP 
cannot be fully restored by the application of exogenous NO indicates that there may 
be an NO-independent component to the initial deficit in LTP observed in eNOS- 
deficient mice. The most likely explanation for this is that compensation mechanisms 
or structural changes have evolved in eNOS-deficient mice to make up for the lack of 
eNOS throughout embryonic development.
Similar to the “rescue” of LTP observed in eNOS knockout mice, we then
tested whether it was possible to “rescue” the deficit in LTP observed following 
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nNOS inhibition by pairing a low exogenous concentration of DEA/NO with tetanic 
stimulation. However, in contrast to the “rescue” of LTP observed in eNOS knockout 
mice, 0.3 pM DEA/NO resulted in only a partial “rescue” of LTP. This result is not 
completely unexpected, given that nNOS would typically generate a higher NO 
concentration following tetanic stimulation than is required to maintain tonic NO at 
active levels (Chetkovich et al., 1993). Therefore, application of a low exogenous NO 
concentration (reflective of basal NO levels) would not be expected to substitute for 
the burst of NO produced as a consequence of NMD A receptor activation at the time 
of tetanic stimulation. In accordance with this, 3 pM DEA/NO restored LTP in 
1400W-treated hippocampal slices when paired with a weak tetanus: a concentration 
thought to result in NO levels similar to those produced as a consequence of NMD A 
receptor activation (Bon & Garthwaite, 2003). Interestingly, the initial transient phase 
of LTP was also fully restored, indicating that the deficit in LTP observed in the 
presence of 1400W is likely to be explained simply by an insufficient level of NO 
being present at the time of LTP induction.
The final issue we addressed was whether there is a frequency dependence of
the NOS-sensitive component of LTP. It is widely becoming realised that the
frequency at which electrophysiological experiments are undertaken is of great
importance, especially given the recent report by Bon & Garthwaite (2001b) that
stimulation frequencies as low as 0.2 Hz may trigger long lasting plastic changes in
central synapses in normal animals that do not occur at 0.033 Hz. In this study NO
triggered a long-lasting enhancement of excitatory synaptic transmission that
occluded LTP at 0.2 Hz, but not at 0.033 Hz. Furthermore, this NO-triggered
potentiation appears to share mechanisms in common with normal HFS-induced LTP;
LTP was progressively occluded in proportion with the degree of prior NO-triggered
potentiation, and the NO-triggered potentiation could be inhibited by NMD A receptor
antagonists, similar to HFS-induced LTP (Bon & Garthwaite, 2001a). One possibility
which has been put forward to explain this is that synapses could become “primed” at
frequencies as low as 0.2 Hz, possibly as a consequence of the partial loss of GABA-
mediated inhibition resulting from GABAb autoreceptor activation (Davies &
Collingridge, 1993). However, in contrast to the robust rebound potentiation observed
by Bon & Garthwaite, the depression was followed by only minimal rebound
potentiation. Subsequent tetanus-induced LTP (one train of 100 Hz; Is) was found to
be normal. The explanation for this discrepancy is also unclear. The same frequency 
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of synaptic transmission (0.2 Hz), the same strength of presynaptic stimulation (~ 30 
% of maximum fEPSP slope), and the same source of DEA/NO (Alexis 
Biochemicals), were used in both the current study and in previous reports. Similar 
observations were also made in both the rat and the mouse hippocampus. 
Furthermore, various experiments carried out on the same electrophysiological set-up 
used to obtain the previous findings again resulted in only minimal rebound 
potentiation.
Given the fact that different groups use widely varying frequencies by which 
to stimulate baseline fEPSPs, the highest of which being 0.2 Hz (Bohme et al, 1991, 
1993), this “priming” may go some way towards explaining the conflicting results 
regarding the NO dependence of LTP. However, in our experiments we found that 
there was no difference in the deficit in LTP observed in eNOS knockout animals 
between 0.2 Hz and at 0.033 Hz. This result therefore indicates that there is little or no 
frequency dependence to the NOS-sensitive component of LTP at the stimulation 
frequencies tested.
Overall our findings provide good support for the hypothesis that NO serves as 
an important messenger in hippocampal LTP, and present evidence for a contribution 
from both constitutive forms of NOS. The results also propose the interesting 
possibility that the different isoforms of NOS may possess distinct roles in the 
modulation of synaptic events; that is eNOS appears to be important for the early 
phase of LTP, whereas nNOS seems to exert a greater influence on the late phase. 
However, given the observation that the initial transient phase of LTP remains 
reduced following the “rescue” of LTP in eNOS-deficient mice, an indication that 
there may be an NO-independent component to this initial deficit in LTP, the 
possibility that eNOS and nNOS may carry out the same role cannot be ruled out. We 
postulate that the previously reported observations of normal LTP in the absence of 
nNOS (O’Dell et al., 1994; Son et al., 1996) may be explained by either the LTP 
induction protocol, or more likely, by the activity of alternatively spliced isoforms of 
nNOS that remain in the nNOS knockout (Eliasson et al, 1997) providing a 
physiological source of NO capable of potentially compensating for the absence of 
nNOSa in these animals. Therefore acute inhibition of nNOS in wild type mice, as 
carried out in the present study, is likely to provide a more accurate portrayal of the 
contribution that nNOS plays in synaptic transmission.
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7.1 General Discussion
The aim of my research was to investigate and further characterise the role that 
NO plays in synaptic plasticity in the hippocampus. Given that hippocampal LTP is 
critically dependent on post-synaptic activation of the NMDA receptor (Bliss & 
Collingridge, 1993), I initially set out to test some of the primary predictions of the 
hypothesis that NO regulates NMDA receptor function in central synapses. In chapter 
3 the role of endogenous and exogenous NO in synaptic function was investigated on 
native or cloned NMDA receptors, in acute rat hippocampal slices and HEK-293 cells 
respectively, and found to have no observable effect on NMDA receptor function. 
Importantly, these results also indicate that previously reported observations of 
synaptic NMDA receptor block by NO (Murphy et al, 1994; Murphy & Bliss, 1999) 
may be artifactual: examination utilising transfected cells demonstrated that NO itself 
was not responsible for inhibition of NMDA receptor currents, but the combination of 
NO and UV light. Further inspection revealed the previous indirect evidence that NO 
affects NMDA receptor function to be questionable, and this, together with the 
additional direct evidence presented in the current study, places the hypothesis that 
NO regulates the functioning of synaptic NMDA receptors in serious doubt.
Given the importance of the NO/cGMP pathway in hippocampal LTP, I then 
went on to investigate the isoform of NOS which mediates the involvement of NO in 
LTP in chapters 4 and 5. Collectively these results provide good support for the 
hypothesis that hippocampal LTP requires both a tonic NO level, and a phasic NO 
signal arising from tetanic stimulation (Bon & Garthwaite, 2003). I additionally 
present evidence that both eNOS and nNOS contribute to this phenomenon, since a 
deficit in LTP was observed in both eNOS-deficient mice, and in wild type mice 
subjected to selective nNOS inhibition. Furthermore, the results propose the 
interesting possibility that the different isoforms of NOS (nNOS and eNOS) may 
possess distinct roles in the modulation of synaptic events.
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With respect to the tonic component, we found that eNOS is most likely 
responsible for basal NO production in the hippocampus, and that NO generated from 
this source appears to be important in the early phase of LTP. In particular, the initial 
phase of LTP is significantly reduced in eNOS -/- slices when compared to their wild 
type counterparts. However, this reduction in early LTP does not seem to hinder the 
capacity of the hippocampus to maintain stable LTP, albeit to a lesser degree than in 
wild type mice. As these early time points in LTP are considered to represent the 
presynaptic accumulation and rapid release of Ca2+ during tetanisation (Stevens et al, 
1994; Zucker, 1999), the observation that the initial phase of LTP is reduced in 
eNOS-deficient mice presents the possibility that eNOS may mediate, at least in part, 
an action of NO on the presynaptic terminal.
With respect to the phasic component, it is widely recognised that tetanic
simulation results in NMDA receptor activation leading to the consequent influx of
2+
Ca into the postsynaptic cell. Given the physical coupling of NMDA receptors and 
nNOS, and the absolute requirement of nNOS for Ca2+, it strongly suggests that the 
increase in intracellular Ca2+ following NMDA receptor activation stimulates the 
production of NO from nNOS. In our experiments we found that, in contrast to a role 
for eNOS in early LTP, nNOS primarily appears to influence the late-phase of LTP, a 
phase dependent on protein and mRNA synthesis (Frey et al., 1993; Huang & Kandel, 
1994; Krug et al., 1984; Nguyen et al., 1994; Otani & Abraham, 1989). The gradual 
decay in potentiation resulting from nNOS inhibition (figure 5.9) is comparable to that 
observed in the presence of protein synthesis inhibitors. That is, the initial phase of 
LTP was normal, but there was a deficit that only became apparent ~ 60 min post 
tetanus.
The mechanism by which NO mediates its effect remains a matter of debate,
in part because cGMP and cGK appear to be involved under some circumstances, but
not under others (Hawkins et al., 1998). A number of studies indicate that NO
contributes to the maintenance of LTP through the stimulation of NO-activated GC
and cGK, presumably acting in parallel with the cAMP/PKA pathway to increase
phosphorylation of the transcription factor CREB (Lu et al., 1999; Lu & Hawkins,
2002; Kleppisch et al., 2003). Some studies indicate that the protein synthesis most
likely occurs in the post-synaptic neuron since late-phase LTP is blocked when the
dendrites are surgically separated from the postsynaptic bodies (Frey et al., 1989),
whereas both late-phase LTP by tetanic stimulation and late-phase potentiation by NO 
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or cGMP analogues are normal in slices from which the presynaptic cell bodies have 
been removed (Lu et al., 1999). Other studies in cultured hippocampal neurons find 
that intracellular injection o f  cGK  inhibitors into the presynaptic (but not the 
postsynaptic) neuron blocked LTP. Conversely, cGK injected into the presynaptic 
(but not the postsynaptic) cell elicited LTP (Arancio et al, 2001).
It is generally accepted that tetanic stimulation produces an increase in 
postsynaptic Ca2+ from a variety o f  sources. In addition to Ca2+ influx through 
postsynaptic N M D A  receptors, two other important Ca2+ sources are thought to 
increase intracellular Ca2+ concentration: voltage-dependent Ca2+ channels and mGlu  
receptor-linked IP3 production with the consequent release o f  Ca2+ from IP3 - and 
ryanodine-sensitive intracellular stores (Harvey & Collingridge, 1992; Bortollo & 
Collingridge, 1993; Behnisch & Reymann, 1995; W ilsch et al., 1998). 
Phosphorylation o f  IP3 receptors has been demonstrated in intact aorta in response to 
elevated cGMP levels, and cGK has been shown to catalyse this phosphorylation in 
both intact and permeablised cells (Murthy & M akhlouf, 1995; Komalavilas & 
Lincoln, 1996; Schlossm an et al., 2000). NO  gas has additionally been found to 
induce IP3 phosphorylation (Osct-Gasque et al., 1994), an effect m im icked by 
analogues o f  cGM P, but inhibited by inhibitors o f  NO-activated GC (Vicente et al., 
2005). The consequence o f  cGK activation and IP3 phosphorylation is the inhibition
 ^I
o f  IP3 -dependent Ca release from intracellular stores (Cavallini et al., 1996; Murthy, 
2001).
A  second downstream effector o f  cGK is ADP-ribosyl cyclase, an endogenous 
modulator o f  ryanodine receptor Ca2+-releasing channels. Activation o f  ADP-ribosyl 
cyclase stimulates the production o f  cyclic ADP-ribose (cADPR). Enhancement o f  
cADPR formation has been demonstrated in response to N O  and cGMP in both rat 
hippocampal slices (Reyes-Harde et al, 1999) and in hom ogenates o f  sea urchin eggs 
(Galione et al., 1993). Furthermore, blockade o f  cADPR reduced LTP with a profile 
similar to protein synthesis inhibition (Reyes-Harde et al., 1999), indicating that the 
cADPR pathway may be involved in late-phase, as opposed to early-phase, LTP. This 
pathway is thought to act synergistically with cytoplasmic Ca2+ to cause release o f  
Ca2+ from ryanodine-sensitive intracellular stores (Galione et al., 1993; Lee, 1993; 
Lee et al., 1995; Lu et al., 2002), and thereby amplify the Ca2+ signal generated from  
other sources (Alford et al., 1993; B liss & Collingridge, 1993; Emptage et al., 1999). 
In agreement with this, Ca2+ release from intracellular stores has been implicated in
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the induction of LTP in hippocampal slices (Harvey & Collingridge, 1992; Wang et 
al, 1996). When the Ca2+ signal is sufficiently large it would trigger CREB 
phosphorylation and induction of L-LTP in parallel with PKA (Lu et al., 1999, 2002). 
Consequently, activation of the NO/cGMP/cGK/ryanodine receptor pathway would 
lower the stimulation threshold for LTP induction, and inhibiting this pathway would 
have the opposite effect. The effect of NOS inhibitors is therefore to lower the 
intracellular Ca signal from above to below the threshold for synaptic plasticity for 
the weaker protocols, but not with the stronger protocols.
In contrast to the cGMP-dependent mechanisms involved in LTP, there are
several reports that cGMP analogues or cGK inhibitors have no effect on NO-
dependent LTP (Schuman et al, 1994; Selig et al, 1996; Kleppisch et al, 1999). In
these cases it has been proposed that NO may induce LTP through an alternative
cGMP-independent mechanism, possibly via ADP-ribosylation. In support of this
hypothesis, ADP-ribosyl transferase (ADPRT) activity that can be enhanced by NO
has been shown in the CA1 region of the hippocampus (Sullivan et al., 1997), but
attenuated by inhibition of ADP-ribosylation (Schuman et al., 1994). Although both
of these studies utilised SIN-1 and sodium nitroprusside as NO donors (see chapter 3
for problems regarding these compounds), the authors concluded that the
enhancement in ADPRT activity was due to NO as ADP ribosylation was not
stimulated by non-NO decomposition products, application of a superoxide scavenger
did not inhibit ADP-ribosylation, whereas an NO-scavenger (Hb) prevented the
enhancement of ADPRT activity (Briine & Lapentina, 1989; Sullivan et al, 1997;
Schuman et al., 1994). Additional evidence supporting a cGMP-independent
mechanism comes from the observation that ADP-ribosylation cannot be mimicked
by cGMP (Briine & Lapentina, 1989). Electrophysiological studies also support a role
for ADP-ribosylation in LTP: LTP is suppressed in the murine hippocampus by
ADPRT inhibitors (at a concentration which does not affect basal excitatory or
inhibitory synaptic transmission; Schuman et al., 1994), and a marked reduction in
LTP can be observed in cGK-deficient animals following ADPRT inhibition
(Kleppisch et al., 1999). The authors in the latter study found that LTP was not
reduced in cGKI, cGKII, or double mutant mice when compared to control wild type
animals, and that incubation with an NO-activated GC inhibitor also had no effect.
Furthermore, NOS inhibitors and NMDA receptor antagonists produced a marked
decrease in LTP which was not restored by exogenous cGMP, indicating that LTP is 
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NO-dependent but cGMP and cGK independent. This therefore challenges the view 
that expression of LTP involves a cGK-dependent step, and strengthens the 
hypothesis that NO may act, at least in part, via ADP-ribosylation.
All the evidence points toward the conclusion that NO is capable of 
influencing both pre- and postsynaptic protein synthesis events. In keeping with this, 
LTP has been recently demonstrated to involve the rapid formation of clusters or 
puncta of presynaptic, as well as of postsynaptic, proteins (Wang et al, 2005), both of 
which are blocked by NMDA receptor antagonists. Because the maintenance of LTP 
is also thought to involve the growth of new synapses (Luscher et al., 2000; Bozdagi 
et al, 2000), the rapid formation (< 2 min) of new clusters or puncta may represent a 
very early step in this process. Early stages in LTP are also accompanied by the 
enlargement of existing postsynaptic spines (Matsukaki et al, 2004), in addition to the 
formation of new presynaptic filopodia which has been found to involve NO 
(Nikonenko et al., 2003). These results therefore propose a sequence in that NMDA 
receptor activation triggers postsynaptic NO production from nNOS, which could then 
play some role in the formation of new presynaptic filopodia. Accordingly, the new 
presynaptic filopodia could then influence the formation of new postsynaptic spines 
and morphologically mature synapses that occurs at around 30 - 60 min post tetanus 
(Engert & Bonhoeffer, 1999; Maletic-Savatic et al, 1999; Toni et al, 1999; 
Nikonenko et a l, 2003). The time scale for these morphological changes is consistent 
with our finding of a gradually decaying potentiation following selective nNOS 
inhibition which only becomes apparent at ~ 60 min post tetanus. Any of these early 
structural changes could represent the short-lasting (< 3 h) protein synthesis- 
independent synaptic “tag” proposed by Frey and Morris (1997) which enables the 
specific targeting of newly synthesized proteins crucial for late-phase LTP to the 
synapses that are stimulated during LTP induction.
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NO and learning behaviour
As mentioned previously, synaptic plasticity is commonly considered to be the 
cellular correlate to learning and memory. However, despite the well-described 
involvement of NO in hippocampal synaptic plasticity, inhibition of NOS has 
generated conflicting results. General NOS inhibition has been reported to slow down 
(Chapman et al, 1992), as well as to accelerate (Du & Harvey, 1996), classical 
conditioning. Application of NO donors either improved or impaired avoidance 
learning, depending on the dose applied (Huang & Lee, 1995). Furthermore, in the 
Morris water maze systemic NOS inhibition had detrimental effects in some studies 
(Chapman et al, 1992; Estall et al., 1993; Yamada et al., 1995), whereas other groups 
demonstrate no effect of either systemic or intrahippocampal inhibition of NO 
synthesis (Bannerman et al, 1994; Blokland et al., 1999).
Attempts to clear up this issue by means of genetic manipulations have also 
proved unsuccessful. Given the LTP deficits observed in the absence of eNOS and/or 
nNOS (Doyle et al, 1996; Kantor et al, 1996; Son et al, 1996; Wilson et al, 1997), 
and the traditional view of a positive functional relationship between LTP and 
learning capacity, it would be predicted that disruption of either eNOS or nNOS 
would result in an impaired learning capacity. However, contrary to the expected 
learning deficit, various studies indicate that eNOS -/- mice may in fact display 
improved learning and memory capabilities. Frisch et a l (2000) reported that eNOS 
knockout mice performed better in the Morris water maze than control animals, 
whereas a more recent study by Reif et a l (2004) found that eNOS-deficient mice 
were less helpless in a learned helplessness paradigm. In contrast, nNOS-deficient 
mice have been found to exhibit impaired spatial performance in the Morris water 
maze (Kirchner et al, 2004).
Behavioural assessment of anxiety and activity-related traits also revealed 
various differences; aggressive behaviour was diminished in eNOS-deficient mice, 
whereas it was increased in nNOS-deficient animals (Demas et al, 1999). 
Additionally, eNOS knockout mice were found to be less active than wild-type 
controls (Firsch et al., 2000), as opposed to nNOS -/- mice which exhibited slightly 
increased locomotive activity (Kirchner et al, 2004). No other prominent differences 
were observed between knockout and wild type animals in alternative behavioural 
paradigms (Demas et al, 1999; Dere et al, 2001; Reif et al, 2004).
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The fact that eNOS-deficient mice displayed superior water maze performance 
whilst exhibiting a deficit in LTP challenges the widely held assumption that LTP 
represents the molecular basis for memory storage processes. However, it is feasible 
that the behavioural effects of eNOS inactivation may be due to effects not directly 
relating to learning and memory, but instead depend on factors such as anxiety 
predisposition (Frisch et al, 2000), changes in cerebral and peripheral blood flow 
(Endres et al., 1998; Godecke et al., 1998), body temperature control (Steiner et al, 
1998), or muscular oxygen supply during exercise (Nakane et al., 1993; Shen et al., 
1995).
7.2 General Conclusion
Overall our findings provide good support for the hypothesis that NO serves as an 
important messenger in hippocampal LTP, and presents evidence for a contribution 
from both nNOS and eNOS. The results also propose the interesting possibility that 
the different isoforms of NOS may possess distinct roles in the modulation of synaptic 
events; that is eNOS appears to be important for the early phase of LTP, whereas 
nNOS seems to exert a greater influence on late phase LTP. Since the majority of 
studies report hippocampal eNOS expression to be restricted to the vascular 
endothelium, and the finding from the present work that eNOS is likely to be 
responsible for tonic NO production in the hippocampus, I hypothesise that the role of 
eNOS may be to keep the synapse in a state of ‘relaxation’ capable of allowing 
plasticity to occur, possibly acting via the NO/cGMP/cGK/ryanodine pathway to 
lower the threshold required for LTP. In contrast, I propose that NO generated from 
nNOS can be viewed as a mediator of LTP which acts both presynaptically (as a 
retrograde messenger) and postsynaptically to influence synaptic “tagging” and 
transcriptional/translational events.
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Hopper, R., Garthwaite, J. Does nitric oxide regulate the NMDA receptor? J. Physiol. 
(Lond) 547P; C35 (2003).
Wolfson Institute for Biomedical Research, University College London, Gower 
Street, London, WC1E 6BT, UK
Nitric oxide (NO) functions as a messenger throughout the central nervous system, 
where many of its actions are exerted through guanylyl cyclase activation, leading to 
cGMP formation. A putative alternative transduction pathway is the modification of 
protein function by nitrosation of thiol groups (Ahem et al., 2002). A prototypic 
protein considered to be regulated in this way is the NMDA receptor but, despite 
extensive research, there is little direct evidence that NO performs this function. To 
address this issue, we have investigated the effect of NO on native or cloned NMDA 
receptors (NMDARs) in hippocampal slices and HEK-293 cells respectively.
Field EPSPs were recorded from the CA1 stratum radiatum of hippocampal slices 
obtained from 6- to 8-week-old rats killed humanely according to Home Office 
regulations (Bon and Garthwaite, 2001). EPSPs mediated through NMDARs were 
isolated pharmacologically. The responses were not significantly changed by bath 
application of the NO synthase substrate, L-arginine (100 pM), nor by inhibition of 
NO synthase using L-nitroarginine (100 pM). Diethylamine NO adduct (DEA/NO) 
was used to supply NO exogenously. Whilst DEA/NO at a concentration of 10 pM 
caused maximal cGMP accumulation in hippocampal slices, concentrations up to 30- 
fold higher produced no detectable change in the NMDAR-mediated synaptic 
responses. However, in accordance with a previous study (Murphy et al., 1994), 
photolysis of a caged NO derivative using a flash of UV light depressed NMDAR- 
mediated EPSPs by 94 ± 3 % (mean ± S.E.M; n = 4).
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As a further test, whole-cell membrane currents in response to 100 ms pulses of 100 
pM glutamate were recorded at -60 mV from HEK-293 cells transfected with 
NMDAR subunits NR1 and NR2A (Kohr and Seeburg, 1996). Similar to findings in 
the slices, photolysis of the caged compound by UV light depressed the NMDAR 
currents by 55 ± 3 % (n = 5), whereas 100 pM DEA/NO had no significant effect on 
the NMDAR current alone, but depressed the NMDAR currents by 35 ± 7 % (n = 4) 
when in combination with UV light. Perfusion of 100 nM DEA/NO had no effect on 
NMDAR function.
The results suggest that NO released endogenously, or exogenous NO in 
concentrations well in excess of those needed to activate guanylyl cyclase, does not 
modify NMDAR function. It is possible that other factors, such as UV light, may have 
contributed to the inhibition of NMDAR responses observed previously (Murphy et 
al., 1994).
Ahem, G.P., Kylachko, V.A., Jackson, M.B. (2002) Trends Neurosci. 25: 510-517. 
Bon, C.L.M., Garthwaite, J. (2001). Eur. J. Neurosci. 14; 585-594.
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M a te r ia l s  a n d  m e t h o d s  
Tissue preparation
Hippocampal slices were prepared from 6 to 8-week-old male Spra- 
gue-D aw ley rats. The animals were killed by stunning follow ed by 
cervical dislocation and decapitation. The brain was rapidly removed 
and the hippocampus dissected out and placed in cold (0 -4  °C) 
artificial cerebrospinal fluid (ACSF) o f the follow ing composition  
(in mM): NaCl 124, KC13, NaH2P 0 4 1.25, M g S 04 l ,  N aH C 0326, 
CaCl22, D-glucose 10, equilibrated with 95% 0 2 and 5% C 0 2. Trans­
verse slices (400 pan thick) were cut and maintained in an interface 
holding chamber containing ACSF at room temperature.
Electrophysiological recording from hippocampal slices
Extracellular recordings o f  field excitatory postsynaptic potentials 
(fEPSPs) were made at room temperature (2 2 -2 4  °C) from the stratum 
radiatum o f the CA1 area follow ing electrical stimulation (baseline 
frequency =  0.033 Hz) o f  the Schaffer collateral-commissural path­
way. NM DA receptor-mediated responses were isolated pharmacolo­
gically using nominally M g2+-free ACSF containing 10 pM 6-cyano- 
7-nitroquinoxaline-2,3-dione (CNQX) to block AMPA receptors. 
D(-)-2-amino-5-phosphonopentanoate (D-AP5) was added to confirm 
that the responses were NM DA receptor-mediated. AMPA receptor- 
mediated responses were obtained in normal ACSF. Photolysis o f  
caged NO (potassium pentachloronitrosylruthenate, K2Ru(NO)C15; 
Alfa Aesar, Karlsruhe, Germany) was performed using the l  ms 
discharge from a xenon arc bulb (Zeiss) transmitted through a fibre 
optic, and filtered with a U G 11 filter (2 7 0 -3 7 0  nm). Stock solutions o f  
the NONOate NO  donor, diethylamine/NO adduct (DEA/NO) were 
made up in lOmM NaOH and diluted at least 1 :1 0 0  into the ACSF  
solution. Separate slices were used for each DEA /N O  concentration 
tested. Slope measurements were made during the initial linear phase 
o f  each evoked potential (20-50%  o f  the peak) and the values were 
normalized relative to the mean values obtained within the first 10 or 
15 min o f recording in the absence o f  any treatment.
W hole-cell current-clamp recordings were made from CA1 hippo­
campal cells at room temperature using an Axoclamp 2A (Axon Instru­
ment, Foster city, CA). Typical pipette resistance was 2 -4  M O. Pipette 
solutions contained (in mM): K M eS04 150, KC110, H E PE S10, NaCl 4, 
Mg2ATP4. The pH was adjusted to 7.4 and the osmolarity to 2 8 0 -  
290 mOsm/L. NM DA receptor-mediated responses were isolated using 
ACSF containing lOpM CNQX and 50 pM picrotoxin. Som e experi­
ments (n =  2) were carried out in the nominal absence o f  extracellular 
Mg2+ with the membrane potential being held at — 80 mV by current 
injection through the recording electrode; in others (n — 2) normal 
extracellular M g2+ was used and the membrane potential was held at 
—60 mV. A short current pulse was included in every trace to ensure 
correct adjustment o f bridge balance. Slope measurements were 
made during the initial linear phase (20-50% ) o f  each evoked potential 
and the values were normalized relative to the mean values obtained 
within the first 10 min o f  recording in the absence o f  any treatment
All data are presented as the means ±  SEM.
Measurement of cGMP
Determination o f cGMP levels was carried out as described previously 
(Boulton et al., 1995). Briefly, hippocampal slices were allowed to 
recover for 1 -2  h in gassed ACSF maintained in a shaking water bath at 
22.5 °C (the average temperature in the electrophysiological experi­
ments). The slices were then transferred to a fresh solution containing 
the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (Im M ) 
for 15 min, before being exposed to the NO donor, diethylamine/NO  
adduct (DEA/NO) for 2 min. At the end o f  the exposure the slices were
removed, inactivated by immersion in boiling hypotonic buffer, and 
hom ogenized by sonication. The protein content was determined using 
the bicinchoninic acid method (Pierce Rockford, IL, U SA ) with bovine 
serum albumin as standard. Following centrifugation, the cGMP  
content o f  the supernatant was determined by radioimmunoassay. 
Results are expressed as mean cGM P content/mg protein ±  SEM.
Cell culture
Human embryonic kidney 293 cells (HEK-293 cells; European Col­
lection o f  Cell Cultures, CAMR, Salisbury, ECACC no. 85120602) 
were grown in DM EM  containing 10% fetal bovine serum (FBS) and 
lOOU/mL o f  both penicillin and streptomycin, at 37 °C in a 5% C 0 2 
incubator. Exponentially growing cells were plated onto 9 mm dia­
meter coverslips 24 h prior to transfection. HEK-293 cells were 
transfected with a mixture o f  plasm ids containing the NR1 (provided 
by DrR. Shoepfer, University College London, UK ) and NR2a (from 
Dr P. Seeburg, Heidelberg, Germany) subunits o f  the NM DA receptor, 
and green fluorescent protein (Clontech, U SA ) to allow visualization 
o f the transfected cells. Transfections were performed using Effectene 
Transfection Reagent (Qiagen UK , Ltd) follow ing the manufacturer’s 
instructions. Approximately 76% o f  cells expressing green fluorescent 
protein also expressed functional N M D A  receptors. Following trans­
fection, 500 p,M ketamine was added to the DM EM  culture medium to 
reduce glutamate-mediated cell toxicity. Studies on the recombinantly 
expressed receptors were performed two days after transfection, which 
gave optimal transient expression o f  the proteins.
Whole-cell electrophysiology
Transfected HEK-293 cells were studied at room temperature. The 
recording chamber was mounted on an inverted microscope (Zeiss), 
and was continuously perfused with extracellular solution containing 
(in mM): NaCl 135, KC15.4, CaCl2 1.8, glycineO.Ol, H EPES5. The 
pH w as adjusted to 7.25 with NaOH and osmolarity was maintained at 
28 0 -3 0 0  mOsm/L with sucrose. W hole-cell voltage clamp recordings 
were made from green fluorescent protein-positive cells using an 
Axopatch ID  (Axon Instrument, Foster city, CA) after capacitance 
and series resistance compensation. Typical pipette resistance was 3 -  
6 M il. Patch pipette solutions contained (in mM): CsCl 140, M gCl2 1, 
EGTA10, HEPES 10, M g-ATP4, pH 7.25 (CsOH) and osmolarity 
28 0 -3 0 0  mOsm/L (adjusted with sucrose).
Immediately after establishing the w hole-cell configuration, short 
(100 m s) pressure pulses o f  glutamate (100 pM dissolved in external 
solution) were applied with a Picospritzer (Picospritzer HD, General 
Valve Corporation; N ew  Jersey, U SA ) every 20 s. Photolysis o f  caged  
NO was performed by illuminating an wlOOpre diameter circle 
surrounding the cell o f  interest using a mercury vapour 50 W  bulb 
(Osram, UK) filtered with the U G 11 filter used in the slice experiments 
(see above). Data acquisition and analysis were with pClamp6 or 
pClamp8 (Axon Instruments, CA, USA).
Measurement of NO
NO concentrations were measured using an electrochemical probe 
(ISO-NO; World Precision Instruments, Stevenage, UK) under the 
same experimental conditions used to record currents from the HEK- 
293 cells.
R e s u l t s
Effect of endogenous NO on NMDA receptor-mediated 
synaptic transmission
Electrophysiological recordings o f  pharmacologically isolated NM DA  
receptor-mediated fEPSPs were made from the CA1 region o f adult rat
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